A publication of the
American Pharmaceutical Association—
the National Professional Society
of Pharmacists

JOURNAL OF PHARMACEUTICAL SCIENCES

INDEX TO AUTHORS
INDEX TO SUBJECTS

VOLUME 70
JANUARY TO DECEMBER, 1981

Published monthly under the supervision of the Board of Trustees

MARY H. FERGUSON
Editor

NANCY E. BROWN
Production Editor

JOHN PATRICK EVANS
Copy Editor

MICHAEL K. HAYES
Copy Editor

EDWARD G. FELDMANN
Contributing Editor

SAMUEL W. GOLDSTEIN
Contributing Editor

BELLE R. BECK
Editorial Secretary

EDWARD G. FELDMANN
Acting Director of Publications

EDITORIAL ADVISORY BOARD

John Autian
Norman R. Farnsworth
William J. Jusko
Herbert A. Lieberman
David E. Mann, Jr.
Ian W. Mathison
Gerald J. Papariello
Edward G. Rippie

© Copyright 1981 by the American Pharmaceutical Association; all rights reserved.

AUTHOR INDEX

A

Abbott, F. S., *see* Au, D. S.-L., 917
Abdel-Hamid, M. E., *see* Belal, S., 127
Abdine, H., *see* Belal, S., 127
Abdullah, M. E., *see* Said, S. A., 621
Abou-Gharbia, M., Pashko, L., Schwartz, A., and Swern, D., synthesis of dehydroepiandrosterone sulfatide and 16α-halogenated steroids, 1154
Abouzeit-Har, M. S., *see* Soliman, R., 94
Abrahams, L. J., *see* Fox, J. L., 910
Abramson, F. P., two-compartment pharmacokinetic models: computer simulations of their characteristics and clinical consequences, 141
Abtahi, F., *see* Shafiee, A., 510
Aceto, M. D., *see* Vincek, W. C., 1292
Acree, W. E., Jr., and Bertrand, G. L., thermochemical investigations of nearly ideal binary solvents VII: monomer and dimer models for solubility of benzoic acid in simple binary and ternary solvents, 1033
Adjei, A., *see* Martin, A., 1115, 1260
Ahlrichs, J. L., *see* Oscarson, D. W., 657
Akaho, E., Iga, K., Kraal, J., and Hussain, A., solubility behavior of phenolic compounds in hexane–ethyl acetate, hexane–ethyl myristate, and hexane–ethyl pivalate cosolvent systems, 1225
Alam, A. S., and Gregoriades, D., physicochemical properties of magnesium salicylate, 961
Alexander, T., *see* Aszalos, A., 878
Ali, A., Kazmi, S., and Plakogiannis, F. M., high-pressure liquid chromatographic determination of ibuprofen in plasma, 944
Ali, A., *see* Chu, S. Y., 990
Alkan, M. H., *see* Su, C. C., 713
Allen, L. V., Jr., Levinson, R. S., Robinson, C., and Lau, A., effect of surfactant on tetracycline absorption across everted rat intestine, 269
Al-Shora, H. I., *see* Said, S. A., 67
Aly, R., antimicrobial activity of chlorhexidine gluconate against natural and artificial contamination during simulation of in-use conditions, 964
Amann, A. H., *see* Malick, A. W., 798
Amato, R. J., *see* Jones, G. L., 618
Amick, E. N., *see* Mason, W. D., 707
Amidon, G. E., Smith, D. P., and Hiestand, E. N., rotary press utilizing a flexible die wall, 613
Amidon, G. L., *see* Banerjee, P. K., 1299, 1304, 1307
Amos, B., *see* Lee, C., 669
Amsel, L., *see* Raghunathan, Y., 379
An, S. H., *see* Foye, W. O., 1059
Anderson, A., *see* Jarrott, B., 665
Anderson, B. D., and Taphouse, V., initial rate studies of hydrolysis and acyl migration in methylprednisolone 21-hemisuccinate and 17-hemisuccinate, 181
Anderson, J. R., Drehsen, G., and Pitman, I. H., effect of caffeine on ergotamine absorption from rat small intestine, 651
Angeli, P., Brasili, L., Giardinà, D., and Melchiorre, C., molecular requirements of active site of cholinergic receptors XV: synthesis and biological activity of 2,3-dehydrodeoxamuscarone and 2,3-dehydrodeoxamuscarines, 489
Anik, S. T., and Sukumar, L., extreme vertexes design in formulation development: solubility of butoconazole nitrate in a multicomponent system, 897
Aniuha, G. I., *see* Kar, A., 690
Arakawa, M., and Kondo, T., preparation of hemolysate-loaded poly(N^{ε},N^{ε}-L-lysinediylterephthaloyl) nanocapsules, 354
Aratani, T., *see* Ishida, T., 406
Asakawa, Y., Taira, Z., Takemoto T., Ishida, T., Kido, M., and Ichikawa, Y., X-ray crystal structure analysis of 14-hydroxycaryophyllene oxide, a new metabolite of (−)-caryophyllene, in rabbits, 710
——*see* Ishida, T., 406
Ashley, J. J., *see* Petersen, M. C., 1139
Aszalos, A., Crawford, J., Vollmer, P., Kantor, N., and Alexander, T., high-performance liquid chromatographic determination of components of bleomycin preparations, 878
——*see* Haneke, A. C., 1112
Au, D. S.-L., Runikis, J. O., Abbott, F. S., and Burton, R. W., GLC analysis of hydrocortisone, triamcinolone acetonide, and desonide in culture media of mouse and human dermal fibroblasts using flame-ionization detection, 917
Augsburger, L. L., review of "Essentials of Drug Product Quality: Concepts and Methodology," 348
Averbuch, S. D., Finkelstein, T. T., Fandrich, S. E., and Reich, S. D., anthracycline assay by high-pressure liquid chromatography, 265
Awazu, S., *see* Igari, Y., 1049
Ayres, J. W., review of "Controlled Release Technologies: Methods, Theory, and Applications," 1178
Azibi, M., *see* Bouche, R. P., 968

B

Baaske, D. M., *see* Malick, A. W., 798
Baba, S., Furuta, T., Horie, M., and Nakagawa, H., studies on drug metabolism by use of isotopes XXVI: determination of urinary metabolites of rutin in humans, 780
Bachmann, K. A., *see* Crider, A. M., 1319
Bailey, L., *see* Castellano, T., 104
Bainbridge, C. A., *see* Janicki, C. A., 778
Baker, J. K., *see* Hufford, C. D., 151, 155
Baldwin, H. J., review of "Pharmacy: A Profession in Search of a Role," 233
Banerjee, P. K., and Amidon, G. L., physicochemical property modification strategies based on enzyme substrate specificities III: Carboxypeptidase A hydrolysis of aspirin derivatives, 1307
——and Amidon, G. L., physicochemical property modification strategies based on enzyme substrate specificities II: α-chymotrypsin hydrolysis of aspirin derivatives, 1304
——and Amidon, G. L., physicochemical property modification strategies based on enzyme substrate specificities I: rationale, synthesis, and pharmaceutical properties of aspirin derivatives, 1299
Bansal, P. C., Pitman, I. H., and Higuchi, T., *N*-hydroxymethyl derivatives of nitrogen heterocycles as possible prodrugs II: possible prodrugs of allopurinol, glutethimide, and phenobarbital, 855
——Pitman, I. H., Tam, J. N. S., Mertes, M., and Kaminski, J. J., *N*-hydroxymethyl derivatives of nitrogen heterocycles as possible prodrugs I: *N*-hydroxymethylation of uracils, 850
Barbhaiya, R. H., Phillips, T. A., and Welling, P. G., high-pressure liquid chromatographic determination of chlorothiazide and hydrochlorothiazide in plasma and urine: preliminary results of clinical studies, 291
Barbhaiya, R., *see* Garrett, E. R., 39
Barrett, M., *see* Behl, C. R., 835, 1212
Barry, R. H., Rubin, H., Johnson, J. B., and Lazarus, J. H., theophylline magnesium salicylate, a new xanthine compound, 204
Basmadjian, G. P., *see* Hinkle, G. H., 312
——*see* Mills, S. L., 1
Bates, T. R., *see* Ebling, W. F., 224
Bauer, L., *see* Wood, L. E., 199
Bauguess, C. T., Lee, Y. Y., Kosh, J. W., and Wynn, J. E., comparison of quantitation methods for L-1210 cell populations and evaluation of selected cytotoxic agents in leukemic mice, 46
Bawarshi, R., *see* Hussain, A. A., 466
Bayne, W. F., East, T., and Dye, D., high-pressure liquid chromatographic method with postcolumn, in-line hydrolysis and fluorometric detection for indomethacin in biological fluids, 458
——Tao, F. T., Rogers, G., Chu, L. C., and Theeuwes, F., time course and disposition of methazolamide in human plasma and red blood cells, 75
Beaubien, L. J., *see* Snider, B. G., 1347
Beaudoin, N., *see* McGilveray, I. J., 524
Beerbower, A., *see* Martin, A., 1260
Behl, C. R., and Barrett, M., hydration and percutaneous absorption II: influence of hydration on water and alkanol permeation through swiss mouse skin; comparison with hairless mouse, 1212
——Wittkowsky, A., Barrett, M., Pierson, C. L., and Flynn, G. L., technique for preparing appendage-free skin (scar) on hairless mouse, 835
Behm, H. L., and Wagner, J. G., parabolic equation relating free and total drug concentrations in cases of nonlinear plasma protein binding, 802
Behn, R. M., and Digenis, G. A., noninvasive dissolution measurement using perturbed angular correlation, 1325
Belair, E. J., Carlson, G. R., Melamed, S., Moss, J. N., and Tansy, M. F., effects of spermine and spermidine on gastric emptying in rats, 347
Belal, S., Elsayed, M. A.-H., Abdel-Hamid, M. E., and Abdine, H., utility of chloranil in assay of naphazoline, clemizole, penicillin G sodium, and piperazine, 127
Beltagy, Y. A., *see* Repta, A. J., 634
Benjamin, E. J., *see* Pento, J. T., 399
Berner, B., *see* Cooper, E. R., 57
Bertrand, G. L., *see* Acree, W. E., Jr., 1033
Bevill, R. F., *see* Bourne, D. W. A., 1068
Beyerman, H. C., *see* Noordam, A., 96
Bialer, M., El-On, J., Yagen, B., and Mechoulam, R., antiparasitic structure–activity relationships of congocidine derivatives, 822
——*see* Bourne, D. W. A., 1068
Bianchi, M., *see* Pantarotto, C., 871
Bickler, J. R., *see* Reich, S. D., 268
Biehl, E. R., *see* Williams, P. A., 530
Bingel, A. S., *see* Hsu, C. C., 682
Birch, G. G., Dziedzic, S. Z., Shallenberger, R. S., and Lindley, M. G., structural functions of the sweet pharmacophore, 277
Bjornsson, T. D., Brown, J. E., and Tschanz, C., importance of radiochemical purity of radiolabeled drugs used for determining plasma protein binding of drugs, 1372
Black, D. B., Lawrence, R. C., Lovering, E. G., and Watson, J. R., routine quality evaluation of benzodiazepine drugs to USP–NF specifications, 208
Block, A. J., *see* Sowell, J. W., Sr., 135, 537
Block, J. H., review of "Analytical Profiles of Drug Substances," Vol. 9., 973
——*see* Chiou, C. T., 1176
Bloedow, D. C., *see* Thompson, J. A., 1284
Bodor, N., *see* Loftsson, T., 743, 750, 756
Bogaert, M. G., *see* Monbaliu, J. G., 965
——*see* Rosseel, M. T., 688
Bolhuis, G. K., Smallenbroek, A. J., and Lerk, C. F., interaction of tablet disintegrants and magnesium stearate during mixing I: effect on tablet disintegration, 1328
Bolton, B. A., and Prasad, P. N., laser raman investigation of pharmaceutical solids: griseofulvin and its solvates, 789
Booncong, C., *see* Tan, H. S. I., 783
Bopp, R. J., Farid, K. Z., and Nash, J. F., high-performance liquid chromatographic assay for fenoprofen in human plasma, 507
Bouche, R. P., Azibi, M., and Draguet-Brughmans, M. G., observed artifacts due to pellet preparation in IR spectrometry, 968
Bourne, D. W. A., Bialer, M., Dittert, L. W. Hayashi, M., Rudawsky, G., Koritz, G. D., and Bevill, R. F., disposition of sulfadimethoxine in cattle: inclusion of protein binding factors in a pharmacokinetic model, 1068
——review of "Handbook of Basic Pharmacokinetics, 2nd Ed.," 348
Brasili, L., *see* Angeli, P., 489
Breen, P. J., *see* Newton, D. W., 122
Briley, M. R., *see* Otani, T. T., 464

Brodeur, G. M. *see* Evans, W. E., 1194
Brown, D. E., *see* Newton, D. W., 122
Brown, J. E., *see* Bjornsson, T. D., 1372
Brown, K. F., *see* Whitlam, J. B., 146
Brown, R. G., *see* Prabhu, V. A., 558
Bruce, R. D., *see* Cooper, E. R., 57
Bryant, W., *see* Raghunathan, Y., 379
Bucci, A. J., Myre, S. A., Tan, H. S. I., and Shenouda, L. S., *in vitro* interaction of quinidine with kaolin and pectin, 999
Burger, J., *see* Cutie, A., 1085
Burns, H. D., Sowa, D. T., Worley, P., Vaum, R., and Marzilli, L. G., electrophoretic determination of charge on carrier-free ^{99m}Tc-labeled complexes, 436
——*see* Dannals, R. F., 439
Burton, R. W., *see* Au, D. S.-L., 917
Butler, S. S., *see* Roseman, T. J., 562, 646
Butterfield, A. G., *see* Midha, K. K., 1043
Byfield, J. E., *see* Hornbeck, C. L., 1163
Byrn, S. R., and Siew, P. Y., crystal structure and solid-state behavior of aspirin anhydride crystals, 280
——*see* Migliaccio, G. P., 284
Byron, P. R., Guest, R. T., and Notari, R. E., thermodynamic dependence of interfacial transfer kinetics of nonionized barbituric acid derivatives in two-phase transfer cell, 1265

C

Cabana, B. E., *see* Hunt, J. P., 796
——*see* Shah, V. P., 833
Cadwallader, D. E., and Madan, D. K., effect of macromolecules on aqueous solubility of cholesterol and hormone drugs, 442
Caldwell, K. D., Karaiskakis, G., Myers, M. N., and Giddings, J. C., characterization of albumin microspheres by sedimentation field-flow fractionation, 1350
Canada, A. T., *see* Lesko, L. J., 1366
Capiton, G. A., *see* Hufford, C. D., 151
Capomacchia, A. C., *see* Wu, S. C., 685
Caprioli, R. M., *see* Lin, S.-N., 1276
Cardinal, J. R., *see* Song, S. Z., 216
——*see* Zentner, G. M., 975
Carlson, G. R., *see* Belair, E. J., 347
Carmichael, G. R., Shah, S. A., and Parrott, E. L., general model for dissolution rates of *n*-component, nondisintegrating spheres, 1331
Caron, J.-C., and Shroot, B., high-pressure liquid chromatographic determination of anthralin in ointments, 1205
Carpenter, B. E., *see* Walker, M. C., 99
Carstensen, J. T., and Kothari, R., solid-state decomposition of alkoxyfuroic acids, 1095
——Marty, J.-P., Puisieux, F., and Fessi, H., bonding mechanisms and hysteresis areas in compression cycle plots, 222
——*see* Fessi, H., 1005
——*see* Laughlin, S. M., 711
——*see* Martin, A., 170
——*see* Vaution, C., 1238
Cascella, P. J., Huppler, E. G., II, and Johnson, J. D., alterations in integrity of goldfish membrane induced by edetate disodium, 1128
Castellano, T., Medwick, T., Shinkai, J. H., and Bailey, L., differential titration of bases in glacial acetic acid, 104
Cawein, M., *see* Weiner, D., 1079
Chafetz, L., see Chen, T. M., 804
Chambliss, W. G., Cleary, R. W., Fischer, R., Jones, A. B., Skierkowski, P., Nicholes, W., and Kibbe, A. H., effect of docusate sodium on drug release from a controlled-release dosage form, 1248
Chan, K. K., review of "Recent Developments in Mass Spectrometry in Biochemistry and Medicine," 6, 1179
Chan, S. F., *see* Hennig, U. G., 317
Changchit, A., *see* Yeh, S. Y., 867
Chao, D., *see* Luders, R. C., 1370
Chaplin, M., *see* Fass, M., 1338
Chapman, J. M., Jr., *see* Hall, I. H., 326
Charette, C., *see* McGilveray, I. J., 524
Chasseaud, L. F., *see* Doyle, E., 1270
Chatten, L. G., *see Hennig, U. G.,* 317
——*see* Moskalyk, R. E., 496
Chen, C.-Y., *see* Ravis, W. R.,
Chen, M.-L., *see* Chiou, W. L., 1037
Chen, S. T., Thompson, R. C., and Poust, R. I., measurement of pseudoephedrine hydrochloride dissolution using chloride-ion electrode, 1288
Chen, T.-M., and Chafetz, L., high-pressure liquid chromatographic assay of theophylline, ephedrine hydrochloride, and phenobarbital tablets, 804
Cheng, C. C., *see* Uyeki, E. M., 1011
——*see* Weinstock, L. T., 956
Cheon, J. W., *see* Nagwekar, J. B., 295
Chi, L.-H., *see* Chowhan, Z. T., 243, 247
Chien, Y. W., Van Nostrand, P., Hurwitz, A. R., and Shami, E. G., drug–disintegrant interactions: binding of oxymorphone derivatives, 709
Chiou, C. T., and Block, J. H., correlation of water solubility with octanol–water partition coefficient, 1176
Chiou, W. L., Lam, G., Chen, M.-L., and Lee, M. G., instantaneous input hypothesis in pharmacokinetic studies, 1037
——and Lam, G., simplified physiologically based method to estimate steady-state volume of distribution, 967
——Lui, C. Y., and Lam, G., plasma area method in relative bioavailability evaluation of drugs with changing biological half-lives, 109
——*see* Lam, G., 1373
Chmielewski, K. F., *see* Karch, F. E., 229
Chow, S.-L., and Sims, B. E., micellar solubilization of cetaben sodium in surfactant and lipid solutions, 924
Chow, Y. P., *see* Chowhan, Z. T., 1134
Chowhan, Z. T., and Chi, L.-H., mixing of pharmaceutical solids III: multivariate statistical analysis of multicomponent mixing, 247
——and Chow, Y. P., compression properties of granulations made with binders containing different moisture contents, 1134
——Linn, E. E., and Chi, L.-H., mixing of pharmaceutical solids II: evaluation of multicomponent mixing of cohesive powders in cylindrical shear mixer, 243
——and Yang, I.-C., powder flow studies III: tensile strength, consolidation ratio, flow rate, and capsule-filling-weight variation relationships, 927
Chu, L. C., *see* Bayne, W. F., 75
Chu, S.-Y., Vega, S. M., Ali, A., and Sennello, L. T., radioimmunoassay of carteolol in human plasma, 990
Chung, M., *see* Korduba, C. A., 521
Clark, A. M., El-Feraly, F. S., and Li, W.-S., antimicrobial activity of phenolic constituents of *Magnolia grandiflora* L., 951
——*see* Hufford, C. D., 151, 155
Clawans, C., *see* Cutie, A., 1085
Cleary, R. W., *see* Chambliss, W. G., 1248
Coburn, R. A., Taylor, M. D., and Wright, W. L., preliminary evaluation of mesoionic 6-substituted 1-methylimidazo[2,1-*b*] [1,3]thiazine-5,7-diones as potential novel prodrugs of methimazole, 1322
Coburn, T. C., *see* Evans, W. E., 1194
Cocchetto, D. M., kinetics of pharmacological effects on constant-rate intravenous infusion, 578
——and Levy, G., absorption of orally administered sodium sulfate in humans, 331
Cocolas, G. H., *see* Hall, I. H., 326
Cohen, A. I., review of "Biochemical Applications of Mass Spectrometry: First Supplementary Volume," 581
Colburn, W. A., first-pass clearance of lidocaine in healthy volunteers and epileptic patients: influence of effective liver volume, 969
Colombo, R., *see* Ventura, P., 334
Combs, A. B., *see* McGinity, J. W., 372
Connors, K. A., *see* Lin, S.-F., 235
Cooper, E. L., see Walker, M. C., 99
Cooper, E. R., Berner, B., and Bruce, R. D., kinetic analysis of relationship between partition coefficient and biological response, 57
Cooper, J. K., *see* Midha, K. K., 1043
Cooper, T. B., *see* Suckow, R. F., 257
Cornejo, J., *see* Hermosin, M. C., 189
Corrigan, O. I., *see* Su, C. C., 713
Cossum, P. A., and Roberts, M. S., stability of nitroglycerin ointment, 832
Cotton, M. L., *see* Taguchi, V. Y., 64
Courtois, Ph., *see* Fourtillan, J. B., 573
Cousse, H., Mouzin, G., Ribet, J.-P., and Vezin, J.-C., physicochemical and analytical characteristics of itanoxone, 1245
——Ribet, J. P., and Vezin, J. C., GLC determination of itanoxone in biological fluids, 860
Cradock, J. C., *see* Poochikian, G. K., 159
Crawford, J., *see* Aszalos, A., 878
——*see* Haneke, A. C., 1112
Crider, A. M., Grubb, R., Bachmann, K. A., and Rawat, A. K., convenient synthesis of 6-nor-9,10-dihydrolysergic acid methyl ester, 1319
——Kolczynski, T. M., and Miskell, D. L., synthesis and anticonvulsant activity of racemic 2-amino-*N*-substituted succinimide derivatives, 192
Crom, W. R., *see* Evans, W. E., 1194
Cruz, J. E., *see* Yakatan, G. J., 949
Cuff, G. W., *see* McGinity, J. W., 372
Cutie, A., Burger, J., Clawans, C., Dolinsky, D., Feinstein, W., Gupta, B., Grueneberg, A., and Sciarra, J., test for reproducibility of metered-dose aerosol valves for pharmaceutical solutions, 1085

D

Daabees, T. T., *see* Omar, A. M. M. E., 1075
Daniels, R., *see* Wood, L. E., 199
Daniels, S. L., and Vanderwielen, A. J., stability-indicating assay for hydrochlorothiazide, 211
Danielson, D. W., *see* Rippie, E. G., 476
Dannals, R. F., Burns, H. D., Marzilli, L. G., Trageser, T. C., and Wagner, H. N., Jr., radiolabeled benzoylcholine derivatives as possible myocardial-imaging agents, 439
Danzinger, R. G., *see* Su, C. C., 713
Das, M. K., *see* Hall, I. H., 339
Davis, J. M., *see* Javaid, J. I., 813
Davis, M. A., *see* Hanson, R. N., 91
Day, R. O., Dromgoole, S. H., Furst, D. E., Hignite, C., and Paulus, H. E., formation of methyl ester of salicyluric acid during quantitation of salicyluric acid in urine by high-pressure liquid chromatography, 1090
Dean, A. V., *see* Singhvi, S. M., 885
DeBerardinis, M., Jr., *see* Wurster, D. E., 764
DeBold, C. R., and Elwood, J. C., mevalonic acid analogs as inhibitors of cholesterol biosynthesis, 1007
De Fabrizio, F., GLC analysis of menthol, phenol, benzocaine, and pyrilamine maleate in aerosol spray lotion, 1151
De Groote, R. A. M. C., *see* Neumann, M. G., 863
Deguchi, Y., *see* Tsuji, A., 1120
Deiben, F., Paoletti, S., Manzini, G., and Nisi, C., influence of serum albumins on decomposition rates of *para*-substituted 1-phenyl-3-methyltriazenes and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide in near physiological conditions, 892
De Leenheer, A. P., *see* Nelis, H. J. C. F., 226
Delgado, J. N., *see* Prabhu, V. A., 558
DeLuca, P. P., *see* Slack, J. D., 660
De Nève, R. E., *see* Plaizier-Vercammen, J. A., 1252
Der Marderosian, A., *see* Lee, T. M., 89
Derr, G. R., *see* Roseman, T. J., 646
Derrick, M. E., *see* Sowell, J. W., Sr., 135, 537
Deutsch, T., *see* Sotiropoulus, J. B., 422
Digenis, G. A., Vincent, S. H., Kook, C. S., Reiman, R. E., Russ, G. A., and Tilbury, R. S., tissue distribution studies of [^{18}F]haloperidol, [^{18}F]-β-(4-fluorobenzoyl)propionic acid, and [^{82}Br]bromperidol by external scintigraphy, 985
——*see* Beihn, R. M., 1325
DiRubio, R., *see* Waraszkiewicz, S. M., 1215
Ditter, W., *see* Frömming, K. H., 738
Dittert, L. W., *see* Bourne, D. W. A., 1068
Divoll, M., Greenblatt, D. J., Harmatz, J. S., and Shader, R. I., effect of age and gender on disposition of temazepam, 1104
Dixon, R., Glover, W., and Earley, J., specific radioimmunoassay for flunitrazepam, 230
Dobberstein, R. H., *see* Hsu, C. C., 682
Dolinsky, D., see Cutie, A., 1085
Dorsey, E. D., *see* Dunn, D. L., 446
——*see* Scott, B. S., 1046
Doyle, E., and Chasseaud, L. F., pharmacokinetics of isosorbide dinitrate in rhesus monkey, cynomolgus

monkey, and baboon, 1270
Draguet-Brughmans, M. G., *see* Bouche, R. P., 968
Drehsen, G., *see* Anderson, J. R., 651
Drew, J. H., Loeffler, L. J., and Hall, I. H., antifertility activity of *N*-protected glycine activated esters, 60
Driscoll, J. S., *see* Lin, A. J., 806
Dromgoole, S. H., *see* Day, R. O., 1090
Drummer, O. H., McNeil, J., Pritchard, E., and Louis, W. J., combined high-performance liquid chromatographic procedure for measuring 4-hydroxypropranolol and propranolol in plasma: pharmacokinetic measurements following conventional and slow-release propranolol administration, 1030
——*see* Horowitz, J. D., 320
Dubick, M. A., and Yang, W. C. T., effects of chronic emetine treatment on mitochondrial function, 343
Dukes, G. R., *see* Tafolla, W. H., 1273
Dunn, D. L., Scott, B. S., and Dorsey, E. D., analysis of pilocarpine and isopilocarpine in ophthalmic solutions by normal-phase high-performance liquid chromatography, 446
——*see* Scott, B. S., 1046
Durrani, M. J., *see* Kamath, B. L., 299
Dürrheim, H., *see* Flynn, G. L., 52
Dusebout, T., *see* Weiner, D., 1079
Dye, D., *see* Bayne, W. F., 458
Dziedzic, S. Z., *see* Birch, G. G., 277

E

Earley, J., *see* Dixon, R., 230
East, T., *see* Bayne, W. F., 458
Ebling, W. F., Murro, A. F., Voelker, F. J., Resetarits, D. E., and Bates, T. R., chlorothiazide absorption from solution and tablet dosage forms in dogs, 224
Eckert, D. J., *see* Powers, L. J., 419
Edafiogho, I. O., *see* Owoyale, J. A., 963
Edds, G. T., *see* Suber, R. L., 981
Edelson, J., *see* Scrime, M., 1199
Edman, P., and Sjöholm, I., prolongation of effect of asparaginase by implantation in polyacrylamide in rats, 684
Egoville, J. C., *see* Galante, R. N., 167
El-Feraly, F. S., *see* Clark, A. M., 951
Ellis, K. O., *see* Wessels, F. L., 1088
El-On, J., *see* Bialer, M., 822
El Sadany, S. K., *see* Soliman, R., 606
Elsayed, M. A.-H., *see* Belal, S., 127
ElSohly, M. A., *see* Skierkowski, P., 829
——*see* Watson, E. S., 785
Elwood, J. C., *see* DeBold, C. R., 1007
El-Yazigi, A., disintegration–dissolution analysis of percent dissolved–time data, 535
——and Sawchuk, R. J., theophylline absorption and disposition in rabbits: oral, intravenous, and concentration-dependent kinetic studies, 452
Endo, K., *see* Ishizaka, T., 358
Engasser, J. M., Sarhan, F., Falcoz, C., Minier, M., Letourneur, P., and Siest, G., distribution, metabolism, and elimination of phenobarbital in rats: physiologically based pharmacokinetic model, 1233
Erlich, R. H., *see* Janicki, C. A., 778
Eshba, N. H., *see* Omar, A. M. M. E., 1075
Evans, W. E., Tsiatis, A., Crom, W. R., Brodeur, G. M., Coburn, T. C., and Pratt, C. B., pharmacokinetics of sustained serum methotrexate concentrations secondary to gastrointestinal obstruction, 1194
Ezzedeen, F. W., Masoud, A. N., Stohs, S. J., and Lerman, S. J., high-performance liquid chromatographic analysis of iodochlorhydroxyquin in plasma, 889

F

Fabre, H., and Mandrou, B., quality control of phenylbutazone I: analysis of phenylbutazone and decomposition products in drugs by TLC, 460
Falcoz, C., *see* Engasser, J. M., 1233
Fandrich, S. E., *see* Averbuch, S. D., 265
——see Hull, D. A., 500
Fanelli, R., *see* Pantarotto, C., 871
Farghaly, A. M., *see* Omar, A. M. M. E., 1075
Farid, K. Z., *see* Bopp, R. J., 507
Farnsworth, N. R., *see* Hsu, C. C., 682
Fass, M., Zaro, B., Chaplin, M., and Matin, S., reversed-phase high-pressure liquid chromatographic analysis of sulconazole in plasma, 1338
Fehske, K. J., and Müller, W. E., optical studies on interaction of biliary contrast agents with native and modified human serum albumin, 549
Feid-Allah, H. M., *see* Soliman, R., 602, 606, 952
Feinstein, W., *see* Cutie, A., 1085
Feld, K. M., and Higuchi, W. I., dissolution rate behavior of solid cholesterol preparations in bile acid solutions, 717
——and Higuchi, W. I., variability in dissolution rates of cholesterol pellets in bile acid solutions, 723
Feldkamp, J. R., Shah, D. N., Meyer, S. L., White, J. L., and Hem, S. L., effect of adsorbed carbonate on surface charge characteristics and physical properties of aluminum hydroxide gel, 638
——*see* Lipka, E. A., 936
Fessi, H., Marty, J.-P., Puisieux, F., and Carstensen, J. T., energy relations in compression of polymeric materials and granulations, 1005
——*see* Carstensen, J. T., 222
Findlay, J. W. A., Warren, J. T., Hill, J. A., and Welch, R. M., stereospecific radioimmunoassays for d-pseudoephedrine in human plasma and their application to bioequivalency studies, 624
Fine, S. L., *see* Tan, H. S. I., 783
Finkelstein, T. T., *see* Averbuch, S. D., 265
——*see* Hull, D. A., 500
Fischer, R., *see* Chambliss, W. G., 1248
Flinn, P. E., *see* Juenge, E. C., 415
Floyd, R. A., *see* Hornbeck, C. L., 1163
Flynn, G. L., Dürrheim, H., and Higuchi, W. I., permeation of hairless mouse skin II: membrane sectioning techniques and influence on alkanol permeabilities, 52
——*see* Behl, C. R., 835
Fong, H. H. S., *see* Hsu, C. C., 682
Fourtillan, J. B., Lefebvre, M. A., Girault, J., and Courtois, Ph., mass fragmentographic determination of timolol in human plasma and urine, 573
Fox, J. L., Yonese, M., Iyer, B. V., Abrahams, L. J., and Higuchi, W. I., novel topical fluoride delivery system II: remineralization of human teeth, 910
——*see* Yonese, M., 904, 907
Fox, S. W., *see* Nozawa, Y., 385
Foye, W. O., and An, S. H., synthesis of *N*-glycosylthioureas, *N*-glycosylrhodanines, and *N*-glycosyl-2-aminothiazoles and their antimicrobial activity, 1059
——Lai-Chen, Y.-L., and Patel, B. R., inhibition of mucopolysaccharide sulfation, 49
Freeman, A. S., and Martin, B. R., quantification of phencyclidine in mainstream smoke and identification of phenylcyclohex-1-ene as pyrolysis product, 1002
Freeman, J. J., *see* Sowell, J. W., Sr., 135, 537
——*see* Wang, L. D., 699
——*see* Ward, H. E., Jr., 433
Frömming, K. H., Ditter, W., and Horn, D., sorption properties of cross-linked insoluble polyvinylpyrrolidone, 738
Fuchs, J. E., *see* Shargel, L., 599
Fung, H.-L., *see* McNiff, E. F., 1054
Furst, D. E., *see* Day, R. O., 1090
Furuta, T., *see* Baba, S., 780

G

Gabr, M., *see* Soliman, R., 94
Gaginella, T. S., *see* Savina, P. M., 239
Galante, R. N., Egoville, J. C., Visalli, A. J., and Patel, D. M., simultaneous GLC analysis of aspirin and nonaspirin salicylates in pharmaceutical tablet formulations, 167
Gálvez, E., *see* Trigo, G. G., 87
García, I., *see* Tarrus, E., 542
Garrett, E. R., and Barbhaiya, R., prediction of stability in pharmaceutical preparations XVIII: application of high-pressure liquid chromatographic assays to study of nafronyl stability and bioanalysis, 39
Garteiz, D., *see* Weiner, D., 1079
Gasco, M. R., and Trotta, M., determination of hematoporphyrin and protoporphyrin by ion-pair extraction with chlorpromazine, 1294
Gautieri, R. F., *see* McDevitt, J. M., 631
Gaylord, J. C., *see* Whitney, C. C., 462
Gearien, J. E., *see* Wood, L. E., 199
Gehrlein, L., *see* Powers, L. J., 419
Geryes, A., *see* Yanuka, Y., 675, 679
Giacomini, K. M., Roberts, S. M., and Levy, G., evaluation of methods for producing renal dysfunction in rats, 117
Giardinà, D., *see* Angeli, P., 489
Giddings, J. C., *see* Caldwell, K. D., 1350
Gifford, P., *see* Patton, T. F., 1131
Gillilan, R., and Mason, W. D., high-pressure liquid chromatographic determination of viloxazine in human plasma and urine, 220
Girault, J., *see* Fourtillan, J. B., 573
Glasser, A. C., *see* Tan, H. S. I., 693
Glover, W., *see* Dixon, R., 230
Goble, A. J., *see* Horowitz, J. D., 320
Goehl, T. J., *see* Sundaresan, G. M., 702
Golden, L. H., *see* McNiff, E. F., 1054
Goldfarb, A., *see* McNiff, E. F., 1054
Gollamudi, R., Straughn, A. B., and Meyer, M. C., urinary excretion of methenamine and formaldehyde: evaluation of 10 methenamine products in humans, 596
Gonczy, C., *see* Senyei, A. E., 389
Gouda, M. W., *see* Moustafa, M. A., 1172
Grebow, P. E., and Treitman, J. A., pharmacokinetics of indapamide in dogs, 1310
——Treitman, J. A., Yeung, A. K., and Johnston, M. M., semiautomated assay for indapamide in biological fluids, 306
Greenblatt, D. J., *see* Divoll, M., 1104
Greene, D. S., *see* Schwartz, P. A., 114
Gregoriades, D., *see* Alam, A. S., 961
Griffiths, J. C., *see* Hornbeck, C. L., 1163
Grubb, R., *see* Crider, A. M., 1319
Grueneberg, A., *see* Cutie, A., 1085
Grundy, R., *see* Taylor, D. C., 516
Guest, R. T., *see* Byron, P. R., 1265
Guillory, J. K., review of "Solid pharmaceutics: Mechanical Properties and Rate Phenomena," 974
Gupta, B., *see* Cutie, A., 1085
Gupta, S. D., *see* Kamath, B. L., 299
Gurka, D. F., *see* Juenge, E. C., 589
Guy, R. H., and Hadgraft, J., theoretical comparison of release rates of drugs into sink and nonsink conditions, 1243
Gwilt, P. R., general equation for assessing drug removal by extracorporeal devices, 345

H

Habara, T., *see* Sasahara, K., 730, 1157
Haddadin, M., *see* Hirai, S., 403
Hadgraft, J., *see* Guy, R. H., 1243
Haffajee, C., *see* Lesko, L. J., 1366
Haley, T. J., review of "The Use of Alternatives in Drug Research," 838
Hall, I. H., Chapman, J. M., Jr., and Cocolas, G. H., effects of imide analogs on enzymes required for cholesterol and fatty acid synthesis, 326
——Das M. K., Harchelroad, F., Jr., Wisian-Neilson, P., McPhail, A. T., and Spielvogel, B. F., antihyperlipidemic activity of amine cyanoboranes, amine carboxyboranes, and related compounds, 339
——Lee, K. H., Okano, M., Sims, D., Ibuka, T., Liou, Y. F., and Imakura, Y., antitumor agents XLII: comparison of antileukemic activity of helenalin, brusatol, and bruceantin and their esters on different strains of P-388 lymphocytic leukemic cells, 1147
——*see* Drew, J. H., 60
Hall, L. H., *see* Kier, L. B., 583
Hammarlund, E. R., review of "Pharmaceutical Calculations," 2nd Ed., 1094
——sodium chloride equivalents, cryoscopic properties, and hemolytic effects of certain medicinals in aqueous solution IV: supplemental values, 1161
Hanano, M., *see* Igari, Y., 1049
——*see* Yu, H. Y., 323
Haneke, A. C., Crawford, J., and Aszalos, A., quantitation of daunorubicin, doxorubicin, and their aglycones by ion-pair reversed-phase chromatography, 1112

Hanson, R. N., and Davis, M. A., selenium–sulfur analogs III: synthesis and biodistribution of two ^{75}Se-labeled 4-substituted-1,2,3-selenadiazoles, 91
Harchelroad, F., Jr., *see* Hall, I. H., 339
Harland, E. C., *see* Skierkowski, P., 829
Harmatz, J. S., *see* Divoll, M., 1104
Harris, L. S., see Vincek, W. C., 1292
Harris, M. S., preparation and release characteristics of potassium chloride microcapsules, 391
Hayashi, M., see Bourne, D. W. A., 1068
Haynes, J. D., statistical simulation study of new proposed uniformity requirement for bioequivalency studies, 673
Hazzai, A. A. B., *see* Omar, A. M. M. E., 1075
Hefferren, J. J., *see* Yonese, M., 904, 907
Heidemann, D. R., high-pressure liquid chromatographic determination of methscopolamine nitrate, phenylpropanolamine hydrochloride, pyrilamine maleate, and pheniramine maleate in tablets, 820
Heindel, N. D., and Minatelli, J. A., synthesis and antibacterial and anticancer evaluations of α-methylene-γ-butyrolactones, 84
Hellige, G., *see* Wolpers, H. G., 231
Hem, S. L., *see* Feldkamp, J. R., 638
——*see* Hermosin, M. C., 189
——*see* Lipka, E. A., 936
——*see* Shah, D. N., 1101
——*see* Teagarden, D. L., 758, 762, 808
Hennig, U. G., Moskalyk, R. E., Chatten, L. G., and Chan, S. F., semiaqueous potentiometric determinations of apparent pKa_1 values for benzothiadiazines and detection of decomposition during solubility variation with pH studies, 317
Hermosin, M. C., Cornejo, J., White, J. L., and Hem, S. L., sepiolite, a potential excipient for drugs subject to oxidative degradation, 189
Heusner, J. J., and McCormack, J. J., enzymatic assays for 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino) methyl]quinazoline, a promising new "nonclassical" antifolate, 827
Hiestand, E. N., *see* Amidon, G. E., 613
Hignite, C., *see* Day, R. O., 1090
Higuchi, T., *see* Bansal, P. C., 855
——*see* Kovach, I. M., 881
——*see* Nishihata, T., 71
Higuchi, W. I., *see* Feld, K. M., 717, 723
——*see* Flynn, G. L., 52
——*see* Fox, J. L., 910
——*see* Su, C. C., 713
——see Yonese, M., 904, 907
Hill, J. A., *see* Findlay, J. W. A., 624
Himmelstein, K. J., *see* Mooney, K. G., 13, 22, 1358
Hinderling, P. H., *see* Roos, A., 252
Hinkle, G. H., Basmadjian, G. P., Kirschner, A. S., and Ice, R. D., kit preparation of radioiodinated *o*-iodohippuran, 312
Hinsvark, O., *see* Raghunathan, Y., 379
Hirai, S., Hussain, A., Haddadin, M., and Smith, R. B., first-pass metabolism of ethinyl estradiol in dogs and rats, 403
——*see* Hussain, A. A., 466
Hirano, K., *see* Yamada, H., 112, 113
Hirata, M., *see* Koike, M., 308
Hodges, N. A., and Walton, P. G., temperature-dependent effect of edetate disodium on neomycin stability, 960
Hofmann, A. F., *see* Laker, M. F., 1065
——*see* Su, C. C., 713
Hokanson, G. C., and Matyunas, N. J., dry column chromatographic procedures for rapid concentration of biological activity in natural products fractionation, 329
Honda, K., and Nishijima, Y., convenient synthesis of alkyl esters of urocanic acid, 98
Hong, W. H., and Szulczewski, D. H., characteristics of equilibrium reaction of zolazepam, 691
Hooper, R., *see* Jarrott, B., 665
Hooper, W. D., and Smith, M. T., novel source of ubiquitous phthalates as analytical contaminant, 346
Horie, M., *see* Baba, S., 780
Horiuchi, S., *see* Tsuji, A., 1120
Horn, D., *see* Frömming, K. H., 738
Hornbeck, C. L., Floyd, R. A., Griffiths, J. C., and Byfield, J. E., improved liquid chromatographic assay for serum fluorouracil concentrations in the presence of ftorafur, 1163
Horowitz, J. D., Morris, P. M., Drummer, O. H., Goble, A. J., and Louis, W. J., high-performance liquid chromatographic assay of perhexiline maleate in plasma, 320
Hsu, C. C., Dobberstein, R. H., Bingel, A. S., Fong, H. H. S., Farnsworth, N. R., and Morton, J. F., biological and phytochemical investigation of plants XVI: *Strumpfia maritima* (Rubiaceae), 682
Huang, J.-D., *see* Oie, S., 1344
Hubbard, J. W., *see* Midha, K. K., 1043
Huber, H. E., optical characterization of a low solubility organic compound, 1152
Hufford, C. D., Baker, J. K., and Clark, A. M., metabolism of phencyclidine by microorganisms, 155
——Capiton, G. A., Clark, A. M., and Baker, J. K., metabolism of imipramine by microorganisms, 151
Hull, D. A., Muhammad, N., Lanese, J. G., Reich, S. D., Finkelstein, T. T., and Fandrich, S., determination of platinum in serum and ultrafiltrate by flameless atomic absorption spectrophotometry, 500
Hunke, W. A., and Matheson, L. E., Jr., mass transport properties of co(polyether)polyurethane membranes II: permeability and sorption characteristics, 1313
——*see* Matheson, L. E., Jr., 571
Hunneman, D. H., *see* Wolpers, H. G., 231
Hunt, C. A., *see* Pidgeon, C., 173
Hunt, J. P., Shah, V. P., Prasad, V. K., Schuirmann, D. J., and Cabana, B. E., dissolution profiles and specifications for dihydroergotoxine sublingual tablets using a new *in vitro* method, 796
——see Shah, V. P., 833
Huppler, E. G., II, *see* Cascella, P. J., 1128
Hurwitz, A. R., *see* Chien, Y. W., 709
Hussain, A. A., Hirai, S., Bawarshi, R., nasal absorption of natural contraceptive steroids in rats—progesterone absorption, 466
——*see* Akaho, E., 1225
——*see* Hirai, S., 403
——see Iga, K., 108, 939

I

Ibuka, T., *see* Hall, I. H., 1147
Ice, R. D., *see* Hinkle, G. H., 312
——*see* Mills, S. L., 1
Ichihashi, T., *see* Yamada, H., 112, 113
Ichikawa, Y., *see* Asakawa, Y., 710
Ichioka, K., *see* Kurono, Y., 1297
Iga, K., Hussain, A., and Kashihara, T., effect of complex formation between 4-hexylresorcinol and ethyl myristate on release rate of 4-hexylresorcinol from petrolatum base, 939
——Hussain, A., and Kashihara, T., new direct calculation of $K_{1:1}$ and $K_{1:2}$ complexation constants using solubility method, 108
——*see* Akaho, E., 1225
——*see* Yu, H. Y., 323
Igari, Y., Sugiyama, Y., Awazu, S., and Hanano, M., interspecies difference in drug protein binding–temperature and protein concentration dependency: effect on calculation of effective protein fraction, 1049
Ikeda, K., *see* Kurono, Y., 1297
Ikonomovski, K., colorimetric determination of thebaine in *Papaver bracteatum*, 102
Imakura, Y., *see* Hall, I. H., 1147
Isaac, W., *see* Reigle, T. G., 816
Isaac, W. L., *see* Reigle, T. G., 816
Ishida, T., Asakawa, Y., Takemoto, T., and Aratani, T., terpenoids biotransformation in mammals III: biotransformation of α-pinene, β-pinene, pinane, 3-carene, carane, myrcene, and *p*-cymene in rabbits, 406
——*see* Asakawa, Y., 710
Ishikawa, K., *see* Tsuji, A., 1120
Ishizaka, T., Endo, K., and Koishi, M., preparation of egg albumin microcapsules and microspheres, 358
Iyer, B. V., *see* Fox, J. L., 910
——*see* Yonese, M., 907

J

Jackson, A. J., Miller, A. K., and Narang, P. K., human blood preservation: effect on *in vitro* protein binding, 1168
Jalšenjak, I., and Kondo, T., effect of capsule size on permeability of gelatin–acacia microcapsules toward sodium chloride, 456
Janicki, C. A., Walkling, W. D., Erlich, R. H., and Bainbridge, C. A., xilobam: analysis, determination of decomposition products, and assessment of stability, 778
Jansen, A., *see* van de Waterbeemd, H., 1081
Jarowski, C. I., *see* Narurkar, A. N., 810
——*see* Shah, N. H., 611
——*see* Torre, G. M., 114
Jarrott, B., Anderson, A., Hooper, R., and Louis, W. J., high-performance liquid chromatographic analysis of captopril in plasma, 665
Javaid, J. I., and Davis, J. M., GLC analysis of phenylalkyl primary amines using nitrogen detector, 813
Jederström, G., and Russell, G., size exclusion chromatography of liposomes on different gel media, 874
Johnson, J. B., *see* Barry, R. H., 204
Johnson, J. D., *see* Cascella, P. J., 1128
Johnston, M. M., *see* Grebow, P. E., 306
Jones, A. B., *see* Chambliss, W. G., 1248
Jones, G. L., Amato, R. J., Wimbish, G. H., and Peyton, G. A., comparison of anticonvulsant potencies of cyheptamide, carbamazepine, and phenytoin, 618
Jonkman, J. H. G., Westenberg, H. G. M., and Van Der Kleyn, E., hepatic first-pass effect of thiazinamium methylsulfate (*N*-methylpromethazine methylsulfate) in dogs, 947
Judis, J., binding of prostaglandins E_1 (alprostadil), E_2 (dinoprostone), $F_{1\alpha}$, and $F_{2\alpha}$ (dinoprost) to human serum proteins, 945
Juenge, E. C., and Flinn, P. E., quantitative TLC determination of epimeric ratios of 16-methyl 17-ketone oxidation products of dexamethasone and related drugs, 415
——Gurka, D. F., and Kreienbaum, M. A., analysis of drug contamination from parabens in theophylline olamine, 589
Julian, E. A., and Plein, E. M., optical crystallographic properties of drugs of abuse: commonly used amine street drugs, 704
Jusko, W. J., *see* Rocci, M. L., Jr., 1160, 1201

K

Kagami, I., *see* Tsuji, A., 768, 772
Kamath, B. L., Lai, C.-M., Gupta, S. D., Durrani, M. J., and Yacobi, A., pharmacokinetics of procainamide and *N*-acetylprocainamide in rats, 299
——Stampfli, H. F., Lai, C. M., and Yacobi, A., pharmacokinetics of [^{14}C]bretylium tosylate in rats, 667
Kaminski, J. J., *see* Bansal, P. C., 850
——*see* Loftsson, T., 743
Kanke, M., *see* Slack, J. D., 660
Kantor, N., *see* Aszalos, A., 878
Kapetanović, I. M., and Kupferberg, H. J., GC and GC-mass spectrometric determination of *p*-hydroxyphenobarbital extracted from plasma, urine, and hepatic microsomes, 1218
Kapur, P. A., *see* Watson, E., 800
Kar, A., and Aniuha, G. I., spectrophotometric determination of dimenhydrinate with reinecke salt, 690
Karaiskakis, G., *see* Caldwell, K. D., 1350
Karch, F. E., and Chmielewski, K. F., GLC assay for lidocaine in human plasma, 229
Kashihara, T., *see* Iga, K., 108, 939
Kavanagh, F., review of "How to Write and Publish a Scientific Paper," 234
——review of "Official Methods of Analysis of the AOAC, 13th ed.," 468
——review of "Pharmaceutical Microbiology, 2nd Ed.," 116
Kawahara, Y., *see* Sasahara, K., 730
Kawashima, Y., Ohno, H., and Takenaka, H., preparation of spherical matrixes of prolonged-release drugs from liquid suspension, 913
——*see* Takenaka, H., 302, 1256
Kazmi, S., *see* Ali, A., 944
Keim, G. R., *see* Singhvi, S. M., 885, 1108
Keller, F., and Scholle, J., first-pass effect: nonlinear

concept comprising an explicit solution of integrated Michaelis–Menten equation, 195
Kelley, J. A., *see* Poochikian, G. K., 162
Kelley, J. L., McLean, E. W., and Miller, C. A., inhibition of histidine decarboxylase by imidazole derivatives, 341
——Miller, C. A., and Schaeffer, H. J., acyclic puromycin analogs: 9-[(2-phenylalanylamidoethoxy) methyl]adenine and 9-(3-phenylalanylamidopropyl)adenine, 1169
Khalil, S. K. W., see Shimek, J. L., 514
Khoyi, A., *see Shafiee, A., 510*
Khwaja, T. A., *see* Selassie, C. D., 1281
Kibbe, A. H., *see* Chambliss, W. G., 1248
Kido, M., *see* Asakawa, Y., 710
Kier, L. B., quantitation of solvent polarity based on molecular structure, 930
——review of "Drug Design, Vol. IX," 468
——and Hall, L. H., derivation and significance of valence molecular connectivity, 583
Kim, S. W., *see* Song, S. Z., 216
——*see* Zentner, G. M., 975
King, B. S., *see Skierkowski, P., 829*
King, M. M., *see* Pento, J. T., 399
Kinoshita, H., *see* Yamada, H., 112, 113
Kirschbaum, J. J., *see* Patel, B. R., 336
Kirschner, A. S., *see* Hinkle, G. H., 312
Klein, A. E., *see* Smith, R. V., 1144
Kluza, R. B., *see* Newton, D. W., 122
Knight, P. W., *see* Rapaka, R. S., 131
Koike, M., Sugeno, K., and Hirata, M., *sulfoconjugation* and glucuronidation of salicylamide in isolated rat hepatocytes, 308
Koishi, M., *see* Ishizaka, T., 358
Kojima, T., *see* Sasahara, K., 730
Kolczynski, T. M., *see* Crider, A. M., 192
Komolafe, O. O., high-pressure liquid chromatographic analysis of sennosides A and B purgative drugs, 727
Kondo, T., *see* Arakawa, M., 354
——*see* Jalšenjak, I., 455
Kook, C. S., *see* Digenis, G. A., 985
Kool, L. B., *see* Nolen, R. L., Jr., 364
Koplowitz, B., *see* Tse, F. L. S., 395
Korduba, C. A., Veals, J., Radwanski, E., Symchowicz, S., and Chung, M., bioavailability of orally administered propiram fumarate in humans, 521
Koritz, G. D., *see* Bourne, D. W. A., 1068
Kornet, M. J., review of "The Organic Chemistry of Drug Synthesis, Vol. 2," 350
Kosh, J. W., *see* Bauguess, C. T., 46
——*see* Sowell, J. W., Sr., 135, 537
——*see* Wang, L. D., 699
——*see* Ward, H. E., Jr., 433
Kothari, R., *see* Carstensen, J. T., 1095
Koup, J. R., direct linear plotting method for estimation of pharmacokinetic parameters, 1093
Kovach, I. M., Pitman, I. H., and Higuchi, T., amino acid esters of phenols as prodrugs: synthesis and stability of glycine, β-aspartic acid, and α-aspartic acid esters of *p*-acetamidophenol, 881
Kozlowski, J. F., *see* Teagarden, D. L., 758
Kraal, J., *see* Akaho, E., 1225
Krebs, H. A., *see* Yeh, S. Y., 482, 867
Krehel, W. W., *see* Reich, S. D., 268
Kreienbaum, M. A., *see* Juenge, E. C., 589
Kreuter, J., and Liehl, E., long-term studies of microencapsulated and adsorbed influenza vaccine nanoparticles, 367
Krikorian, S. E., review of "Essentials of Drug Product Quality: Concepts and Methodology," 348
Kripalani, K. J., *see* Singhvi, S. M., 885
Kroon, A. M., *see* C. van den Bogert, 186
Kulesza, J. S., *see* Singhvi, S. M., 885
Kupferberg, H. J., *see* Kapetanovic, I. M., 1218
Kurono, Y., Ichioka, K., Mori, S., and Ikeda, K., kinetic study on rapid reaction of trinitrobenzenesulfonate with human serum albumin, 1297
Kwok, R. P., Rose, W. P., Tabor, R., and Pattison, T. S., simultaneous determination of vitamins B_1, B_2, B_6, and niacinamide in multivitamin pharmaceutical preparations by paired-ion reversed-phase high-pressure liquid chromatography, 1014

L

Lahan, G. D., *see* Owoyale, J. A., 963
Lal, C.-M., *see* Kamath, B. L., 299, 667
Lai-Chen, Y.-L., *see* Foye, W. O., 49
Laker, M. F., and Hofmann, A. F., effective therapy of enteric hyperoxaluria: *in vitro* binding of oxalate by anion-exchange resins and aluminum hydroxide, 1065
Lalka, D., review of "Clinical Pharmacokinetics: Concepts and Applications," 973
Lam, G., Chiou, W. L., determination of renal clearance of procainamide in rabbits using arterial and venous plasma, 1373
——*see* Chiou, W. L., 109, 967, 1037
Lanese, J. G., *see* Hull, D. A., 500
Larlon, L. J., *see* Roseman, T. J., 562
Lau, A., *see* Allen, L. V., Jr., 269
Laughlin, S. M., and Carstensen, J. T., relationship *between flow rates of granular powders through* stationary and moving orifices, 711
Lawrence, R. C., *see* Black, D. B., 208
Lazarus, J. H., *see Barry, R. H., 204*
——*see* Shah, N. H., 611
Lee, C., Amos, B., and Matin, S. B., high-performance liquid chromatographic measurement of cloprednol in human plasma, 669
——*see* Suber, R. L., 981
Lee, K.-H., *see* Hall, I. H., 1147
Lee, M. G., *see* Chiou, W. L., 1037
Lee, T. M., and Der Marderosian, A., two-dimensional TLC analysis of ginsenosides from root of dwarf ginseng (*Panax trifolius* L.) Araliaceae, 89
Lee, Y. Y., *see* Bauguess, C. T., 46
Lefebvre, M. A., *see* Fourtillan, J. B., 573
Leffert, F. H., *see* Thompson, J. A., 1284
Lerk, C. F., *see* Bolhuis, G. K., 1328
Lerman, S. J., *see* Ezzedeen, F. W., 889
Le Sher, A. R., *see* Thompson, T. A., 1040
Lesko, L. J., Marion, A., Canada, A. T., and Haffajee, C., high-pressure liquid chromatography of amiodarone in biological fluids, 1366
——*see* Woodford, D. W., 1341
Letourneur, P., *see* Engasser, J. M., 1233
Levinson, R. S., *see* Allen, L. V., Jr., 269
Levy, G., *see* Cocchetto, D. M., 331
——*see* Giacomini, K. M., 117
Levy, R. H., *see* Viswanathan, C. T., 1279
Li, W.-S., *see* Clark, A. M., 951
Lieberman, B. L., *see* Roseman, T. J., 646
Liehl, E., *see* Kreuter, J., 367
Lien, E. J., *see* Selassie, C. D., 1281
Lim, F., and Moss, R. D., microencapsulation of living cells and tissues, 351
Lin, A. J., and Driscoll, J. S., catecholamine analogs as potential antitumor agents II, 806
Lin, K.-T., Momparler, R. L., and Rivard, G. E., high-performance liquid chromatographic analysis of chemical stability of 5-aza-2′-deoxycytidine, 1228
Lin, S.-F., and Connors, K. A., kinetics of *trans*-cinnamic anhydride reactions catalyzed by pyridine, 4-dimethylaminopyridine, and *N*-methylimidazole, 235
Lin, S.-N., Wang, T.-P. F., Caprioli, R. M., and Mo, B. P. N., determination of plasma fentanyl by GC–mass spectrometry and pharmacokinetic analysis, 1276
Lin, S. Y., *see* Takenaka, H., 302, 1256
Lindley, M. G., *see* Birch, G. G., 277
Linn, E. E., *see* Chowhan, Z. T., 243
Liou, Y. F., *see* Hall, I. H., 1147
Lipka, E. A., Feldkamp, J. R., White, J. L., and Hem, S. L., investigation of gel structure of aluminum hydroxycarbonate gel using a tension cell, 936
Locock, R. A., *see* Moskalyk, R. E., 496
Loeffler, L. J., *see* Drew, J. H., 60
Loftsson, T., Kaminski, J. J., and Bodor, N., improved delivery through biological membranes VII: design, synthesis, and *in vivo* testing of true prodrugs of aspirin, 743
——and Bodor, N., improved delivery through biological membranes IX: kinetics and mechanism of hydrolysis of methylsulfinylmethyl 2-acetoxybenzoate and related aspirin prodrugs, 750
——and Bodor, N., improved delivery through biological membranes X: percutaneous absorption and metabolism of methylsulfinylmethyl 2-acetoxybenzoate and related aspirin prodrugs, 756
Louis, W. J., *see* Drummer, O. H., 1030
——*see* Horowitz, J. D., 320
——*see* Jarrott, B., 665
Loveday, B., *see* Taylor, D. C., 516
Lovering, E. G., *see* Black, D. B., 208
Luders, R. C., and Chao, D., effect of pirprofen on *protein binding on warfarin and tolbutamide in* human plasma, 1370
Lui, C. Y., *see* Chiou, W. L., 109
Lynch, V. D., *see* Torre, G. M., 114

M

Maal, L., *see* Noordam, A., 96
Mackie, J. F., Jr., *see* Newton, D. W., 122
Madan, D. K., *see* Cadwallader, D. E., 442
Madan, P. L., clofibrate microcapsules II: effect of wall thickness on release characteristics, 430
Magarian, R. A., review of "The Basis of Medicinal Chemistry: Burger's Medicinal Chemistry, 4th Ed., Part I," 348
——*see* Pento, J. T., 399
Mak, A. L. C., *see* Moskalyk, R. E., 496
Malick, A. W., Amann, A. H., Baaske, D. M., and Stoll, R. G., loss of nitroglycerin from solutions to intravenous plastic containers: a theoretical treatment, 798
Mandrou, B., *see Fabre, H., 460*
Manius, G., Tscherne, R., Venteicher, R., and Secker, A., high-performance liquid chromatographic determination of free myxin and its reduction product as impurities in cuprimyxin-containing creams, 1024
Mann, D. E., Jr., review of "Goodman and Gilman's The Pharmacological Basis of Therapeutics: 6th Ed.," 581
——*see* McDevitt, J. M., 631
Manzini, G., *see* Delben, F., 892
Marion, A., Martin A., and Carstensen, J., extended solubility approach: solubility parameters for crystalline solid compounds, 170
——Paruta, A. N., and Adjei, A., extended Hildebrand solubility approach: methylxanthines in mixed solvents, 1115
——Wu, P. L., Adjei, A., Beerbower, A., and Prausnitz, J. M., extended Hansen solubility approach: naphthalene in individual solvents, 1260
——see McGinity, J. W., 372
Martin, B. R., *see* Freeman, A. S., 1002
——*see* Vincek, W. C., 1292
Martin, G. E., ^{13}C-NMR experimental methods for determination of resonance multiplicities: *Strychnos* alkaloids, 81
Martinez, L., *see* Reich, S. D., 268
Martinez, M., *see* Trigo, G. G., 87
Marty, J.-P., *see* Carstensen, J. T., 222
——*see* Fessi, H., 1005
Marzilli, L. G., *see* Burns, H. D., 436
——*see* Dannals, R. F., 439
Mason, W. D., and Amick, E. N., high-pressure liquid chromatographic analysis of phenylpropanolamine in human plasma following derivatization with *O*-phthalaldehyde, 707
——and Winer, N., kinetics of aspirin, salicylic acid, and salicyluric acid following oral administration of aspirin as a tablet and two buffered solutions, 262
——*see* Gillilan, R., 220
Masoud, A. N., *see* Ezzedeen, F. W., 889
Matheson, L. E., Jr., and Hunke, W. A., mass transport properties of co(polyether) polyurethane membranes I: preparation and characterization, 571
——*see* Hunke, W. A., 1313
Matin, S. B., *see* Fass, M., 1338
——*see* Lee, C., 669
——*see* Nerenberg, C., 900
——*see* Tsina, I. W., 858
Matsuoka, K., *see* Tsubouchi, M., 1286
Mattocks, A. M., *see* Williams, M. G., 576
Mattson, R. J., *see* Sowell, J. W., Sr., 135
Matyunas, N. J., *see* Hokanson, G. C., 329
May, E. L., *see* Vincek, W. C., 1292
Mayersohn, M., area under the plasma concentration–time curve resulting from constant-rate drug input, 1296
McCormack, J. J., *see* Heusner, J. J., 827
McDevitt, J. M., Gautieri, R. F., and Mann, D. E., Jr.,

comparative teratogenicity of cortisone and phenytoin in mice, 631
McErlane, K. M., *see* Pilai, G. K., 1072
McGilveray, I. J., Midha, K. K., Rowe, M., Beaudoin, N., and Charette, C., bioavailability of 11 quinidine formulations and pharmacokinetic variation in humans, 524
——*see* Midha, K. K., 1043
——*see* Sved, S., 1368
McGinity, J. W., review of "Controlled Release of Bioactive Materials," 837
——Martin, A., Cuff, G. W., and Combs, A. B., influences of matrixes on nylon-encapsulated pharmaceuticals, 372
McGlinchey, G., *see* Spillane, W. J., 933
McKibben, D. M., *see* Tan, H. S. I., 693
McLean, E. W., *see* Kelley, J. L., 341
McLean, W. M., *see* Sved, S., 1368
McNeil, J., *see* Drummer, O. H., 1030
McNiff, E. F., Yacobi, A., Young-Chang, F. M., Golden, L. H., Goldfarb, A., and Fung, H.-L., nitroglycerin pharmacokinetics after intravenous infusion in normal subjects, 1054
McPhail, A. T., *see* Hall, I. H., 339
Mechoulam, R., *see* Bialer, M., 822
Medwick, T., *see* Castellano, T., 104
Meeker, F. S., Jr., *see* Singhvi, S. M., 885
Melamed, S., *see* Belair, E. J., 347
Melchiorre, C., *see* Angeli, P., 489
Menon, G. N., and Norris, B. J., simultaneous determination of hydroxyzine hydrochloride and benzyl alcohol in injection solutions by high-performance liquid chromatography, 697
——and Norris, B. J., simultaneous determination of tetracaine and its degradation product, *p-n*-butylaminobenzoic acid, by high-performance liquid chromatography, 569
——and White, L. B., simultaneous determination of hydrochlorothiazide and triamterene in capsule formulations by high-performance liquid chromatography, 1083
Mertes, M., *see* Bansal, P. C., 850
Metzler, C. M., and Tong, D. D. M., computational problems of compartment models with Michaelis–Menten-type elimination, 733
Meyer, M. C., review of "Applied Biopharmaceutics and Pharmacokinetics," 1179
——*see* Gollamudi, R., 596
——*see* Raghow, G., 1166
——*see* Yau, M. K. T., 1017
Meyer, S. L., *see* Feldkamp, J. R., 638
Midha, K. K., Cooper, J. K., McGilveray, I. J., Butterfield, A. G., and Hubbard, J. W., high-performance liquid chromatographic assay for nanogram determination of chlorpromazine and its comparison with a radioimmunoassay, 1043
——*see* McGilveray, I. J., 524
Migdalof, B. H., *see* Singhvi, S. M., 885, 1108
Migliaccio, G. P., and Byrn, S. R., comparisons of rotamer populations of nialamide, azaperone, and chloroquine in solid state and in solution, 284
Milano, E. A., *see* Waraszkiewicz, S. M., 1215
Millar, J. F., *see* Taguchi, V. Y., 64
Miller, A. K., *see* Jackson, A. J., 1168
Miller, C. A., *see* Kelley, J. L., 341, 1169
Mills, S. L., Basmadjian, G. P., and Ice, R. D., radiopharmaceuticals used in myocardial imaging, 1
Minatelli, J. A., *see* Heindel, N. D., 84
Minier, M., *see* Engasser, J. M., 1233
Mintun, M. A., *see* Mooney, K. G., 13, 22, 1358
Miskell, D. L., *see* Crider, A. M., 192
Mitchell, A. G., *see* Suryanarayanan, R., 968
Mitsushio, H., *see* Tsubouchi, M., 1286
Miyazaki, S., Oshiba, M., and Nadai, T., precaution on use of hydrochloride salts in pharmaceutical formulation, 594
Mizutani, T., estimation of protein and drug adsorption onto silicone-coated glass surfaces, 493
Mo, B. P. N., *see* Lin, S.-N., 1276
Mohamadpour, M., *see* Shafiee, A., 510
Mohamed, H. F., *see* Soliman, R., 606, 952
Molokhia, A. M., *see* Moustafa, M. A., 1172
Momparler, R. L., *see* Lin, K.-T., 1228
Monbaliu, J. G., Rosseel, M. T., and Bogaert, M. G., analysis of methoxsalen in plasma by reversed-phase high-performance liquid chromatography, 965
Mooney, K. G., Mintun, M. A., Himmelstein, K. J., and Stella, V. J., dissolution kinetics of carboxylic acids II: effect of buffers, 22
——Mintun, M. A., Himmelstein, K. J., and Stella, V. J., dissolution kinetics of carboxylic acids I: effect of pH under unbuffered conditions, 13
——Rodriguez-Gaxiola, M., Mintun, M. A., Himmelstein, K. J., and Stella, V. J., dissolution kinetics of phenylbutazone, 1358
Mori, S., *see* Kurono, Y., 1297
Morioka, T., *see* Sasahara, K., 730, 1157
Morris, P. M., *see* Horowitz, J. D., 320
Morton, J. F., *see* Hsu, C. C., 682
Moskalyk, R. E., Mak, A. L. C., Chatten, L. G., and Locock, R. A., synthesis of tetracycline ring A analogs, 496
——*see* Hennig, U. G., 317
Moss, J. N., *see* Belair, E. J., 347
Moss, R. D., *see* Lim, F., 351
Moustafa, M. A., Molokhia, A. M., and Gouda, M. W., phenobarbital solubility in propylene glycol–glycerol–water systems, 1172
Mouzin, G., *see* Cousse, H., 1245
Mubarak, P. F., *see* Sowell, J. W., Sr., 135, 537
Muhammad, N., *see* Hull, D. A., 500
Müller, W. E., *see* Fehske, K. J., 549
Munson, J. W., review of "Drug Level Monitoring—Analytical Techniques, Metabolism, and Pharmacokinetics," 349
——and Wilson, T. D., high-performance liquid chromatographic determination of hydrocortisone cypionate: method development and characterization of chromatographic behavior, 177
Murphy, J. C., *see* Skierkowski, P., 829
——*see* Watson, E. S., 785
Murro, A. F., *see* Ebling, W. F., 224
Myers, M. N., *see* Caldwell, K. D., 1350
Myre, S. A., *see* Bucci, A. J., 999

N

Nadai, T., *see* Miyazaki, S., 594
Nagwekar, J. B., and Cheon, J. W., pharmacokinetic evidence for possible renal accumulation of model organic anions in rats, 295
Nakagawa, H., *see* Baba, S., 780
Nakajima, E., *see* Sasahara, K., 730, 1157
Nakashima, E., *see* Tsuji, A., 768, 772, 1120
Nambu, N., *see* Yonese, M., 904
Narang, P. K., *see* Jackson, A. J., 1168
Narurkar, A. N., and Jarowski, C. I., modified colorimetric method for plasma prednisolone, 810
Nash, J. F., *see* Bopp, R. J., 507
Nation, R. L., *see* Petersen, M. C., 1139
Neiman, Z., and Quinn, F. R., quantitative structure–activity relationships of purines I: choice of parameters and prediction of pKa values, 425
Nelis, H. J. C. F., and De Leenheer, A. P., evidence for metabolic inertness of doxycycline, 226
Nelson, K. G., *see* Roseman, T. J., 646
Nerenberg, C., and Matin, S. B., radioimmunoassay of flunisolide in human plasma, 900
Neumann, M. G., and De Groote, R. A. M. C., synthesis, structure, and features of anilinium anilinomethanesulfonates, 863
Newton, D. W., Breen, P. J., Brown, D. E., Mackie, J. F., Jr., and Kluza, R. B., physicochemical characteristics of patent blue violet dye, 122
Nicholes, W., *see* Chambliss, W. G., 1248
Nichols, D. E., structure–activity relationships of phenethylamine hallucinogens, 839
Nishide, K., *see* Tsuji, A., 1120
Nishihata, T., Rytting, J. H., and Higuchi, T., effects of salicylate on rectal absorption of theophylline, 71
Nishijima, Y., *see* Honda, K., 98
Nishio, A., *see* Uyeki, E. M., 1011
Nisi, C., *see* Delben, F., 892
Nitanai, T., *see* Sasahara, K., 730, 1157
Nixon, J. R., *in vitro* and *in vivo* release of microencapsulated chlorothiazide, 376
Nolen, R. L., Jr., and Kool, L. B., microencapsulation and fabrication of fuel pellets for inertial confinement fusion, 364
Noordam, A., Maat, L., and Beyerman, H. C., quantitative determination of pilocarpine, isopilocarpine, pilocarpic acid, and isopilocarpic acid in clinical ophthalmic pilocarpine formulations by reversed-phase liquid chromatography, 96
Norris, B. J., *see* Menon, G. N., 569, 697
Notari, R. E., *see* Byron, P. R., 1265
Nozawa, Y., and Fox, S. W., microencapsulation of methylglyoxal and two derivatives, 385
Nuessle, N. O., review of "Phamaceutical Calculations, 7th Ed.," 715

O

Ohno, H., *see* Kawashima, Y., 913
Øie, S., and Huang, J.-D., influence of administration route on drug delivery to target organ, 1344
Okano, M., *see* Hall, I. H., 1147
Okerholm, R., *see* Weiner, D., 1079
Omar, A. M. M. E., Farghaly, A. M., Hazzai, A. A. B., Eshba, N. H., Sharabi, F. M., and Daabees, T. T., thiourea and thiosemicarbazide derivatives structurally related to hexestrol: synthesis and anticancer and other pharmacological properties, 1075
O'Neill, P. J., plasma protein binding of zomepirac sodium, 818
Oscarson, D. W., Van Scoyoc, G. E., and Ahlrichs, J. L., effect of poly-2-vinylpyridine-*N*-oxide and sucrose on silicate-induced hemolysis of erythrocytes, 657
Oshiba, M., *see* Miyazaki, S., 594
Osuide, G., *see* Owoyale, J. A., 963
Otani, T. T., and Briley, M. R., effect of chloroacetyl derivatives of *para*-substituted phenylalanines on microbial antitumor prescreens, 464
Ovadia, H., *see* Widder, K. J., 387
Owoyale, J. A., Lahan, G. D., Osuide, G., and Edafiogho, I. O., succinimides with oxyacetate side chain as potential anticonvulsant agents, 963

P

Pantarotto, C., Salmona, M., Fanelli, R., Bianchi, M., and Szczawinska, K., GLC–mass fragmentographic determination of saccharin in biological fluids, 871
Paoletti, S., *see* Delben, F., 892
Park, J. Y., *see* Su, C. C., 713
Parravicini, F., *see* Ventura, P., 334
Parrott, E. L., densification of powders by concavo-convex roller compactor, 288
——review of "Introduction to Pharmaceutical Dosage Forms," 1094
——thermal hardness coefficient of tablets, 328
——*see* Carmichael, G. R., 1331
Paruta, A. N., *see* Martin, A., 1115
Pashko, L., *see* Abou-Gharbia, M., 1154
Patel, B. R., Kirschbaum, J. J., and Poet, R. B., high-pressure liquid chromatography of nadolol and other β-adrenergic blocking drugs, 336
——*see* Foye, W. O., 49
Patel, D. M., *see* Galante, R. N., 167
Paterson, P. Y., *see* Widder, K. J., 387
Pattison, T. S., *see* Kwok, R. P., 1014
Patton, T. F., and Gilford, P., effect of various vehicles and vehicle volumes on oral absorption of triamterene in rats, 1131
Paulus, H. E., *see* Day, R. O., 1090
Pedersen, P. V., pharmacokinetic analysis by linear system approach I: cimetidine bioavailability and second peak phenomenon, 32
Pento, J. T., Magarian, R. A., Wright, R. J., King, M. M., and Benjamin, E. J., nonsteroidal estrogens and antiestrogens: biological activity of cyclopropyl analogs of stilbene and stilbenediol, 399
Petersen, M. C., Vine, J., Ashley, J. J., and Nation, R. L., leaching of 2-(2-hydroxyethylmercapto) benzothiazole into contents of disposable syringes, 1139
Peterson, A. E., *see* Singhvi, S. M., 1108
Pettersen, J. E., Teien, G., and Ulsaker, G. A., identification of 2-chlorothioxanthen-9-one in gastric aspirate in a case of chlorprothixene poisoning, 812
Peyton, G. A., *see* Jones, G. L., 618
Pfeffer, M., and Van Harken, D. R., effect of dosing volume on intramuscular absorption rate of aminoglycosides, 449
Phillips, T. A., *see* Barbhaiya, R. H., 291
Pidgeon, C., and Hunt, C. A., calculating number and surface area of liposomes in any suspension, 173

Pierson, C. L., *see* Behl, C. R., 835
Pifferi, G., *see* Ventura, P., 334
Pillai, G. K., and McErlane, K. M., quantitative determination of conjugated estrogens in formulations by capillary GLC, 1072
Pitman, I. H., and Rostas, S. J., topical drug delivery in cattle and sheep, 1181
——*see* Anderson, J. R., 651
——*see* Bansal, P. C., 850, 855
——*see* Kovach, I. M., 881
Plaizier-Vercammen, J. A., and De Nève, R. E., interaction of povidone with aromatic compounds II: evaluation of ion strength, buffer concentration, temperature and pH by factorial analysis, 1252
Plakogiannis, F. M., *see* Ali, A., 944
——*see* Sotiropoulus, J. B., 422
Plein, E. M., *see* Julian, E. A., 704
Poet, R. B., *see* Patel, B. R., 336
Poochikian, G. K., and Cradock, J. C., 2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone I: kinetics in aqueous solutions by high-performance liquid chromatography, 159
——and Kelley, J. A., 2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone II: isolation and characterization of degradation products, 162
Poust, R. I., *see* Chen, S. T., 1288
Powers, L. J., Eckert, D. J., and Gehrlein, L., isolation and identification of impurities in 4-acetyl-2-(2′-hydroxyethyl)-5,6-bis(4-chlorophenyl)-2*H*-pyridazin-3-one, an antihypertensive agent, 419
Prabhu, V. A., Brown, R. G., and Delgado, J. N., synthesis and structure–activity relationships of selected tricyclic oxime *O*-ethers as potential anticholinergic agents, 558
Prasad, P. N., *see* Bolton, B. A., 789
Prasad, V. K., *see* Hunt, J. P., 796
——*see* Rapaka, R. S., 131
——*see* Shah, V. P., 833
——*see* Sundaresan, G. M., 702
Pratt, C. B. *see* Evans, W. E., 1194
Prausnitz, J. M., *see* Martin, A., 1260
Price, J. C., *see* Wu, S. C., 685
Prieto, J. G., *see* Salto, F., 994
Pritchard, E., *see* Drummer, O. H., 1030
Puglisi, C. V., *see* Stoltenborg, J. K., 1207
Puisieux, F., *see* Carstensen, J. T., 222
——*see* Fessi, H., 1005
——*see* Vaution, C., 1238

Q

Quinn, F. R., *see* Neiman, Z., 425

R

Radavich, J. F., *see* Teagarden, D. L., 762
Radwanski, E., *see* Korduba, C. A., 521
Rahn, P. D., *see* Snider, B. G., 1347
Raghow, G., and Meyer, M. C., high-performance liquid chromatographic assay of tolbutamide and carboxytolbutamide in human plasma, 1166
Raghunathan, Y., Amsel, L., Hinsvark, O., and Bryant, W., sustained-release drug delivery system I: coated ion-exchange resin system for phenylpropanolamine and other drugs, 379
Raimondo, T. J., *see* Tse, F. L. S., 395
Rao, N. G. S., *see* Shirnek, J. L., 514
Rapaka, R. S., Knight, P. W., and Prasad, V. K., reversed-phase high-performance liquid chromatographic analysis of liothyronine sodium and levothyroxine sodium in tablet formulations: preliminary studies on dissolution and content uniformity, 131
Ravis, W. R., and Chen, C.-Y., dissolution, stability, and absorption characteristics of dicumarol in polyethylene glycol 4000 solid dispersions, 1353
Rawat, A. K., *see* Crider, A. M., 1319
Reich, S., D., Martinez, L., Krehel, W. W., and Bickler, J. R., addendum to anthracycline assay by high-pressure liquid chromatography: modification of mobile phase for aminocyanosilica columns used for anthracycline assay, 268
——*see* Averbuch, S. D., 265
——*see* Hull, D. A., 500
——*see* Senyei, A. E., 389
Reigle, T. G., Isaac, W. L., and Isaac, W., behavioral and neurochemical interactions of dextroamphetamine and methylphenidate in rats, 816
Reiman, R. E., *see* Digenis, G. A., 985
Repta, A. J., and Beltagy, Y. A., oxidative degradation of 6-selenoguanosine in aqueous solutions, 634
Resetarits, D. E., *see* Ebling, W. F., 224
Rhodes, C. T., *see* Schwartz, P. A., 114
Ribet, J.-P., *see* Cousse, H., 860, 1245
Riffee, W. H., *see* Smith, R. V., 1144
Rippie, E. G., and Danielson, D. W., viscoelastic stress/strain behavior of pharmaceutical tablets: analysis during unloading and postcompression periods, 476
Rivard, G. E., *see* Lin, K.-T., 1228
Roberts, M. S., *see* Cossum, P. A., 832
Roberts, S. M., *see* Giacomini, K. M., 117
Robinson, C., *see* Allen, L. V., Jr., 269
Robinson, J. R., *see* Sieg, J. W., 1026
Rocci, M. L., Jr., and Jusko, W. J., blood collection technique: no effect on *in vitro* protein binding of prednisolone, 1160
——and Jusko, W. J., dose-dependent protein binding and disposition of prednisolone in rabbits, 1201
Rodriguez-Gaxiola, M., *see* Mooney, K. G., 1358
Rogers, G., *see* Bayne, W. F., 75
Roos, A., and Hinderling, P. H., protein binding and erythrocyte partitioning of the antirheumatic proquazone, 252
Rose, W. P., *see* Kwok, R. P., 1014
Roseman, T. J., Derr, G. R., Nelson, K. G., Lieberman, B. L., and Butler, S. S., continuous flow bead-bed dissolution apparatus for suppositories, 646
——Larion, L. J., and Butler, S. S., transport of prostaglandins through silicone rubber, 562
——*see* Valvani, S. C., 502
Ross, J. J., Jr., *see* Singhvi, S. M., 885, 1108
Rosseel, M. T., and Bogaert, M. G., high-performance liquid chromatographic determination of propranolol and 4-hydroxypropranolol in plasma, 688
——*see* Monbaliu, J. G., 965
Rost, W. J., *see* Weinstock, L. T., 956
Rostas, S. J., *see* Pitman, I. H., 1181
Rowe, M., *see* McGilveray, I. J., 524
Rubin, H., *see* Barry, R. H., 204
Rubio, F., *see* Stoltenborg, J. K., 1207
Rudawsky, G., *see* Bourne, D. W. A., 1068
Runikis, J. O., *see* Au, D. S.-L., 917
Russ, G. A., *see* Digenis, G. A., 985
Russell, G., *see* Jederström, G., 874
Rytting, J. H., *see* Nishihata, T., 71

S

Sadik, F., review of "Sustained Release Medications," 716
Said, S. A., and Abdullah, M. E., effect of antacids on activity of oral hypoglycemics, 621
——and Al-Shora, H. I., hypoglycemic activity of oral hypoglycemics with increased hydrophilicity, 67
Salmona, M., *see* Pantarotto, C., 871
Salter, F. J., review of "Iatrogenic Diseases, 2nd Ed.," 116
Salto, F., and Prieto, J. G., interactions of cephalosporins and penicillins with nonpolar macroporous styrenedivinylbenzene copolymers, 994
Sarapu, A. C., *see* Tafolla, W. H., 1273
Sarhan, F., *see* Engasser, J. M., 1233
Sasahara, K., Nitanai, T., Habara, T., Kojima, T., Kawahara, Y., Morioka, T., and Nakajima, E., dosage form design for improvement of bioavailability of levodopa IV: possible causes of low bioavailability of oral levodopa in dogs, 730
——Nitanai, T., Habara, T., Morioka, T., and Nakajima, E., dosage form design for improvement of bioavailability of levodopa V: absorption and metabolism of levodopa in intestinal segments of dogs, 1157
Savina, P. M., Staubus, A. E., Gaginella, T. S., and Smith, D. F., optimal perfusion rate determined for *in situ* intestinal absorption studies in rats, 239
Sawada, Y., *see* Yu, H. Y., 323
Sawchuk, R. J., *see* El-Yazigi, A., 452
Schaeffer, H. J., *see* Kelley, J. L., 1169
Schenk, G. H., *see* Street, K. W., Jr., 641
Schmedding, D. W., *see* Chiou, C. T., 1176
Schoenewaldt, E. F., *see* Smith, G. B., 272
Scholle, J., *see* Keller, F., 195
Schott, H., electrokinetic studies of magnesium hydroxide, 486
Schuirmann, D. J., *see* Hunt, J. P., 796
Schulman, S. G., *see* Visor, G. C., 469
Schwartz, A., *see* Abou-Gharbia, M., 1154
Schwartz, P. A., Greene, D. S., and Rhodes, C. T., effect of variation of plasma oleic acid concentration on relative concentration of free and protein bound warfarin, 114
Sciarra, J., *see* Cutie, A., 1085
Scott, B. S., Dunn, D. L., and Dorsey, E. D., analysis of pilocarpine and isopilocarpine in ophthalmic solutions by UV spectrophotometry-polarimetry, 1046
——*see* Dunn, D. L., 446
Scrime, M., and Edelson, J., concentration of perfluorohexyl bromide in dog plasma and selected tissues, 1199
Sears, D. J., *see* Snider, B. G., 1347
Secker, A., *see* Manius, G., 1024
Segura, J., *see* Tarrus, E., 542
Selassie, C. D., Lien, E. J., and Khwaja, T. A., synthesis and evaluation of guanazole prodrugs as antineoplastic agents, 1281
Sennello, L. T., *see* Chu, S. Y., 990
Senyei, A. E., Reich, S. D., Gonczy, C., and Widder, K. J., *in vivo* kinetics of magnetically targeted low-dose doxorubicin, 389
——*see* Widder, K. J., 387
Shada, D. M., *see* Elrod, L., Jr., 793
Shader, R. I., *see* Divoll, M., 1104
Shafiee, A., Mohamadpour, M., Abtahi, F., and Khoyi, A., synthesis and antihistaminic activity of 1-[(4-substituted-1,2,3-thiadiazol-5-yl)arylmethyl]-4-methylpiperazines, 510
——Vossoghi, M., Wossooghi, J., and Yazdani, S., synthesis and antibacterial and antifungal activities of alkyl and polyhalophenyl esters of benzo[*b*]thiophene-3-carbamic acid, 566
Shah, D. N., White, J. L., and Hem, S. L., mechanism of interaction between polyols and aluminum hydroxide gel, 1101
——*see* Feldkamp, J. R., 638
Shah, N. H., Lazarus, J. H., Sheth, P. R., and Jarowski, C. I., carboxymethylcellulose: effect of degree of polymerization and substitution on tablet disintegration and dissolution, 611
Shah, S. A., *see* Carmichael, G. R., 1331
Shah, V. P., Hunt, J. P., Prasad, V. K., and Cabana, B. E., comparison of plasma and urine analyses for thiazides in bioavailability/bioequivalence study, 833
——*see* Hunt, J. P., 796
Shallenberger, R. S., *see* Birch, G. G., 277
Shami, E. G., *see* Chien, Y. W., 709
Sharabi, F. M., *see* Omar, A. M. M. E., 1075
——*see* Soliman, R., 94
Shargel, L., Stevens, J. A., Fuchs, J. E., and Yu, A. B. C., effect of antacid on bioavailability of theophylline from rapid and timed-release drug products, 599
Shaw, J. M., *see* Singhvi, S. M., 885, 1108
Shenouda, L. S., *see* Bucci, A. J., 999
Sheth, P. R., *see* Shah, N. H., 611
Shimek, J. L., Rao, N. G. S., and Khalil, S. K. W., high-pressure liquid chromatographic determination of ibuprofen in plasma, 514
Shimizu, T., *see* Tsuji, A., 1120
Shinkai, J. H., *see* Castellano, T., 104
Shroot, B., *see* Caron, J.-C., 1205
Shum, Y. Y., *see* Sinsheimer, J. E., 546
Sideman, M. B., effect of elevated blood glucose levels on hepatic microsomal enzyme system in rats, 695
Sieg, J. W., and Robinson, J. R., mechanistic studies on transcorneal permeation of fluorometholone, 1026
Siest, G., *see* Engasser, J. M., 1233
Siew, P. Y., *see* Byrn, S. R., 280
Simmons, G. H., *see* Slack, J. D., 660
Simonotti, L., *see* Ventura, P., 334
Sims, B. E., *see* Chow, S.-L., 924
Sims, D., *see* Hall, I. H., 1147
Singhvi, S. M., Kripalani, K. J., Dean, A. V., Keim, G. R., Kulesza, J. S., Meeker, F. S., Jr., Ross, J. J., Jr., Shaw, J. M., and Migdalof, B. H., absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet, 885
——Peterson, A. E., Ross, J. J., Jr., Shaw, J. M., Keim, G. R., and Migdalof, B. H., pharmacokinetics of

captopril in dogs and monkeys, 1108
Sinsheimer, J. E., and Shum, Y. Y., biodehalogenation and metabolism of [^{125}I]-4-iodobiphenyl, 546
Sjöholm, I., and Stjerna, B., binding of drugs to human serum albumin XVII: irreversible binding of mercaptopurine to human serum proteins, 1290
——*see* Edman, P., 684
Sklerkowski, P., ElSohly, M. A., Harland, E. C., King, B. S., Murphy, J. C., and Watson, E. S., immunological studies of poisonous Anacardiaceae: effect of vehicle on absorption of 3-*n*-pentadecylcatechol and its diacetate ester derivative after oral feeding in rats, 829
——*see* Chambliss, W. G., 1248
——*see* Watson, E. S., 785
Slack, J. D., Kanke, M., Simmons, G. H., and DeLuca, P. P., acute hemodynamic effects and blood pool kinetics of polystyrene microspheres following intravenous administration, 660
Slattery, J. T., single-point maintenance dose prediction: role of interindividual differences in clearance and volume of distribution in choice of sampling time, 1174
Smallenbroek, A. J., *see* Bolhuis, G. K., 1328
Smith, D. F., *see* Savina, P. M., 239
Smith, D. P., *see* Amidon, G. E., 613
Smith, G. B., and Schoenewaldt, E. F., stability of *N*-formimidoylthienamycin in aqueous solution, 272
Smith, M. T., *see* Hooper, W. D., 346
Smith, R. B., *see* Hirai, S., 403
Smith, R. V., Klein, A. E., Wilcox, R. E., and Riffee, W. H., apomorphine: bioavailability and effect on stereotyped cage climbing in mice, 1144
Snider, B. G., Beaubien, L. J., Sears, D. J., and Rahn, P. D., determination of flurbiprofen and ibuprofen in dog serum with automated sample preparation, 1347
Solne, W. H., analytical determination of purity of 1-piperidinocyclohexanecarbonitrile and its hydrobromide salt, 106
Soliman, R., and Feid-Allah, H. M., preparation and antidiabetic activity of new 3-methyl-5-phenylpyrazolesulfonylurea derivatives, 602
——Feid-Allah, H. M., El Sadany, S. K., and Mohamed, H. F., preparation and antidiabetic activity of new substituted 3,5-diarylpyrazolesulfonylurea derivatives, 606
——Feid-Allah, H. M., and Mohamed, H. F., preparation and antidiabetic activity of cyclic sulfonylthiourea derivatives, 952
——Gabr, M., Abouzeit-Har, M. S., and Sharabi, F. M., formation of thiazoles, thiazines, and thiadiazines from 1-phthalazine thiosemicarbazides as potential anticonvulsants, 94
Song, S. Z., Cardinal, J. R., Kim, S. H., and Kim, S. W., progestin permeation through polymer membranes V: progesterone release from monolithic hydrogel devices, 216
Sotiropoulus, J. B., Deutsch, T., and Plakogiannis, F. M., comparative bioavailability of three commercial acetaminophen tablets, 422
Sowa, D. T., *see* Burns, H. D., 436
Sowell, J. W., Sr., Block, A. J., Derrick, M. E., Freeman, J. J., Kosh, J. W., Mattson, R. J., Mubarak, P. F., and Tenthorey, P. A., synthesis of alkylaminoalkylamides of substituted 2-aminopyrroles as potential local anesthetic and antiarrhythmic agents I: α-amines, 135
——Block, A. J., Derrick, M. E., Freeman, J. J., Kosh, J. W., Mubarak, P. F., and Tenthorey, P. A., synthesis of alkylaminoalkylamides of substituted 2-aminopyrroles as potential local anesthetic and antiarrhythmic agents II: β-amines, 537
——*see* Wang, L. D., 699
——*see* Ward, H. E., Jr., 433
Spielvogel, B. F., *see* Hall, I. H., 339
Spillane, W. J., and McGlinchey, G., structure—activity studies on sulfamate sweeteners II: semiquantitative structure–taste relationships for sulfamate ($RNHSO_3^-$) sweeteners—the role of R, 933
Stampfli, H. F., *see* Kamath, B. L., 667
Staubus, A. E., *see* Savina, P. M., 239
Stella, V. J., *see* Mooney, K. G., 13, 22, 1358
Stellwaag, M., *see* Wolpers, H. G., 231
Stevens, J. A., *see* Shargel, L., 599
Stjerna, B., *see* Sjöholm, I., 1290
Stohs, S. J., review of "Concepts in Drug Metabolism, Part A.," 116
——review of "Progress in Drug Metabolism," Vol. 5, 1179
——*see* Ezzedeen, F. S., 889
Stoll, R. G., *see* Malick, A. W., 798
Stoltenborg, J. K., Puglisi, C. V., Rubio, F., and Vane, F. M., high-performance liquid chromatographic determination of stereoselective disposition of carprofen in humans, 1207
Straughn, A. B., *see* Gollamudi, R., 596
Street, K. W., Jr., and Schenk, G. H., spectrofluorometric determination of acetylsalicylic acid, salicylamide, and salicylic acid as an impurity in pharmaceutical preparations, 641
Su, C. C., Park, J. Y., Higuchi, W. I., Alkan, M. H., Corrigan, O. I., Hofmann, A. F., and Danzinger, R. G., mesophase formation during *in vitro* cholesterol gallstone dissolution: a specific effect of ursodeoxycholic acid, 713
Suber, R. L., Lee, C., Torosian, G., and Edds, G. T., pharmacokinetics of sulfisoxazole compared in humans and two monogastric animal species, 981
Suckow, R. F., and Cooper, T. B., simultaneous determination of imipramine, desipramine, and their 2-hydroxy metabolites in plasma by ion-pair reversed-phase high-performance liquid chromatography with amperometric detection, 257
Sugeno, K., *see* Koike, M., 308
Sugiyama, Y., *see* Igari, Y., 1049
——*see* Yu, H. Y., 323
Sukumar, L., *see* Anik, S. T., 897
Sundaresan, G. M., Goehl, T. J., and Prasad, V. K., simple high-performance liquid chromatographic assay for norethindrone–mestranol in combination tablets, 702
Superstine, E., *see* Yanuka, Y., 675, 679
Suryanarayanan, R., and Mitchell, A. G., modified USP assay of calcium gluceptate, 968
Sved, S., McLean, W. M., and McGilveray, I. J., influence of the method of application on pharmacokinetics of nitroglycerin from ointment in humans, 1368
Swern, D., *see* Abou-Gharbia, M., 1154
Symchowicz, S., *see* Korduba, C. A., 521
Szczawinska, K., *see* Pantarotto, C., 871
Szeto, D. W., *see* Tse, F. L. S., 395
Szulczewski, D. H., *see* Hong, W. H., 691

T

Tabor, R., *see* Kwok, R. P., 1014
Tafolla, W. H., Sarapu, A. C., and Dukes, G. R., rapid and specific high-pressure liquid chromatographic assay for folic acid in multivitamin–mineral pharmaceutical preparations, 1273
Taguchi, V. Y., Cotton, M. L., Yates, C. H., and Millar, J. F., determination of drug stability in aspirin tablet formulations by high-pressure liquid chromatography, 64
Taira, Z., *see* Asakawa, Y., 710
Takemoto, T., *see* Asakawa, Y., 710
——*see* Ishida, T., 406
Takenaka, H., Kawashima, Y., and Lin, S. Y., electrophoretic properties of sulfamethoxazole microcapsules and gelatin–acacia coacervates, 302
——Kawashima, Y., and Lin, S. Y., polymorphism of spray-dried microencapsulated sulfamethoxazole with cellulose acetate phthalate and colloidal silica, montmorillonite, or talc, 1256
——*see* Kawashima, Y., 913
Tam, J. N. S., *see* Bansal, P. C., 850
Tan, H. S. I., Booncong, P. C., and Fine, S. L., simultaneous high-performance liquid chromatographic determination of theophylline, ephedrine hydrochloride, and phenobarbital in tablets, 783
——McKibben, D. M., and Glasser, A. C., improved assay for mixtures of citrate and citric acid in systemic alkalizer solutions, 693
——*see* Bucci, A. J., 999
Tansy, M. F., *see* Belair, E. J., 347
Tao, F. T., *see* Bayne, W. F., 75
Taphouse, V., *see* Anderson, B. D., 181
Tarrus, E., Garcia, I., and Segura, J., human metabolism of 7-substituted theophyllines: N^3-demethylation and lack of oxidation of proxyphylline, 542
Taylor, D. C., Grundy, R., and Loveday, B., chronic dog intestinal loop model for studying drug absorption as exemplified by β-adrenoreceptor blocking agents, atenolol and propranolol, 516
Taylor, M. D., *see* Coburn, R. A., 1322
Taylor, V. E., *see* Elrod, L., Jr., 793
Teagarden, D. L., Kozlowski, J. F., White, J. L., and Hem, S. L., aluminum chlorohydrate I: structure studies, 758
——Radavich, J. F., White, J. L., and Hem, S. L., aluminum chlorohydrate II: physicochemical properties, 762
——White, J. L., and Hem, S. L., aluminum chlorohydrate III: conversion to aluminum hydroxide, 808
Teien, G., *see* Pettersen, J. E., 812
Templo, J. S., and Zatz, J. L., interaction of xanthan gum with suspended solids, 554
Tenthorey, P. A., *see* Sowell, J. W., Sr., 135, 537
Theeuwes, F., *see* Bayne, W. F., 75
Thompson, J. A., Bloedow, D. C., and Leffert, F. H. pharmacokinetics of intravenous chlorpheniramine in children, 1284
Thompson, R. C., *see* Chen, S. T., 1288
Thompson, T. A., Vermeulen, J. D., Wagner, W. E., Jr., and Le Sher, A. R., aminoglutethimide bioavailability, pharmacokinetics, and binding to blood constituents, 1040
Tilbury, R. S., *see* Digenis, G. A., 985
Tong, D. D. M., *see* Metzler, C. M., 733
Torosian, G., *see* Suber, R. L., 981
Torre, G. M., Lynch, V. D., and Jarowski, C. I., lowering blood urea nitrogen with amino acid supplementation, 114
Trageser, T. C., *see* Dannals, R. F., 439
Treiner, C., *see* Vaution, C., 1238
Treitman, J. A., *see* Grebow, P. E., 306, 1310
Trigo, G. G., Martinez, M., and Gálvez, E., PMR and ^{13}C-NMR spectroscopy of tropane and *N*-substituted nortropane spirohydantoins, 87
Tripathi, H. L., *see* Vincek, W. C., 1292
Trotta, M., *see* Gasco, M. R., 1294
Tschanz, C. T., *see* Bjornsson, T. D., 1372
Tscherne, R., *see* Manius, G., 1024
Tse, F. L. S., and Valia, K. H., plasma theobromine after oral administration of caffeine to dogs, 579
——Valia, K. H., Szeto, D. W., Raimondo, T. J., and Koplowitz, B., effect of caffeine and circulating theophylline levels in beagle dogs, 395
Tsiatis, A., *see* Evans, W. E., 1194
Tsina, I. W., and Matin, S. B., determination of oxfendazole in cow milk by reversed-phase high-performance liquid chromatography, 858
Tsubouchi, M., Mitsushio, H., Yamasaki, N., and Matsuoka, K., application of one-phase end-point change system in two-phase titration to amine drug analysis, 1286
Tsuji, A., Nakashima, E., Deguchi, Y., Nishide, K., Shimizu, T., Horiuchi, S., Ishikawa, K., and Yamana, T., degradation kinetics and mechanism of aminocephalosporins in aqueous solution: cefadroxil, 1120
——Nakashima, E., Kagami, I., and Yamana T., intestinal absorption mechanism of amphoteric β-lactam antibiotics II: Michaelis–Menten kinetics of cyclacillin absorption and its pharmacokinetic analysis in rats, 772
——Nakashima, E., Kagami, I., and Yamana, T., intestinal absorption mechanism of amphoteric β-lactam antibiotics I: comparative absorption and evidence for saturable transport of amino-β-lactam antibiotics by *in situ* rat small intestine, 768
Twomey, P. A., high-performance liquid chromatographic analysis of carbenicillin and its degradation products, 824

U

Ulsaker, G. A., *see* Pettersen, J. E., 812
Uyeki, E. M., Nishio, A., Wittek, P. J., and Cheng, C. C., antiproliferative activity of doxorubicin and aminoanthraquinone derivatives on chinese hamster ovary cells, 1011

V

Valia, K. H., *see* Tse, F. L. S., 395, 579
Valvani, S. C., Yalkowsky, S. H., and Roseman, T. J.,

solubility and partitioning IV: aqueous solubility and octanol–water partition coefficients of liquid nonelectrolytes, 502
——*see* Yalkowsky, S. H., 1177
van Bakel, P., *see* van de Waterbeemd, H., 1081
van den Bogert, C., and Kroon, A. M., fluorometric determination of tetracyclines in small blood and tissue samples, 186
VandenHeuvel, W. J. A., review of "Biochemical Applications of Mass Spectrometry: First Supplementary Volume," 581
Van Der Kleyn, E., *see* Jonkman, J. H. G., 947
Vanderwielen, A. J., *see* Daniels, S. L., 211
van de Waterbeemd, H., van Bakel, P., and Jansen, A., transport in quantitative structure–activity relationships VI: relationship between transport rate constants and partition coefficients, 1081
Van Harken, D. R., *see* Pfeffer, M., 449
Van Nostrand, P., *see* Chien, Y. W., 709
Van Scoyoc, G. E., *see* Oscarson, D. W., 657
Vane, F. M., *see* Stoltenborg, J. K., 1207
Vaughan, D. P., approximation in point–area deconvolution algorithm as mathematical basis of empirical instantaneous midpoint–input deconvolution method, 831
Vaum, R., *see* Burns, H. D., 436
Vaution, C., Treiner, C., Puisieux, F., and Carstensen, J. T., solubility behavior of barbituric acids in aqueous solution of sodium alkyl sulfonate as a function of concentration and temperature, 1238
Veals, J., *see* Korduba, C. A., 521
Vega, S. M., *see* Chu, S. Y., 990
Venteicher, R., *see* Manius, G., 1024
Ventura, P., Parravicini, F., Simonotti, L., Colombo, R., and Pifferi, G., degradation of propildazine in water, 334
Vermeulen, J. D., *see* Thompson, T. A., 1040
Vezin, J.-C., *see* Cousse, H., 860, 1245
Vincek, W. C., Martin, B. R., Aceto, M. D., Tripathi, H. L., May, E. L., and Harris, L. S., synthesis of 4,4-ditritio-(+)-nicotine: comparative binding and distribution studies with natural enantiomer, 1292
Vincent, S. H., *see* Digenis, G. A., 985
Vine, J., *see* Petersen, M. C., 1139
Visalli, A. J., *see* Galante, R. N., 167
Visor, G. C., and Schulman, S. G., fluorescence immunoassay, 469
Viswanathan, C. T., and Levy, R. H., plasma protein binding interaction between valproic and salicylic acids in rhesus monkeys, 1279
Voelker, F. J., *see* Ebling, W. F., 224
Vollmer, P., *see* Aszalos, A., 878
Vossoghi, M., *see* Shafiee, A., 566

W

Wade, A. E., review of "Clinical Pharmacology, 24th Ed.," 349
Wagner, H. N., Jr., *see* Dannals, R. F., 439
Wagner, J. G., *see* Behm, H. L., 802
Wagner, W. E., Jr., *see* Thompson, T. A., 1040
Walker, M. C., Carpenter, B. E., and Cooper, E. L., simultaneous determination of niacinamide, pyridoxine, riboflavin, and thiamine in multivitamin products by high-pressure liquid chromatography, 99
Walkling, W. D., *see* Janicki, C. A., 778
Walton, P. G., *see* Hodges, N. A., 960
Wang, L. D., Sowell, J. W., Sr., Freeman, J. J., and Kosh, J. W., synthesis and vasodepressor screen of a series of 2-(2-alkylaminoalkylamido)-3-carbamyl-4-methyl-5-benzylpyrroles, 699
Wang, T.-P. F., *see* Lin, S.-N., 1276
Waraszkiewicz, S. M., Milano, E. A., and DiRubio, R., stability-indicating high-performance liquid chromatographic analysis of lidocaine hydrochloride and lidocaine hydrochloride with epinephrine injectable solutions, 1215
Ward, H. E., Jr., Freeman, J. J., Sowell, J. W., and Kosh, J. W., synthesis and preliminary pharmacology of an internal standard for assay of neostigmine, 433
Wargin, W. A., *see* Wurster, D. E., 764
Warren, J. T., *see* Findlay, J. W. A., 624
Watson, E., and Kapur, P. A., high-performance liquid chromatographic determination of verapamil in plasma by fluorescence detection, 800
Watson, E. S., Murphy, J. C., Wirth, P. W., ElSohly, M. A., and Skierkowski, P., immunological studies of poisonous Anacardiaceae: production of tolerance in guinea pigs using 3-*n*-pentadecyl-catechol-"modified" autologous blood cells, 785
——*see* Skierkowski, P., 829
Watson, J. R., *see* Black, D. B., 208
Weiner, D., Garteiz, D., Cawein, M., Dusebout, T., Wright, G., and Okerholm, R., pharmacokinetic linearity of desipramine hydrochloride, 1079
Weinstein, S. H., *see* Whitney, C. C., 462
Weinstock, L. T., Rose, W. J., and Cheng, C. C., synthesis of new polyamine derivatives for cancer chemotherapeutic studies, 956
Welch, R. M., *see* Findlay, J. W. A., 624
Welling, P. G., *see* Barbhaiya, R. H., 291
Wells, C. E., effect of sampling probe size on dissolution of tableted drug samples, 232
Wessels, F. L., Ellis, K. O., and White, R. L., Jr., synthesis and skeletal muscle relaxant activity of 3-(aminoacyl)-1-[[[5-(substituted phenyl)-2-furanyl]methylene]amino]-2,4-imidazolidinediones, 1088
Westenberg, H. G. M., *see* Jonkman, J. H. G., 947
White, J. L., *see* Feldkamp, J. R., 638
——*see* Hermosin, M. C., 189
——*see* Lipka, E. A., 936
——*see* Shah, D. N., 1101
——*see* Teagarden, D. L., 758, 762, 808
White, L. B., *see* Menon, G. N., 1083
White, R. L., Jr., *see* Wessels, F. L., 1088
Whitlam, J. B., and Brown, K. F., ultrafiltration in serum protein binding determinations, 146
Whitney, C. C., Weinstein, S. H., and Gaylord, J. C., high-performance liquid chromatographic determination of ethmozin in plasma, 462
Widder, K. J., Senyei, A. E., Ovadia, H., and Paterson, P. Y., specific cell binding using staphylococcal protein A magnetic microspheres, 387
——*see* Senyei, A. E., 389
Wilcox, R. E., *see* Smith, R. V., 1144
Williams, M. G., and Mattocks, A. M., synthesis of [4-^{14}C]theophylline, 576
Williams, P. A., and Biehl, E. R., high-pressure liquid chromatographic determination of corticosteroids in topical pharmaceuticals, 530
Wilson, T. D., *see* Munson, J. W., 177
Wimbish, G. H., *see* Jones, G. L., 618
Winek, C. L., review of "Analytical Procedures for Therapeutic Drug Monitoring and Emergency Toxicology," 234
Winer, N., *see* Mason, W. D., 262
Wirth, P. W., *see* Watson, E. S., 785
Wisian-Neilson, P., *see* Hall, I. H., 339
Wittek, P. J., *see* Uyeki, E. M., 1011
Wittkowsky, A., *see* Behl, C. R., 835
Wolpers, H. G., Hunneman, D. H., Stellwaag, M., and Hellige, G., calcium binding by arteriographic contrast media, 231
Wood, J. H., review of "Pharmaceutical Dosage Forms: Tablets, Vol. 1," 349
Wood, L. E., Daniels, R., Bauer, L., and Gearien, J. E., syntheses and biological evaluation of 2- and 9-aminobenzonorbornenes as conformationally rigid analogs of amphetamines, 199
Woodford, D. W., and Lesko, L. J., relative bioavailability of aspirin gum, 1341
Worley, P., *see* Burns, H. D., 436
Wossoghi, J., *see* Shafiee, A., 566
Wright, G., *see* Weiner, D., 1079
Wright, R. J., *see* Pento, J. T., 399
Wright, W. L., *see* Coburn, R. A., 1322
Wu, P. L., *see* Martin, A., 1260
Wu, S. C., Capomacchia, A. C., and Price, J. C., fluorometric determination of all-*trans* retinol in rat serum, 685
Wurster, D. E., Wargin, W. A., and DeBerardinis, M., Jr., automated dissolution testing of combination drug product using high-pressure liquid chromatography, 764
Wynn, J. E., *see* Bauguess, C. T., 46

Y

Yacobi, A., *see* Kamath, B. L., 299, 667
——*see* McNiff, E. F., 1054
Yagen, B., *see* Bialer, M., 822
Yakatan, G. J., and Cruz, J. E., high-performance liquid chromatographic analysis of triamterene and *p*-hydroxytriamterene in plasma, 949
Yalkowsky, S. H., solubility and partitioning V: dependence of solubility on melting point, 971
——and Valvani, S. C., correlation of water solubility with octanol–water partition coefficient: A response, 1177
——*see* Valvani, S. C., 502
Yamada, H., Ichihashi, T. Hirano, K., and Konoshita, H., plasma protein binding and urinary excretion of *R*- and *S*-epimers of an arylmalonylamino 1-oxacephem I: in humans, 112
——Ichihashi, T., Hirano, K., and Kinoshita, H., plasma protein binding and urinary excretion of *R*- and *S*-epimers of an arylmalonylamino 1-oxacephem II: in rats, 113
Yamana, T., *see* Tsuji, A., 768, 772, 1120
Yamasaki, N., *see* Tsubouchi, M., 1286
Yang, I.-C., *see* Chowhan, Z. T., 927
Yang, W. C. T., *see* Dubick, M. A., 343
Yanuka, Y., Yosselson-Superstine, S., Geryes, A., and Superstine, E., assignment of conformation and configuration to potassium permanganate oxidation products of quinidine, 675
——Yosselson-Superstine, S., Geryes, A., and Superstine, E., impact of stable conformation of cinchona alkaloids on protonation site, 679
Yates, C. H., *see* Taguchi, V. Y., 64
Yau, M. K. T., and Meyer, M. C., *in vivo–in vitro* correlations with a commercial dissolution simulator I: methenamine, nitrofurantoin, and chlorothiazide, 1017
Yazdani, A., *see* Shafiee, A., 566
Yeh, S. Y., and Krebs, H. A., TLC identification and GLC determination of meperidine and its metabolites in biological fluids, 482
——Krebs, H. A., and Changchit, A., urinary excretion of meperidine and its metabolites, 867
Yeung, A. K., *see* Grebow, P. E., 306
Yonese, M., Fox, J. L., Nambu, N., Hefferren, J. J., and Higuchi, W. I., fluoride remineralization of demineralized bovine tooth enamel and hydroxyapatite pellets, 904
——Iyer, B. V., Fox, J. L., Hefferren, J. J., and Higuchi, W. I., novel topical fluoride delivery system I: remineralization of ground bovine teeth, 907
——*see* Fox, J. L., 910
Yosselson-Superstine, S., *see* Yanuka, Y., 675, 679
Young-Chang, F. M., *see* McNiff, E. F., 1054
Yu, A. B. C., *see* Shargel, L., 599
Yu, H. Y., Sawada, Y., Sugiyama, Y., Iga, T., and Hanano, M., effect of sulfadimethoxine on thiopental distribution and elimination in rats, 323

Z

Zaro, B., *see* Fass, M., 1338
Zatz, J. L., *see* Tempio, J. S., 554
Zentner, G. M., Cardinal, J. R., and Kim, S. W., free fatty acid-induced platelet aggregation: studies with solubilized and nonsolubilized fatty acids, 975

A

Absorption—atenolol and propranolol, studied in chronic *in situ* ileal and jejunal loops in dogs, 516
—ergotamine, effect of caffeine on absorption from rat small intestine, *in vitro* and *in vivo* studies, 651
GI—iopanoic acid from *in situ* rat small intestine, optimal perfusion rate determined, 239
GI—3-*n*-pentadecylcatechol and its diacetate derivative, effect of vehicle, rats, 829
intestinal—mechanism proposed for saturable transport of amphoteric amino-β-lactam antibiotics, *in situ* rat intestinal loops, 768
intramuscular—aminoglycosides, dosing volume effects, 449
kinetics—aspirin in tablet and two buffered solutions, 262
kinetics—rat intestinal loops, blood cyclacillin levels after intravenous, intraportal, and intraduodenal administrations, 772
nasal—progesterone, compared with absorption following intravenous and intraduodenal administration, rats, 466
percutaneous—effect of hydration on water and alkanol permeation through Swiss mouse skin, comparison with hairless mouse, 1212
rectal—theophylline, effects of salicylate, 71
—tolbutamide and acetohexamide, improved absorption through increased hydrophilicity, 67
***p*-Acetamidophenol**—amino acid esters as prodrugs, synthesis and analysis, 881
Acetaminophen—bioavailability, *in vitro* and *in vivo* properties of three commercial tablets compared, 422
—use of sodium sulfate for early treatment of toxicity, absorption of orally administered sodium sulfate, single and divided doses, 331
Acetohexamide—improved absorption through increased hydrophilicity, 67
4-Acetyl-2-(2′-hydroxyethyl)-5,6-bis(4-chlorophenyl)-2*H*-pyridazin-3-one—synthesis, isolation of impurities by low-pressure liquid chromatography and preparative TLC and identification by high-pressure liquid chromatography, biological activity of impurities compared with parent compound, 419
***N*-Acetylprocainamide**—metabolite of procainamide, pharmacokinetic study in rats, compared with human data, 299
Administration routes—effect on vasoactivity, lidocaine analogs, vasoactive agents, 699
—influence on drug delivery to a target organ, mathematical relationships, 1344
β-Adrenergic antagonists—propranolol and 4-hydroxypropranolol, high-performance liquid chromatography, human plasma, 688
β-Adrenergic blockers—high-pressure liquid chromatographic analysis, 336
β-Adrenergic blocking agents—timolol, extraction, derivatization, mass fragmentographic determination, plasma and urine, 573
Adrenergics—radioimmunoassays for *d*-pseudoephedrine in human plasma, bioequivalency studies, immediate- and sustained-release tablets, 624
β-Adrenoreceptor blocking agents—atenolol and propranolol, absorption studied in chronic *in situ* ileal and jejunal loops in dogs, 516
Adsorption—effect of antacids on oral hypoglycemics, dissolution, hypoglycemic activity, 621
—effect of organic modifier on steroid retention, high-performance liquid chromatographic analysis of hydrocortisone cypionate, 177
potential—nitroglycerin loss from solution in plastic intravenous containers, a theoretical treatment, 798
—proteins, drugs onto silicone-coated glass, 493
—sepiolite, potential excipient evaluated for use with drugs subject to oxidative degradation, 189
—xanthan gum by suspended solids, 554
Aerosols—GLC analysis of menthol, phenol, benzocaine, and pyrilamine maleate, 1151
—testing procedure for establishing the reproducibility of metered-dose valves, 1085
Albumin, egg—preparation of microcapsules and microspheres containing fine hydrophilic particles of silica gel beads, iron hydrous oxide-modified nylon 12, and phenacetin, heat coagulation method, 358
human serum—interaction of biliary contrast agents with native and modified albumin, optical studies of warfarin and diazepam binding sites, 549
human serum—kinetics of reaction with trinitrobenzenesulfonate, 1297
Alcohols, normal—permeation through hairless mouse skin strata separated by thermal and stripping techniques, 52
Alkalizer—improved assay of citrate–citric acid mixtures, 693
Alkaloids, cinchona—impact of stable conformation on protonation site, effect of polar and nonpolar solvents on conformation, NMR analyses, 679
—thebaine, colorimetric determination in extract from *Papaver bracteatum*, 102
Alkoxyfuroic acids—Arrhenius relationship, energy of activation and preexponential factors as a function of chain length, 1095
2-(3-Alkylaminoalkylamido)pyrroles—synthesis, evaluated for local anesthetic activity in guinea pigs and for antiarrhythmic activity and CNS toxicity in mice, 537
2-(2-Alkylaminoalkylamido)pyrroles—synthesis and evaluation for local anesthetic and antiarrhythmic properties and CNS toxicity, 135
Allopurinol—*N*-hydroxymethyl derivatives synthesized, structure confirmed by NMR and elemental analyses, potential prodrug, 855
^{27}Al-NMR spectroscopy—aluminum chlorohydrate, structure proposed, 758
Aluminum chlorohydrate—conversion to aluminum hydroxide, 808
—physicochemical properties determined by IR spectroscopy and pH-stat and potentiometric titrations, 762
—structure proposed by X-ray diffraction and IR and ^{27}Al-NMR spectroscopy, 758
Aluminum hydroxide—conversion from aluminum chlorohydrate, 808
gel—effect of adsorbed carbonate on surface charge and physical characteristics, 638
—mechanism of interaction with polyols, 1101
Aluminum hydroxycarbonate gel—gel structure measurement using a tension cell, 936
Amikacin—intramuscular absorption rates, dosing volume effects, 449
Amine carboxyboranes—borane analogs of α-amino acids, evaluation for antihyperlipidemic activity, mice, 339
Amine cyanoboranes—borane analogs of α-amino acids, evaluation for antihyperlipidemic activity, mice, 339
Amine drugs—analysis, two-phase titration, 1286
Amino acid derivatives—*N*-chloroacetyl derivatives of *para*-substituted phenylalanine, structure–activity relationships, growth inhibition in microbial antitumor prescreen, 464
Amino acid esters—as prodrugs of *p*-acetamidophenol, synthesis and analysis, 881
Amino acids—dietary supplementation, effects on blood urea nitrogen, rats, 114
3-Aminoacyl-substituted 2,4-imidazolidinediones—synthesis and evaluation for skeletal muscle relaxant activity, mice, 1088
Aminoanthraquinone derivatives—synthesis and evaluation for antiproliferative activity, Chinese hamster ovary cells, 1011
Aminobenzonorbornenes—syntheses and biological evaluation as conformationally rigid analogs of amphetamines, 199
Aminocephalosporins—intestinal absorption mechanism proposed, compared with monobasic penicillins, *in situ* rat intestinal loops, 768
Aminoglutethimide—bioavailability pharmacokinetics, binding to blood constituents, 1040
Aminoglycosides—effect of dosing volume on intramuscular absorption rate, 449
2-Amino-*N*-substituted succinimide derivatives—synthesis and evaluation for anticonvulsant activity, 192
Aminopenicillins—intestinal absorption mechanism proposed, compared with monobasic penicillins, *in situ* rat intestinal loops, 768
Amiodarone—high-pressure liquid chromatography in biological fluids, 1366
Amphetamines—drugs of abuse, identification of drug substance by optical crystallographic properties, 704
—phenylalkyl primary amines, GLC analysis using nitrogen detection, rat serum, brain, and liver, 813
—syntheses and biological evaluation of the 2- and 9-aminobenzonorbornenes as conformationally rigid analogs, 199
Analgesic activity—activated ester-type prodrugs of aspirin, synthesized and evaluated for analgesia, *in vitro* and *in vivo* studies, 743
Analgesics—aspirin and salicylic acid, high-pressure liquid chromatographic analysis in multicomponent tablets, 64
—ergotamine, effect of caffeine on absorption from rat small intestine, *in vitro* and *in vivo* studies, 651
—magnesium salicylate tablets, effect of calcium stearate on dissolution, 961
—meperidine and its metabolites, urinary excretion in mice, rats, guinea pigs, rabbits, cats, and dogs, 867
narcotic—oxymorphone, binding to disintegrating agents compared, dissolution testing, 709
non-narcotic—zomepirac sodium, plasma protein binding studies in humans, rats, mice, and rhesus monkeys, interaction studies with warfarin and salicylic acid, 818
Analogs—of puromycin, acyclic, synthesis and analysis, evaluation for inhibition of protein synthesis and antiviral and antibacterial activity, 1169
—tetracycline ring A analogs, synthesis, 496
Analysis, simultaneous—high-performance liquid chromatographic method for hydroxyzine hydrochloride–benzyl alcohol injection solutions, 697
Analytical techniques—determination of platinum in serum and ultrafiltrate by flameless atomic absorption spectrophotometry, 500
Anesthetic activity—2-(2-alkylaminoalkylamido)-pyrroles, synthesis and evaluation for local anesthetic activity, 135
potential—2-(3-alkylaminoalkylamido)pyrroles synthesized and evaluated for activity in guinea pigs, structure–activity relationships, 537
Anesthetics—determination of plasma fentanyl by GC–mass spectrometry, 1276
local—lidocaine, GLC assay in human plasma, 229
Anilinomethanesulfonates, derivatives—synthesis and structure elucidation by elemental, IR, and mass spectral analyses, 863
Antacids—effect on oral hypoglycemics, dissolution, adsorption, hypoglycemic activity, 621
—effects on theophylline bioavailability, tablets and timed-release capsules, 599
Anthelmintics—oxfendazole, high-performance liquid chromatographic analysis in cow milk, 858
Anthracyclines—doxorubicin, carubicin, daunorubicin, and marcellomycin, high-pressure liquid chromatographic analysis, dog plasma, 265
Anthralin—high-pressure liquid chromatographic determination in ointments, 1205
Anthraquinone glycosides—high-pressure liquid chromatographic assay, separation of isomeric

sennosides A and B from crude drug and pharmaceutical preparations, 727
Antiadrenergics—carteolol, determination by radioimmunoassay, human plasma, 990
Antiarrhythmic activity, potential—2-(3-alkylaminoalkylamido)pyrroles synthesized and evaluated for activity in mice, structure–activity relationships, 537
Antiarrhythmic agents—2-(2-alkylaminoalkylamido)pyrroles, synthesis and evaluation for activity, 135
—bretylium tosylate, pharmacokinetics studied in rats, compared with human studies, 667
—high-performance liquid chromatography, verapamil, canine plasma, fluorescence detection, 800
—quinidine, interactions with kaolin and pectin, *in vitro*, 999
Antiasthmatics—synthesis of [4-^{14}C]theophylline, 576
Antiatherosclerotic agents—micellar solubilization of cetaben sodium in surfactant and lipid solutions, 924
Antibacterial activity—alkyl and polyhalophenyl esters of benzo[*b*]thiophene-3-carbamic acid, 566
potential—evaluation of α-methylene-γ-butyrolactones, 84
Antibacterial agents—high-performance liquid chromatographic determination of myxin and its reduction product in cuprimyxin-containing creams, 1024
Antibacterials—doxycycline, metabolic fate, analysis in human urine and feces, 226
—sulfisoxazole, pharmacokinetics in humans, dogs, and swine, 981
urinary tract—evaluation of 10 methenamine products, excretion of formaldehyde, 596
Antibiotics, amino-β-lactam—compared with monobasic penicillins, intestinal absorption mechanism proposed, *in situ* rat intestinal loops, 768
amino-β-lactam—cyclacillin, *in situ* intestinal absorption kinetics, blood levels after intravenous, intraportal, and intraduodenal administration to rats, 772
—carbenicillin, high-performance liquid chromatographic analysis, mobile phase modifications, 824
—cephalosporins and penicillins, interactions with a nonpolar, macroporous copolymer stationary phase, 994
—quantitation of doxorubicin, daunorubicin, and their aglycones by high-pressure liquid chromatography, 1112
Anticancer agent—ftorafur potential for treatment of GI cancers, 1163
Anticancer drugs, potential—compounds related to hexestrol, screened against P-388 lymphocytic leukemia, 1075
Anticholinergic activity—1-[(4-substituted-1,2,3-thiadiazol-5-yl)arylmethyl]-4 - methylpiperazines, synthesis, IR, NMR, and mass spectral analyses, 510
Anticholinergics, potential—selected tricyclic oxime *O*-ethers, synthesis, structure–activity relationships, 558
Anticonvulsant activity—2-amino-*N*-substituted succinimide derivatives, synthesis and evaluation for activity, 192
—carbamazepine, cyheptamide, phenytoin, blood and brain concentrations, 618
Anticonvulsants, potential—thiazoles, thiazines, and thiadiazines formed from 1-phthalazine thiosemicarbazides, synthesis and evaluation for activity, 94
—succinimide derivatives, synthesis and analysis, 963
Antidepressants—viloxazine, high-pressure liquid chromatographic analysis, human plasma and urine, 220
Antidiabetic activity—3-methyl-5-phenylpyrazolesulfonylurea derivatives synthesized and tested, 602
—substituted 3,5-diarylpyrazolesulfonylurea derivatives synthesized and tested, 606
—synthesis and evaluation of cyclic sulfonylthiourea derivatives, identification by IR spectroscopy, 952
Antiepileptics—teratogenic effects of phenytoin on mice, 631
Antiestrogenic activity—cyclopropyl analogs of stilbene and stilbenediol, mice, 399
Antifertility activity—evaluation of *N*-protected glycine activated esters, 60
—narcissin, flavonoid isolation from *Strumpfia maritima*, 682
Antifolates—2,4- diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline enzymatic analyses using beef liver reductase and *Lactobacillus casei*, 827
Antifungal activity—alkyl and polyhalophenyl esters of benzo[*b*]thiophene-3-carbamic acid, 566
Antifungal agents—griseofulvin and its solvates, investigation with laser Raman spectroscopy, physicochemical stability, desolvation, 789
—sulconazole, reversed-phase high-pressure liquid chromatographic analysis, 1338
Antihistaminic activity—1-[(4-substituted-1,2,3-thiadiazol-5-yl)arylmethyl]-4 - methylpiperazines, synthesis, IR, NMR, and mass spectral analyses, 510
Antihistaminics—pharmacokinetics of intravenous chlorpheniramine maleate in children, 1284
Antihyperlipidemic activity—effects of amine cyanoboranes and amine carboxyboranes on serum cholesterol and triglyceride levels in mice, 339
Antihypertensive agents—4-acetyl-2-(2′-hydroxyethyl) - 5,6-bis(4-chlorophenyl)-2*H*-pyridazin-3-one, isolation and identification of impurities, high-pressure liquid chromatography, 419
—indapamide, pharmacokinetics in dogs, 1310
—propildazine, degradation in water, identification of degradation products, 334
Antihypertensives—absorption and bioavailability of captopril, gavage and dietary administration, mice and rats, 885
—high-performance liquid chromatographic method for captopril, 665
—pharmacokinetics of captopril in dogs and monkeys, continuous intravenous infusion, 1108
—semiautomated assay of indapamide in biological fluids, 306
Anti-infectives—iodochlorhydroxyquin, high-performance liquid chromatographic analysis, plasma, 889
Anti-inflammatory agents—carprofen, metabolism in humans, and rats, high-performance liquid chromatography, 1207
—cloprednol, high-performance liquid chromatographic analysis, human plasma, 669
—fenoprofen, high-performance liquid chromatographic analysis, human plasma, 507
—ibuprofen, high-pressure liquid chromatographic analysis, plasma, 944
—indomethacin, high-pressure liquid chromatographic determination using fluorescence detection, 458
—phenylbutazone, dissolution kinetics, 1358
—proquazone, erythrocyte partitioning and equilibrium dialysis methods evaluated for determination of proquazone binding to plasma proteins, 252
Anti-inflammatory drugs—clinical determination of plasma levels in humans, 514
Antileukemic activity—*p*-*N*,*N*-bis(2-chloroethyl)-aminophenol ester derivatives, synthesis and evaluation for antileukemic activity and toxicity, comparison of two cell-counting methods, 46
Antileukemic agents—5-aza-2′-deoxycytidine, analysis of chemical stability using high-performance liquid chromatography, 1228
—comparison of helenalin, brusatol, and bruceantin and their esters, 1147
Antimicrobial activity—*N*-glycosylthioureas, *N*-glycosylrhodanines, and *N*-glycosyl-2-aminothiazoles, 1059
—phenolic constituents of *Magnolia grandiflora* L., agar well diffusion assay, 951
Antimicrobial agents—chlorhexidine gluconate, simulation of contamination, 964
Antimuscarinic activity—comparison of synthesized tricyclic oxime *O*-ethers, 558
Antineoplastic activity, potential—*N*-chloroacetyl derivatives of *para*-substituted phenylalanines, tested for growth inhibition in microbial antitumor prescreen, structure–activity relationships, 464
potential—evaluation of α-methylene-γ-butyrolactones, 84
potential—high-pressure liquid chromatographic analysis of anthracyclines in dog plasma, doxorubicin, carubicin, daunorubicin, and marcellomycin, 265
Antineoplastic agents—synthesis and evaluation of guanazole prodrugs, 1281
Antineoplastics—bleomycin, high-performance liquid chromatographic analysis, 878
—mercaptopurine, irreversible binding to human serum proteins, 1290
—puromycin, synthesis and analysis of acyclic analogs, evaluation for inhibition of protein synthesis and antiviral and antibacterial activity, 1169
—6-selenoguanosine, selenium compounds, oxidative degradation in aqueous solutions, kinetics, 634
Antiparasitic activity—tripyrrole derivatives of congocidine synthesized and evaluated for activity in mice, *in vitro* and *in vivo* studies, 822
Antiparkinsonian agents—levodopa, effect of administration route in bioavailability, 730
Antiperspirant activity—aluminum chlorohydrate, structure proposed based on X-ray diffraction and IR and ^{27}Al-NMR spectroscopic studies, 758
—conversion of aluminum chlorohydrate to aluminum hydroxide, 808
Antiproliferative activity—aminoanthraquinone derivatives synthesized and evaluated for activity in Chinese hamster ovary cells, 1011
Antipsychotic phenothiazines—chlorpromazine, high-performance liquid chromatographic analysis and radioimmunoassay comparison, 1043
Antispasmotics—propiram, tablet *versus* solution bioavailability in humans, 521
Antitumor activity—catecholamine analogs synthesized and evaluated for antitumor activity, mice, 806
Antitumor agents—arylmonomethyltriazenes, effect of human serum albumin on decomposition rates, 892
Apomorphine—bioavailability, effect on stereotyped cage climbing, mice, 1144
Aqueous solubility—aliphatic and aromatic hydrocarbons, liquid nonelectrolytes, experimental values compared with calculated values, 502
Aromatic compounds—interaction with povidone, evaluation of complex formation by factorial analysis, 1252
Arteriographic contrast media—calcium binding, effect of additives in media on calcium binding *in vitro*, 231
Arylmonomethyltriazenes—decomposition rates, effect of human serum albumin, 892
L-Asparagine—polyacrylamide microparticles, prolongation of effect by implantation of immobilized enzyme, rats, 684
Aspirin—activated ester-type prodrugs of aspirin synthesized and evaluated for analgesia, *in vivo* and *in vitro* studies, 743
anhydride—determination of crystal structure and solid-state behavior, X-ray crystallography and microscopy of reacting crystals, 280
—derivatives, hydrolysis by carboxypeptidase A, 1307
—derivatives, hydrolysis by α-chymotrypsin, 1304
—derivatives, physicochemical property modification strategies based on enzyme specificities, synthesis and pharmaceutical properties, 1299
gum—relative bioavailability compared to unbuffered aspirin tablets in six normal volunteers, 1341
prodrugs—percutaneous absorption and metabolism, 756
—simultaneous GLC analysis with nonaspirin salicylates in tablet formulations, 167
—simultaneous high-pressure liquid chromatographic analysis with salicylic acid in multi-

component tablets, 64
—spectrofluorometric determination of an impurity in drug combinations, 641
—tablet and two buffered solutions, kinetics following oral administration, salicylic acid and salicyluric acid levels and kinetics, 262
Atenolol—absorption studied in chronic *in situ* ileal and jejunal loops in dogs, 516
Atomic absorption spectrophotometry, flameless—determination of platinum in serum and ultrafiltrate, 500
Autoxidation, aqueous—6-selenoguanosine, selenium compounds, pharmacokinetics, 634
5-Aza-2′-deoxycytidine—analysis of chemical stability using high-performance liquid chromatography, 1228
Azaperone—comparison of rotamer populations in solid state and in solution, IR and NMR spectroscopic and X-ray crystallographic determinations of conformation, 284

B

Barbituric acids—derivatives, thermodynamic dependence of interfacial transfer kinetics in the two-phase transfer cell, 1265
—solubility in aqueous sodium alkyl sulfonate, thermodynamics, 1238
Bases—differential titration in glacial acetic acid, 104
Bawn kinetics—solid and liquid decomposition rate constants of alkoxyfuroic acids, 1095
Behavior—apomorphine-induced cage climbing in mice, intravenous, intraperitoneal, and oral administration, 1144
Benzodiazepines—routine quality evaluation for adherence to USP–NF specifications, 208
Benzoic acid—thermochemical study, monomer and dimer models for solubility in simple binary and ternary solvents, 1033
Benzothiadiazines—apparent pKa_1 values, semiaqueous potentiometry, detection of decomposition, 317
Benzo[*b*]thiophene-3-carbamic acid—alkyl and polyhalophenyl esters, synthesis, antibacterial and antifungal activities, 566
Benzoylcholine, radioiodinated analogs—synthesized and evaluated as possible myocardial-imaging agents, biodistribution studies in mice, 439
Bile acids—cholesterol dissolution, comparison of solid preparations, 717
Biliary contrast agents—interaction with native and modified human serum albumin, optical studies on warfarin and diazepam binding sites of albumin, 549
Binary solvents—thermochemical study of monomer and dimer models for benzoic acid solubility, 1033
Binders—carboxymethylcellulose, effect of polymerization and substitution on tablet disintegration and dissolution, 611
—various, effect of moisture content on compression properties of granulations, 1134
Binding—calcium to ionic arteriographic contrast media, effect of additives, 231
—*evaluation of ultrafiltration technique for use in* clinical serum binding determinations, 146
—interactions of 32 pharmaceuticals of diverse *chemical structures with crosslinked insoluble* polyvinylpyrrolidone, sorption and desorption studies, 738
—*irreversible, of mercaptopurine to human serum* proteins, 1290
kinetics—triazene–albumin interaction, decomposition rates, 892
—nicotine stereoisomers, rats, 1292
plasma protein—effect of blood preservation, humans, 1168
plasma protein—effect of radiochemical impurity *of radiolabeled drugs,* 1372
—prednisolone, effect of blood collection techniques, 1160
protein—binding of prostaglandins, E_1(alprostadil), E_2 (dinoprostone), $F_{1\alpha}$, and $F_{2\alpha}$ (dinoprost) to human serum proteins, equilibrium dialysis of *radiolabeled prostaglandins,* 945
protein—prednisolone, pharmacokinetics, rabbits, 1201
protein—tolbutamide and warfarin, 1370
Binding agents—*in vitro* binding of oxalate by anion-exchange resins and aluminum hydroxide, 1065
Binding sites—warfarin and diazepam binding sites on human serum albumin molecule, interaction of biliary contrast agents with albumin, 549
Bioavailability—acetaminophen, *in vitro* and *in vivo* properties of three commercial tablets compared, 422
—aminoglutethimide, pharmacokinetics, binding to blood constituents, 1040
—apomorphine, intravenous, intraperitoneal, and oral administration, 1144
—aspirin gum compared to unbuffered aspirin tablets in six normal volunteers, 1341
—chlorothiazide, absorption from aqueous solution and tablets, dogs, 224
—determination of flurbiprofen and ibuprofen in dog serum with automated sample preparations, 1347
—ethinyl estradiol, first-pass metabolism in rats and dogs, gut wall metabolism in rats, 403
—levodopa, dosage form design, absorption and metabolism in dog intestinal segments, 1157
—levodopa, effect of administration route, 730
—lidocaine, compared in healthy volunteers and epileptic patients, influence of effective liver volume, 969
—methenamine in 10 products, humans, 596
—method for drugs with changing biological half-lives, alternative calculations to plasma concentration–time curve method, 109
—orally administered propiram in humans, 521
—propranolol, conventional and slow-release formulations compared, 1030
—quinidine formulations evaluated for variations in drug content, dissolution, absorption, and clearance characteristics in humans, 524
—sodium sulfate, comparison of single and divided doses, role in treatment of acetaminophen toxicity, 331
—statistical simulation of the proposed 75/75 requirement, 673
—theophylline, oral administration, aminophylline, intravenous administration, 452
—thiazides, plasma *versus* urine analysis, 833
Biodistribution—radioiodinated benzoylcholine analogs synthesized and evaluated for use as myocardial-imaging agents, mice, 439
—radioiodinated *o*-iodohippuran in rats and rabbits, *kit preparation of radiopharmaceutical developed* and compared with commercial products, 312
Bioequivalence—thiazides, plasma *versus* urine analysis, 833
Bioequivalency studies—radioimmunoassays of *d*-pseudoephedrine in human plasma, bioequivalency studies, *immediate- and sustained-release* tablets, 624
—statistical simulation of the proposed 75/75 requirement, 673
Biotransformation—effect of elevated blood glucose *levels on hepatic microsomal enzyme system,* rats, 695
—neutral and acidic metabolites of α-pinene, *β-pinene, pinane, 3-carene, carane, myrcene,* and *p*-cymene in rabbits, 406
***p*-N,N-Bis(2-chloroethyl)aminophenol**—ester *derivatives synthesized and evaluated for antileukemic* activity and toxicity, comparison of two cell-counting methods, 46
Bleomycin—*high-performance liquid chromatographic* determination, separation of components, 878
Blood—preservation, effect on *in vitro* plasma protein binding, 1168

BOOKS

Abrégé de Droit et Deontalogie du Laboratoire D'Analyses de Biologie Medicale, 582
Abrégé de Matière Médicale (Pharmacognosie), *Tome I,* 716
Abrégé de Pharmacie Galénique, 3rd Ed, 716
Abrégé de Pharmacologie: Générale et Moléculaire, *2nd Ed.,* 716
Advances in Chromatography, Vol. 18, 234
Advances in Chromatography, Vol. 19, 838
Advances in Drying: Vol. 1, 582
The Analysis of Dietary Fiber in Food, 716
Analytical Procedures for Therapeutic Drug Monitoring and Emergency Toxicology, 234
Analytical Profiles of Drug Substances, Vol. 9, 973
Anionic Surfactants: Biochemistry, Toxicology, Dermatology (Surfactant Science Series, Vol. 10), 582
Annual Reports in Medicinal Chemistry, Vol. 15, 716
Applied Biopharmaceutics and Pharmacokinetics, 1179
A–Z of Clinical Chemistry, 582
The Basis of Medicinal Chemistry: Burger's Medicinal Chemistry, 4th Ed., Part I, 348
Biochemical Applications of Mass Spectrometry: First Supplementary Volume, 581
The Biochemistry of Psychiatric Disturbances, 716
Bioenergetics and Thermodynamics: Model Systems, 716
Biomedical Polymers. Polymeric Materials and Pharmaceuticals for Biomedical Use, 350
Blood Cells and Vessel Walls: Functional Interactions, 582
British National Formulary 1981: Number 1, 837
Casarett and Doull's Toxicology—The Basic Science of Poisons, 2nd Ed., 234
Clinical Pharmacokinetics: Concepts and Applications, 973
Clinical Pharmacology, 24th Ed., 349
Clinically Important Adverse Drug Interactions, Vol. 1: Cardiovascular and Respiratory Disease Therapy, 716
A Clinician's Guide to Research Design, 350
Concepts in Drug Metabolism, Part A., 116
Controlled Release of Bioactive Materials, 837
Controlled Release Technologies: Methods, Theory, and Applications, 1178
Development of Mammalian Absorptive Process, 582
Drug Level Monitoring—Analytical Techniques, Metabolism, and Pharmacokinetics, 349
Drying '80: Vol. 1: Developments in Drying, 582
Drying '80: Vol. 2: Proceedings of the Second International Symposium, 582
Elsevier's Dictionary of Pharmaceutical Science and Techniques, Vol. 2: Materia Medica, 350
Environmental Chemicals, Enzyme Function and Human Disease, 582
Essentials of Drug Product Quality: Concepts and Methodology, 348
Extrahepatic Metabolism of Drugs and Other Foreign Compounds, 582
Fundamentals of Human Lymphoid Cell Culture, 234
Further Studies in the Assessment of Toxic Actions. Archives of Toxicology, Supplement 4, 838
Goodman and Gilman's The Pharmacological Basis of Therapeutics: 6th Ed., 581
Handbook of Basic Pharmacokinetics, 2nd Ed., 348
Handbook of Biological Psychiatry, Part III: Brain *Mechanisms and Abnormal Behavior*—Genetics and Neuroendocrinology. Vol. 1, 350
Handbook for Prescribing Medications During *Pregnancy,* 716
Heterocyclic Chemistry, Vol. 1. (A Specialist Periodical Report), 582
High-Performance Liquid Chromatography: Advances and Perspectives, Vol. 1, 838
High-Performance Liquid Chromatography: Advances and Perspectives, *Vol. 2, 838*
How to Write and Publish a Scientific Paper, 234
IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Vol. 23: Some Metals and Metallic Compounds, 838
IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Vol. 22: Some Non-Nutritive Sweetening Agents, 234
IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Supplement 2. Long-Term and Short-Term Screening *Assays for Carcinogens: A Critical Appraisal,* 838

Iatrogenic Diseases, 2nd Ed., 116
Introduction to Bioinstrumentation with Biological, Environmental, and Medical Applications (A Volume of Contemporary Instrumentation and Analysis), 716
Introduction to Pharmaceutical Dosage Forms, 1094
Lecture Notes in Chemistry, Vol. 15. Steric Fit in Quantitative Structure–Activity Relations, 350
Les Cosmétiques, 234
A Literature Survey and Design Study of Fume-cupboards and Fume-Dispersal Systems, 582
Lithium Effects on Granulopoiesis and Immune Function, 234
Manuel de Préparation en Pharmacie d'Officine, 716
Marijuana Research Findings: 1980. NIDA Research Monograph 31, 350
Metal Carcinogenesis Testing: Principles and *In Vitro* Methods, 716
Neurochemistry and Biochemical Pharmacology, 234
Neurological Clinical Pharmacology, 582
Nucleotide Analogs: Synthesis and Biological Function, 582
The Organic Chemistry of Drug Synthesis, Vol. 2, 350
PAR Pseudo-Allergic Reactions: Involvement of Drugs and Chemicals, Vol. 2: Cytotoxic and Complement Mediated Reactions, 582
PAR Pseudo-Allergic Reactions: Involvement of Drugs and Chemicals, Vol. 1: Genetic Aspects and Anaphylactoid Reactions, 582
Pharmaceutical Calculations, 2nd Ed., 1094
Pharmaceutical Calculations, 7th Ed., 715
Pharmaceutical Dosage Forms: Tablets,Vol. 1, 349
Pharmaceutical Microbiology, 2nd Ed., 116
Pharmacy: A Profession in Search of a Role, 233
The Pill, 582
Principles and Methods of Pharmacy Management 2nd Ed., 582
Progress in Drug Metabolism, Vol. 4, 716
Progress in Drug Metabolism, Vol. 5, 1179
Progress in Medicinal Chemistry, Vol. 17, 350
Progress in Pharmacology, Vol. 3, No. 2. Presynaptic Mechanisms/Vasodilator Drugs, 716
Reagents for Organic Synthesis, Vol. 8, 234
Recent Developments in Chromatography and Electrophoresis, 10, 234
Recent Developments in Mass Spectrometry in Biochemistry and Medicine, 6, 1179
The Renin–Angiotensin System, 234
Reviews of Physiology, Biochemistry and Pharmacology, Vol. 87, 350
The Role of Peptides in Neuronal Function, 582
The Safety of Medicines: Evaluation and Prediction, 716
Scientific Considerations in Monitoring and Evaluating Toxicological Research, 838
Second Supplement to USP XX and NF XV, 974
Solid Pharmaceutics Mechanical Properties and Rate Phenomena, 974
Solids Handling, 716
Stabilitätsprüfung in der Pharmazie: Theorie und Praxis, 234
Sustained Release Medications, 716
Synthetic Peptides, Vol. 5, 716
Topics in Antibiotic Chemistry. Vol. 5, 582
Trends in Enzyme Histochemistry and Cytochemistry, 234
The Use of Alternatives in Drug Research, 838
Vitamin D: Molecular Biology and Clinical Nutrition, 234
WHO Expert Committee on Specifications for Pharmaceutical Preparations, 27th Report, 234
Bretylium tosylate—pharmacokinetics, rats, compared with human studies, 667
Bromperidol, radiolabeled—tissue distribution studied in rats and rhesus monkeys using external scintigraphy and serial sacrifice, 985
Bronchodilators—*simultaneous high-performance* liquid chromatographic assay of theophylline, ephedrine hydrochloride, and phenobarbital, 783
Bruceantin—*comparison with helenalin and brusatol* and their esters, antileukemic activity, 1147
Brucine—determination of resonance multiplicities, 81
Brusatol—comparison with helenalin and bruceantin and their esters, antileukemic activity, 1147
Buffer—effect on aspirin kinetics, 262
—effect on dissolution kinetics of carboxylic acids, 22
Burns—examination of scar tissue, technique for preparing appendage-free skin on the hairless mouse, 835
Butoconazole nitrate—solubility, extreme vertexes design in formulation development, 897
***p-n*-Butylaminobenzoic acid**—determination by high-performance liquid chromatography, 569

C

Caffeine—effect on ergotamine absorption from rat small intestine, *in vitro* and *in vivo* studies, 651
—metabolism in dogs, plasma theobromine levels following oral administration of caffeine to dogs, 579
—pharmacokinetic interactions with theophylline, 395
Calcium—binding in plasma by arteriographic contrast media, effect of additives in media, 231
Calcium gluceptate—modified USP assay, 968
Calcium stearate—effect on dissolution rate of tableted magnesium salicylate, 961
Capacity factors—cephalosporins and penicillins, interactions with a nonpolar, macroporous styrene-divinylbenzene copolymer stationary phase, 994
Capsule size—effect on permeability of gelatin–acacia microcapsules, 456
Captopril—absorption and bioavailability, gavage and dietary administration, mice and rats, 885
—analysis using high-performance liquid chromatography, 665
—pharmacokinetics in dogs and monkeys using radiolabeled drug, continuous intravenous infusion, 1108
Carbamazepine—anticonvulsant activity, intraperitoneal dosage, blood and brain concentrations, 618
Carbenicillin—degradation products, high-performance liquid chromatographic analysis, mobile phase modifications, 824
Carbonate, adsorbed—effect on surface charge and physical characteristics of aluminum hydroxide gel, 638
Carboprost—transport through silicone rubber, 562
Carboxylic acids—cohesive powders mixed with lactose for homogeneity evaluation, evaluation of three mixing indexes based on statistical analysis, 243
—dissolution kinetics, effect of buffers, 22
—dissolution kinetics, effect of pH under unbuffered conditions, 13
Carboxymethylcellulose—effect of polymerization and substitution on tablet disintegration and dissolution, 611
Carboxypeptidase A—hydrolysis of aspirin derivatives, 1307
Carboxytolbutamide—simultaneous high-performance liquid chromatographic assay with tolbutamide, human plasma, 1166
Cardiotoxicity—*effects of chronic emetine treatment* on mitochondrial function, 343
Carprofen—stereoselective disposition determination *in human using high-performance liquid chromatography*, 1207
Carriers, drug—doxorubicin-bearing magnetic microspheres, *in vivo*, 389
—magnetic microspheres synthesized with immunological specificity, incorporation of staphylococcal protein A into microsphere matrix, cell binding studies *in vitro*, 387
Carteolol—determination by radioimmunoassay, human plasma, 990
Catecholamine analogs—polyhydroxybenzylamine hydroiodides synthesized and evaluated for antitumor activity, mice, 806
Cathartics—anthraquinone glycosides, isomeric *sennosides A and B, high-pressure liquid chromatographic analysis*, 727
Cattle —topical drug delivery, literature survey, 1181
Cefadroxil—degradation kinetics and mechanism, high-pressure liquid chromatography, pH–rate profile, intramolecular aminolysis to produce piperazinediones, buffer and temperature effects, 1120
Cephalosporins—interactions with a nonpolar, macroporous styrenedivinylbenzene copolymer stationary phase, 994
Cetaben sodium—micellar solubilization in surfactant and lipid solutions, 924
Chelating agents—edetate disodium, effect on membrane permeability, goldfish, 1128
Chemotherapy—synthesis of polyamine derivatives for cancer chemotherapy, 956
Chlordiazepoxide—routine evaluation of content, uniformity, impurities, and identity by retention times and peak areas, 208
Chlorhexidine gluconate—antimicrobial activity, simulation of natural and artificial contamination, 964
Chloride-ion electrode—measurement of pseudoephedrine hydrochloride dissolution, 1288
***N*-Chloroacetyl derivatives of *para*-substituted phenylalanines**—tested for growth inhibition in microbial antitumor prescreen, structure–activity relationships, 464
4-[4′-(2-chlorophenyl)phenyl]-4-oxo-2-methylene butanoic acid—itanoxone, GLC determinations in biological fluids, 860
Chloroquine—comparison of rotamer populations in solid state and in solution, IR and NMR spectroscopic and X-ray crystallographic determination of conformation, 284
Chlorothiazide—bioavailability from tablets and aqueous solution, dogs, 224
—dissolution profile using dissolution simulator, 1017
—*in vitro* and *in vivo* release rates evaluated from plain tablets, compressed tablets of microcapsules, and microcapsules, 376
—simultaneous high-pressure liquid chromatographic determination with hydrochlorothiazide plasma and urine, 291
Chlorpheniramine maleate—pharmacokinetics of intravenous drug in children, 1284
Chlorpromazine—high-performance liquid chromatographic analysis in plasma and comparison with a radioimmunoassay, 1043
Chlorprothixene—degradation product identification, GLC–mass spectrometry, gastric aspirate, 812
Cholesterol—dissolution rate behavior in bile acid solutions, 723
—dissolution rate behavior in bile acid solutions, comparison of solid preparations, 717
—effect of macromolecules on aqueous solubility, 442
—gallstones, mesophase formation during *in vitro* gallstone dissolution, 713
—inhibitors, synthesis and testing of mevalonic acid analogs, 1007
synthesis—effects of 12 imide analogs on related enzymes, 326
Cholinergic receptors—molecular requirements of *active sites, synthesis of 2,3-dehydrodeoxamuscarone and cis-* and *trans*-dehydrodeoxamuscarines, 489
Cholinergics—*neostigmine and analogs, synthesis*, pharmacological activity evaluated in rat brain and smooth muscle, quantification by GLC, 433
Chromatography, *size exclusion*—liposomes, synthesized and fractionated on cross-linked agarose and cross-linked dextran gels, 874
α-Chymotrypsin—hydrolysis of aspirin derivatives, 1304
Cimetidine—evaluation of pharmacokinetics by linear system approach, 32
trans-Cinnamic anhydride—hydrolysis kinetics catalyzed by pyridine, 4-dimethylaminopyridine, and *N*-methylimidazole, 235
Citrate-citric acid mixtures—improved assay of systemic alkalizer solutions, 693
Citric acid–citrate mixtures—improved assay of systemic alkalizer solutions, 693
Clays—*sepiolite, potential as excipient for drugs* subject to oxidative degradation, 189

Clearance—first-pass effect, nonlinear approach to *solution of integrated Michaelis–Menten equation*, 195

Clemizole—spectrophotometric assay in dosage forms using complex formulation with chloranil, 127

Clofibrate—*microcapsules, effect of wall thickness* on release characteristics, 430

Cloprednol—high-performance liquid chromatographic analysis, *human plasma*, 669

Clorazepate, dipotassium and monopotassium—high-performance liquid chromatographic analysis, *solid dosage forms*, 793

CNS agents—dextroamphetamine and methylphenidate, *effects on behavior and neurochemistry*, rats, 816

—xilobam, analysis, determination of decomposition products, stability assessment, 778

Coacervation—acacia–gelatin–sulfamethoxazole coacervates and microcapsules compared electrophoretically, 302

Coagulation—free fatty acid-induced platelet aggregation, solubilized and nonsolubilized fatty acids, 975

Colorimetry—analysis of blood urea nitrogen in rat serum, effects of dietary supplementation of amino acids, 114

—modified method for determination of plasma prednisolone, 810

Column chromatography, dry—rapid concentration of biological activity, natural products fractionation, 329

Combination drugs—dissolution testing using automated high-pressure liquid chromatography, 764

Common ion effect—effect of hydrochlorides on solubility, 594

Compacted granules—densification of powders by a concavo-convex roller compactor, effect on flowability, 288

Compartment models—computational problems of models with Michaelis–Menten-type elimination, parameter estimation, 733

Complexation—calculation of complexation constants using solubility method, derivation of new equation, 108

—evaluation of povidone–aromatic compound interaction by factorial analysis, 1252

Complexes—technetium 99m with iminodiacetic acid derivatives, electrophoretic determination of charge on carrier-free ^{99m}Tc-labeled complexes, evaluation of net biliary excretion, 436

Compressed tablets—produced from modified tableting machine with flexible die wall, compared with tablets produced conventionally, 613

Compression—effect of moisture content on granulations made with various binders, 1134

Compression cycle—analysis of viscoelastic behavior during tablet formulation, 476

—compression at various maximum pressures of substances expected to undergo plastic deformation, 222

Conformation—impact on protonation site of quinidine and other cinchona alkaloids, effect of polar and nonpolar solvents, NMR analyses, 679

—in solid state and in solution, azaperone, nialamide, chloroquine, 284

Conformational requirements—indirectly acting *sympathomimetic agents*, syntheses and biological evaluation of the 2- and 9-aminobenzonorbornenes as amphetamine analogs, 199

Congocidine derivatives—*tri- and monopyrrole analogs*, synthesized and evaluated for antiparasitic activity in mice, *in vivo* and *in vitro* studies, 822

Conjugation—*salicylamide, effect of inorganic sulfate*, 308

Consolidation ratio—powder flow behavior, relationship to tensile strength, 927

Contaminants—2(2 - hydroxyethylmercapto)benzothiazole, leaching from disposable syringes, 1139

—identification and quantitation, theophylline olamine enema solutions, high-performance liquid chromatographic analysis, 589

—phthalates, interference in drug assays using electron-capture detection, 346

Contraceptives, natural—progesterone, nasal absorption compared with that following intravenous and intraduodenal administration, rats, 466

—norethindrone–mestranol tablets, high-performance liquid chromatography, content uniformity studies, 702

Controlled-release delivery—transport of prostaglandins through silicone rubber, 562

formulations—effect of docusate sodium on drug release, 1248

Copolymers, *polyurethane—model membrane systems*, permeability and sorption characteristics, 1313

polyurethane—model membrane systems, synthesis and analysis, mass transport properties, 571

Corneal permeation—transport mechanism, fluorometholone, compared with pilocarpine, rabbits, 1026

Corticoids—flunisolide, radioimmunoassay, human plasma or serum, plasma concentration–time *profiles*, 900

Corticosteroids—analysis of topical pharmaceuticals, high-pressure liquid chromatography, 530

Cortisone—*teratogenic effects on mice*, 631

Critical coagulation concentration—aluminum chlorohydrate, physicochemical properties determined using IR spectroscopy and pH-stat and potentiometric titrations, 762

Cryoscopic properties—data for 29 drugs, 1161

Crystalline compounds—polycyclic aromatic hydrocarbons, dependence of solubility on melting point, 971

Crystallography—optical characterization of a low solubility organic compound, 5-(tetradecyloxy)-2-furancarboxylic acid, 1152

Crystal structure—aspirin anhydride, determination of solid-state behavior of crystals, 280

Cuprimyxin—high-performance liquid chromatographic determination of free myxin and its reduction product, 1024

Cyclacillin—intestinal absorption kinetics *in situ*, blood levels in rats after intravenous, intraportal, and intraduodenal administration, 772

Cyclic sulfonylthiourea derivatives—preparation and evaluation for antidiabetic activity, IR and PMR spectroscopy, 952

Cyheptamide—anticonvulsant activity, intraperitoneal dosage, blood and brain concentrations, 618

D

Dantrolene sodium—related compounds synthesized and evaluated for skeletal muscle relaxant activity, mice, 1088

Daunorubicin—high-pressure liquid chromatography assay, quantitation of impurities, 1112

Decomposition—benzothiadiazines, solubility variation with pH studies, 317

products—xilobam, analysis, stability assessment, 778

Degradation—carbenicillin, high-performance liquid chromatographic analysis, 824

—2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, isolation and characterization of degradation products, 162

—2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, kinetics, monitoring by high-performance liquid chromatography, 159

kinetics—cefadroxil, high-pressure liquid chromatography assay, pH–rate profile, intramolecular aminolysis to produce piperazinediones, buffer and temperature effects, 1120

—methylprednisolone 17- and 21-succinates, hydrolysis and acyl migration, initial rate studies, 181

—phenylbutazone, qualitative and quantitative analyses, 460

—propildazine in water and methanolic solutions, determination of products, 334

—stability-indicating high-pressure liquid chromatographic assay of hydrochlorothiazide, 211

thermal—aspirin anhydride products crystal structure and solid-state behavior as aspirin anhydride determined, 280

2,3-Dehydrodeoxamuscarone and 2,3-dehydrodeoxamuscarine—synthesis and biological activity, 489

Dehydroepiandrosterone sulfatide—synthesis, tested as *glucose-6-phosphate dehydrogenase inhibitor*; 1154

Delivery devices, controlled—hydrogel membranes, *progesterone permeation*, 216

—fluoride, remineralization of bovine teeth, effect of film thickness and particle size, 907

—fluoride, remineralization of human teeth *in vitro*, effect of surface treatment on remineralization, 910

Delivery, drug—magnetic microspheres as drug carriers, doxorubicin, *in vivo*, 389

Density—*effects of a concavo-convex roller compactor*, 288

Derivatives—6-alkyl, of 6-nor-9,10-dihydrolysergic *acid methyl ester*, 1319

—aspirin, hydrolysis by carboxypeptidase A, 1307

—aspirin, physicochemical property modification strategies based on enzyme specificities, synthesis and pharmaceutical properties, 1299

—aspirin, synthesis by α-chymotrypsin hydrolysis, 1304

—*polyamines, synthesis, cancer chemotherapy*, 956

—of succinimides, synthesis and analysis, 963

Derivatization—*O-phthalaldehyde*, high-pressure liquid chromatographic analysis in human plasma, 707

Desipramine hydrochloride—pharmacokinetic linearity, bioavailability, comparison of two tablet dose levels, humans, 1079

—simultaneous determination with imipramine and their 2-hydroxymetabolites, ion-pair reversed-phase high-performance liquid chromatography, 257

Desonide—GLC–mass spectrometric analysis, cell *culture media*, 917

Dexamethasone impurities—16α- and 16β-methyl 17-ketone oxidation products, identification and quantitative detection by TLC, 415

Dextroamphetamine—effects on behavior and neurochemistry, rats, coadministration with methylphenidate, 816

Diagnostic imaging agents, myocardial—use of radiopharmaceuticals, 1

3,5′-Diallyl-2′-hydroxy-4-methoxybiphenyl—phenolic constituent of *Magnolia grandiflora* L., antimicrobial activity, 951

Dialysis—equilibrium and flow techniques, effects of temperature and protein concentration on plasma and tissue binding, interspecies differences, 1049

2,4 - Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino) methyl]quinazoline—two enzyme assays using beef liver reductase and *Lactobacillus casei*, 827

3,5-Diarylpyrazolesulfonylurea derivatives, substituted—preparation and evaluation for antidiabetic activity, 606

Diatrizoate meglumine sodium—arteriographic contrast medium, effect on calcium binding, 231

Diazepam—routine evaluation of content, uniformity, *impurities, and identity by retention times and peak* areas, 208

2,5 - Diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone—degradation kinetics, monitoring by high-performance liquid chromatography, 159

—isolation and characterization of degradation products, 162

Dicumarol—dissolution, stability, and absorption characteristics in polyethylene glycol 4000 solid dispersions, 1353

Dietary supplements—*amino acids, effects on blood* urea nitrogen in rats, 114

Differential titration—bases in glacial acetic acid, 104

Dihydroergotoxine—*in vitro* dissolution method for sublingual tablets, dissolution profiles, 796

Dimenhydrinate—spectrophotometric determination with reinecke salt, 690

3,4-Dimethylphenol—formation of 1:1 complexes with esters, 1225

***N*-(2,6-Dimethylphenylcarbamoylmethyl)iminodiacetic acid**—complexation with technetium 99m, electrophoretic determination of charge on carrier-free ^{99m}Tc-labeled complexes, synthesis and

evaluation of net biliary excretion, 436
Dinoprost—transport through silicone rubber, 562
Direct linear plotting method—estimation of pharmacokinetic parameters, 1093
Disintegrants—carboxymethylcellulose, effect of polymerization and substitution on tablet disintegration and dissolution, 611
Disintegrating agents—carboxymethylcellulose sodium, sodium starch glycolate, povidone, and modified cornstarch, binding to oxymorphone derivatives compared, 709
Disintegration–dissolution—analysis of percent dissolved–time data, 535
—tablets, effect of carboxymethylcellulose polymerization and substitution, 611
—tablets, effect of magnesium stearate during mixing, 1328
Dissolution—automated high-pressure liquid chromatography, combination drug product, 764
—bead-bed apparatus for suppositories, evaluation, drug release rate, 646
—cholesterol, comparison of solid preparations in bile acid solution, 717
—cholesterol gallstones, effect of bile acid, 713
—dicumarol in polyethylene glycol 4000 solid dispersions, 1353
—dihydroergotoxine sublingual tablets, *in vitro* method, 796
—effect of antacids on oral hypoglycemics, adsorption, hypoglycemic activity, 621
—effect of calcium stearate on magnesium salicylate tablets, 961
—general model for *n*-component, nondisintegrating spheres, 1331
kinetics—carboxylic acids, effect of buffers, 22
kinetics—carboxylic acids, effect of pH under unbuffered conditions, 13
—kinetics of phenylbutazone, 1358
model—method for analysis of percent dissolved–time data, 535
—noninvasive measurement *in vivo* and *in vitro* using perturbed angular correlation, solid dosage forms, 1325
—profiles for methenamine, nitrofurantoin, and chlorothiazide, dissolution simulator, 1017
—pseudoephedrine hydrochloride, measurement using chloride-ion electrode, 1288
—rate behavior of cholesterol in bile acid solutions, 723
rates—effect of sampling probe size on dissolution rate of tableted drug samples, USP paddle method, 232
simulator—profiles for methenamine, nitrofurantoin, and chlorothiazide, 1017
—tablets, effect of carboxymethylcellulose polymerization and substitution, 611
testing systems—various sampling probe sizes evaluated for effect on dissolution rate of tableted drug samples, 232
Distribution—4-iodobiphenyl and metabolites, metabolism and distribution studies in rats, 546
—methazolamide, time course and disposition in human plasma and red blood cells, 75
4,4-Dithio-(+)-nicotine—synthesis, comparative binding and distribution with the natural enantiomer, 1292
Diuretics—benzothiadiazines, semiaqueous potentiometric determination of apparent pKa_1 values, detection of decomposition, 317
—chlorothiazide, bioavailability from aqueous solution and tablets, dogs, 224
—high-performance liquid chromatographic analysis of triamterene and *p*-hydroxytriamterene, plasma 949
—proxyphylline, metabolism after oral administration, N^3-demethylation, 542
thiazides, plasma *versus* urine analysis in bioavailability/bioequivalence study, 833
Docusate sodium—effect on drug release from a controlled-release dosage form, 1248
Dosage forms—comparison of salicylate availability from aspirin gum and unbuffered aspirin tablets, 1341
design—bioavailability of levodopa, absorption and metabolism in dog intestinal segments, 1157
design—multicomponent mixing of cohesive powders to determine homogeneity of individual components, three mixing indexes evaluated, 243
design—multicomponent mixing of cohesive powders to determine homogeneity of mixture, comparison of univariate and multivariate statistical analyses, 247
—tablets and timed-release capsules, effect of antacid on theophylline bioavailability, 599
—transport of prostaglandins through silicone rubber, 562
—high-pressure liquid chromatographic assay, quantitation of impurities, 1112
—*in vivo* fate of localized low dose, kinetics, 389
—substituted aminoanthraquinone derivatives synthesized and evaluated for antiproliferative activity, Chinese hamster ovary cells, 1011
Doxycycline—fluorometric determination in small blood and tissue samples, 186
—tetracycline analogs, metabolic fate, analysis, human urine and feces, 226
Drug delivery system—polystyrene microspheres, acute hemodynamic effects and blood pool kinetics following intravenous administration, dogs, 660
delivery systems, potential—liposomes, simple formulas for calculating number and surface area, 173
delivery systems—sustained release of phenylpropanolamine, ion-exchange resin–drug complex, 379
delivery—to a target organ, influence of administration route, mathematical relationships, 1344
disposition—two-compartment models, computer simulations of their characteristics and clinical consequences, 141
infusion—relationship with area under the plasma concentration–time curve, 1296
protein binding—effects of temperature and protein concentration, interspecies differences, 1049
release—potassium chloride microcapsules, preparation and release characteristics, 391
release—suppositories, evaluation of a bead-bed dissolution apparatus, 646
removal—by extracorporeal devices, general equation, 345
transport—relationship between drug transport rate constants and partition coefficients, 1081
Drug absorption—point–area deconvolution algorithm compared with instantaneous midpoint–input deconvolution method, 831
—relative bioavailability calculated for drugs with changing biological half-lives, compared to plasma concentration–time curve method, 109
Drug–carrier protein conjugate—overview of fluorescence immunoassay methods currently in use, 469
Drug–disintegrant interactions—binding of oxymorphone derivatives to disintegrating agents, dissolution testing, Freundlich adsorption isotherm, 709
Drug–protein binding—Langmuir and parabolic models compared, parameter estimation, equilibrium dialysis of salicylic acid and tolmetin with human serum albumin, 802
Drugs, radiolabeled—effect of radiochemical impurity on determination of plasma protein binding of drugs, 1372
Drugs of abuse—substance identification by optical crystallographic properties of diluturate derivatives of amine drugs, 704
Dyes—patent blue violet, physicochemical characteristics, 122

E

Edetate disodium—effect on membrane permeability, goldfish, 1128
—temperature-dependent effect on neomycin stability, 960

EDITORIALS

Drug Industry's "Paper Tiger" (May)
Drug Patent Reform Legislation (July)
FDA Laboratories in Jeopardy (December)
FDA Takes a Turn in The Road (September)
New Drug Development Costs (February)
The Passing of a Giant (August)
Science Advisor or Science Advocate? (October)
The Science Hall of Fame (March)
Toward Social Responsibility (April)
Transforming Policy into Behavior (November)
USAN Program—20 Years Old (June)
75 Years of Drug Regulation (January)
Effective protein fraction—effects of temperature and protein concentration, interspecies differences, 1049
Electrocapillary emulsification—synthesis of poly(Nα,Nϵ-L-lysinediylterephthaloyl) microcapsules containing hemolysate, effect of temperature, emulsifier concentration, and applied potential on polyamide capsule-size distribution, 354
Electronegativity—mathematical estimation, usefulness of molecular connectivity indexes, relationship between molecular volume and electronic composition, 583
Electrophoretic mobility—magnesium hydroxide in aqueous solution, 486
Emetics—apomorphine, bioavailability, effect on stereotyped cage climbing in mice, 1144
Emetine—effects of chronic treatment on heart and liver mitochondrial metabolism, 343
Energy relationships—tablet compression, polymeric materials and granulations, 1005
Enteric hyperoxaluria—dietary oxalate, *in vitro* binding by anion-exchange resins and aluminum hydroxide, 1065
Enzymatic analyses—2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline using beef liver reductase and *Lactobacillus casei*, 827
Enzyme systems—effect of elevated blood glucose levels on hepatic microsomal enzymes, rats, 695
Ephedrine hydrochloride—simultaneous determination with theophylline and phenobarbital by high-pressure liquid chromatography, conventional and sustained-action tablet formulations, 804
Epimers—16α- and 16β-methyl 17-ketone oxidation products, possible impurities in dexamethasone, betamethasone, and related drugs, TLC detection and identification of α- and β-epimers, 415
Epinephrine—high-performance liquid chromatographic procedure for assaying components of injectable solutions, 1215
Equations—relationship between infusion equation and area under the plasma concentration–time curve, 1296
Equilibrium—analysis of zolazepam in reaction, 691
Equilibrium dialysis—drug–protein binding, Langmuir and parabolic models compared for free drug concentration estimation, 802
—of radiolabeled prostaglandins E_1 (alprostadil), E_2 (dinoprostone), $F_{1\alpha}$, and $F_{2\alpha}$ (dinoprost) bound to human serum proteins, 945
Ergolines—demethylation of the *N*-6 methyl group by 2,2,2-trichloroethyl chloroformate, 1319
Ergotamine—effect of caffeine on absorption from rat small intestine, *in vitro* and *in vivo* studies, 651
Estrogenic activity—cyclopropyl analogs of stilbene and stilbenediol, mice, 399
Estrogens, conjugated—quantitative determinations by capillary GLC, 1072
Ethinyl estradiol—first-pass metabolism in dogs and rats, gut wall metabolism in rats, 403
Ethmozin—analysis, high-performance liquid chromatography, plasma, 462
Ethyl myristate—effect on release rate of 4-hexylresorcinol from petrolatum, quantitative analysis, 393
Euphorbia cyparissias—separation of anticancer active fraction, dry column chromatography, 329
Excipients—potential of sepiolite as excipient for drugs subject to oxidative degradation, 189
Excretion, urinary—meperidine and its metabolites in mice, rats, guinea pigs, rabbits, cats, and dogs, 867
Extended Hansen solubility approach—compared with extended Hildebrand and UNIFAC approaches,
Extracorporeal devices—general equation for measurement of drug removal, 345
Extreme vertexes design—formulation development, butoconazole nitrate solubility in a multicomponent system, 897

naphthalene solubility in various solvents, 1260

F

Factorial analysis—evaluation of complex formation, povidone–aromatic compound interaction, 1252
Fatty acid synthesis—effect of 12 imide analogs on related enzymes, 326
Fatty acids—induced platelet aggregation, solubilized and nonsolubilized fatty acids, 975
Fenoprofen—high-performance liquid chromatographic analysis, human plasma, 507
Fentanyl—determination by GC–mass spectrometry and pharmacokinetic analysis in dog plasma, 1276
Field-flow fractionation—characterization of albumin microspheres, 1350
First-pass effect—nonlinear approach to solution of integrated Michaelis–Menten equation, 195
—thiazinamium methylsulfate, dogs, plasma concentration–time curves, 947
Flocculation—bridging mechanism, magnesium carbonate and aluminum hydroxide with xanthan gum, 554
Flow rates—of powder granulations, prediction of dynamic flow rate from static flow measurements, 711
Flunisolide—radioimmunoassay, human plasma or serum, plasma concentration–time profiles, 900
Flunitrazepam—quantitation by radioimmunoassay, compared with electron-capture GLC, human plasma, 230
Fluorescence immunoassay—overview of methods currently in use, homogeneous and heterogeneous methods compared to radioimmunoassay and chromatographic determinations, 469
Fluoride—delivery devices for remineralization of human teeth *in vitro*, effect of surface treatment on remineralization, 910
—delivery devices for remineralization of bovine teeth, effect of film thickness and particle size on remineralization, 907
—remineralization of demineralized bovine tooth enamel and hydroxyapatite pellets, 904
Fluorocarbons—perfluorohexyl bromide, tissue and blood plasma levels in dogs after oral and intratracheal administration, 1199
Fluorometholone—mechanistic studies on transcorneal permeation, compared with pilocarpine, rabbits, 1026
Fluorometry—analysis, indapamide in plasma, whole blood, and urine, 306
—analysis, tetracyclines in small blood and tissue samples, 186
—determination of all-*trans* retinol in rat serum, 685
Flurazepam—routine evaluation of content, uniformity, impurities, and identity by retention times and peak areas, 208
Flurbiprofen—determination in dog serum with automated sample preparation, 1347
Folic acid—high-pressure liquid chromatography, multivitamin–mineral pharmaceutical preparations, 1273
***N*-Formimidoylthienamycin**—stability in aqueous solution at 25 and 40°, 272
Formulation development—extreme vertexes design, butoconazole nitrate solubility in a multicomponent system, 897
Fractionation—size exclusion chromatography of liposomes on different gel media, 874
Freundlich adsorption isotherm—binding of oxymorphone derivatives to disintegrating agents compared, dissolution testing, 709
Ftorafur—stability study, no *in vitro* formation of fluorouracil, 1163
Fuel pellets—fabrication and microencapsulation, various microencapsulation techniques, glasses, and polymers compared, 364

G

Gallstones—cholesterol dissolution, comparison of solid preparations in bile acid solutions, 717
—cholesterol, dissolution rate behavior in bile acid solutions, 723
cholesterol—effect of bile acid on gallstone dissolution *in vitro*, 713
GC—nitrogen-selective detection of *p*-hydroxyphenobarbital in urine, plasma, and hepatic microsomes, 1218
GC–mass spectrometry—determination of plasma fentanyl, pharmacokinetic analysis, 1276
Gelatin-acacia coacervates—chlorothiazide, *in vitro* and *in vivo* release rates evaluated from compressed tablets of microcapsules, plain tablets, and microcapsules, 376
coacervates—sulfamethoxazole microcapsules and coacervates compared electrophoretically, 302
microcapsules—prepared by phase separation, capsule-size effect on permeability toward sodium chloride, 456
Gels—aluminum hydroxycarbonate, gel structure measurement using a tension cell, 936
Ginseng, dwarf—two-dimensional TLC analysis of ginsenosides from root, 89
Ginsenosides—two dimensional TLC analysis from root and dwarf ginseng, 89
Glass containers—adsorption of proteins onto silicone-coated surfaces, 493
GLC—analysis, aspirin and nonaspirin salicylates in tablet formulations, 167
—analysis, lidocaine in human plasma, 229
—analysis of menthol, phenol, benzocaine, and pyrilamine maleate in aerosol form, 1151
capillary—quantitative determination of conjugated estrogens, 1072
determination, electron-capture detection—analysis, itanoxone, biological fluids, 860
—determination of saccharin in human biological fluids, plasma kinetics and urinary excretion, 871
flame ionization—analysis, neostigmine and analogs, synthesis, preliminary pharmacological studies in rats, 433
—nitrogen detection, analysis, phenylalkyl primary amines in rat serum, brain, and liver, 813
—routine evaluation of benzodiazepines, 208
GLC–mass spectrometry—analysis, chlorprothixene and degradation product, gastric aspirate, 812
—analysis of hydrocortisone, triamcinolone acetonide, and desonide in cell culture media, 917
—analysis, methazolamide, human plasma and red blood cells, 75
—analysis, urinary metabolites of rutin in humans, 780
—determination of meperidine and metabolites in biological fluids of rat, dog, and human, 482
Glucocorticoids—GLC–mass spectrometric analysis of hydrocortisone, triamcinolone acetonide, and desonide in cell culture media, 917
—prednisolone, colorimetric determination in plasma, 810
Glucopyranosylthioureas—synthesis, screened for antimicrobial activity, 1059
Glucose levels, blood—effect of elevation on hepatic microsomal enzyme system, rats, 695
Glucose-6-phosphate dehydrogenase—synthesis of dehydroepiandrosterone sulfatide and 16α-halogenated steroids, 1154
Glutethimide—*N*-hydroxymethyl derivative synthesized, structure confirmed by NMR and elemental analyses, potential prodrug, 855
Glycine esters—*N*-protected analogs, evaluation for antifertility activity, 60
***N*-Glycosylthioureas, rhodanines, and 2-aminothiazoles**—synthesis, screened for antimicrobial activity, 1059
Granulations—effect of moisture content on compression properties, various binders, 1134
Griseofulvin—unsolvated and solvate forms, laser Raman spectroscopy, physicochemical stability, desolvation, 789
Guanazole—synthesis and evaluation of prodrugs as antineoplastic agents, 1281

H

Hallucinogens—phenethylamines, structure–activity relationships, compared with other hallucinogens, animal, human, and *in vitro* studies reviewed, literature survey, 839
16α-Halogenated derivatives of epiandrosterone—synthesis, tested as glucose-6-phosphate dehydrogenase inhibitors, 1154
Haloperidol, radiolabeled—tissue distribution studied in rats and rhesus monkeys using external scintigraphy and serial sacrifice, 985
Helenalin—comparison with brusatol, bruceantin, and their esters, antileukemic activity, 1147
Hematoporphyrin—determination by ion-pair extraction with chlorpromazine, 1294
Hemolysis—effect of poly-2-vinylpyridine-*N*-oxide, silicates, 657
Hemolytic effects—data for 29 drugs, 1161
Hepatic retention—effect on first-pass clearance of lidocaine, healthy volunteers and epileptic patients compared, 969
Hepatocytes, rat—sulfoconjugation and glucuronidation of salicylamide, 308
Hexestrol—structurally related thiourea and thiosemicarbazide derivatives as anticancer agents, 1075
4-Hexylresorcinol—effect of ethyl myristate on release rate from petrolatum, quantitative analysis, 939
—formation of 1:1 and 1:2 complexes with esters in hexane, 1225
High-performance liquid chromatography—analysis of captopril in plasma, 665
—analysis, carbenicillin, resolution of diastereomer pair or single-peak elution by mobile phase modifications, 824
—analysis of chemical stability of 5-aza-2′-deoxycytidine, 1228
—analysis, cloprednol in human plasma, 669
—analysis of clorazepate dipotassium and monopotassium in solid dosage forms, 793
—analysis, 2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, degradation kinetics, 159, 162
—analysis, iodochlorhydroxyquin, plasma, 889
—analysis, liothyronine sodium and levothyroxine sodium in tablet formulations, 131
—analysis of oxfendazole in cow milk, 858
—analysis, perhexiline in human plasma, 320
—analysis, plasma ethmozin levels, 462
analysis—triamterene and *p*-hydroxytriamterene, plasma, 949
—assay, fenoprofen, human plasma, 507
—contamination from paraben preservatives in theophylline olamine enema solutions, 589
—determination of free myxin and its reduction product in cuprimyxin-containing creams, 1024
—determination of stereoselective disposition of carprofen in humans, 1207
—determination of tetracaine, *p*-*n*-butylaminobenzoic acid, 569
—hydrocortisone cypionate in bulk and oral solution, chromatographic behavior evaluated, 177
—methoxsalen, human plasma, 965
—norethindrone–mestranol tablets, content uniformity studies, 702
—propranolol and 4-hydroxypropranolol, human plasma, 618
reversed phase—analysis, pilocarpine, isopilocarpine, pilocarpic acid, and isopilocarpic acid in ophthalmic pilocarpine formulations, 96
—reversed phase, bleomycin assay, separation of bleomycin components, 878
—separation of pilocarpine and isopilocarpine, ophthalmic solutions, 446
—simultaneous assay of propranolol and 4-hydroxypropranolol, conventional and slow-release formulations compared, 1030
—simultaneous assay of theophylline, ephedrine hydrochloride, and phenobarbital, 783
—simultaneous assay of tolbutamide and carboxytolbutamide, 1166
—simultaneous determination of hydrochlorothiazide and triamterene, capsule formulation, 1083
—simultaneous determination of hydroxyzine hydrochloride and benzyl alcohol, injection solutions, 697
—simultaneous determination of imipramine, desipramine, and their 2-hydroxy metabolites, 257
—specific and quantitative stability-indicating

procedure for lidocaine hydrochloride, epinephrine, and methylparaben, 1215
—verapamil, canine plasma, fluorescence detection, 800
High-pressure liquid chromatography—amiodarone in biological fluids, 1366
—analysis, anthraquinone glycosides, separation of isomeric sennosides A and B from crude drug and pharmaceutical preparations, 727
—analysis, corticosteroids in topical pharmaceuticals, 530
—analysis of doxorubicin, carubicin, daunorubicin, and marcellomycin in dog plasma, 265
—analysis, ibuprofen in plasma, 944
—analysis, indomethacin, fluorometric detection following hydrolysis of indomethacin to fluorophore, 458
—analysis, nadolol and 10 other β-adrenergic agents, 336
—analysis, nafronyl oxalate, application to stability studies, 39
—analysis, niacinamide, pyridoxine, riboflavin, and thiamine in multivitamin products, 99
—analysis, salicylic acid and aspirin multicomponent tablets, 64
—analysis of sulconazole in plasma, 1338
—analysis, viloxazine, human plasma and urine, 220
—with automated dissolution testing of a combination drug product, 764
—determination of anthralin in ointments, 1205
—determination of ibuprofen in human plasma, 514
—folic acid, multivitamin–mineral pharmaceutical preparations, 1273
—identification of impurities in 4-acetyl-2-(2′-hydroxyethyl)-5,6-bis(4-chlorophenyl)-2*H*-pyridazin-3-one, isolation of impurities by low-pressure liquid chromatography and preparative TLC, 419
—phenylpropanolamine analysis in human plasma, *O*-phthalaldehyde derivatization, 707
—quantitation of doxorubicin, daunorubicin, and their aglycones, 1112
—salicyluric acid in urine, methylation, 1090
—simultaneous determination of methscopolamine nitrate, phenylpropanolamine hydrochloride, pyrilamine maleate, and pheniramine maleate in tablets, 820
—simultaneous determination of theophylline, ephedrine hydrochloride, and phenobarbital, conventional and sustained-action tablet formulations, 804
—simultaneous analyses of various water-soluble vitamins in multivitamin preparations, 1014
—simultaneous determinations of chlorothiazide and hydrochlorothiazide, plasma and urine, 291
—stability-indicating assay of hydrochlorothiazide, 211
Hildebrand–Scatchard equation—modified, solubility profiles of methylxanthines in mixed solvents, 1115
Histidine decarboxylase—inhibition, synthesis and evaluation of 4-substituted imidazoles, 341
Homogeneous fluorescence immunoassays—reactant-labeled fluorescence, quenching and enhancement immunoassays, fluorescence polarization, time-resolved fluorescence immunoassays, role in pharmaceutical analysis, 469
Honokiol—phenolic constituent of *Magnolia grandiflora* L., antimicrobial activity, 951
Hormone drugs—effect of macromolecules on aqueous solubility, 442
Hormones, synthetic—norethindrone–mestranol tablets, high-performance liquid chromatography, content uniformity studies, 702
Hydration—effect on water and alkanol permeation through Swiss mouse skin, comparison with hairless mouse, 1212
Hydrocarbons, aliphatic and aromatic—aqueous solubility and partition coefficients obtained experimentally compared with calculated values, 502
Hydrochlorides—effect on solubility, common ion effect, 594
Hydrochlorothiazide—simultaneous determination by high-performance liquid chromatography with triamterene, capsule formulations, 1083
—simultaneous high-pressure liquid chromatographic determinations with chlorothiazide, plasma and urine, 291
—stability-indicating high-pressure liquid chromatographic method, 211
Hydrocortisone cypionate—high-performance liquid chromatographic analysis, bulk drug and oral solution, chromatographic behavior evaluated, 177
—GLC–mass spectrometric analysis, cell culture media, 917
Hydrodynamics—dissolution rates affected by sampling probe size, USP paddle method, 232
Hydrogels—progesterone permeation, release from monolithic devices of various comonomer compositions evaluated, 216
Hydrolysis—fluorescence analysis, despropionylpropiram, 521
—kinetics and mechanism established for methylsulfinylmethyl 2-acetoxybenzoate and other related aspirin prodrugs, 750
kinetics—*trans*-cinnamic anhydride, catalyzed by pyridine, 4-dimethylaminopyridine, and *N*-methylimidazole, 235
—methylprednisolone 17- and 21-succinates, initial rate studies, 181
Hydroxyapatite pellets—remineralization along with demineralization bovine tooth enamel, 904
2-(2-Hydroxyethylmercapto)benzothiazole—leaching into content of disposable syringes, isolation, identification, and quantitation, 1139
***N*-Hydroxymethyl derivatives**—of uracil, synthesis, structures confirmed by NMR and elemental analyses, potential prodrugs, 850
***p*-Hydroxyphenobarbital**—determination by GC and GC–mass spectrometry in urine, plasma, and hepatic microsomes, 1218
4-Hydroxypropranolol—analysis, high-performance liquid chromatography, human plasma, 688
***p*-Hydroxytriamterene**—high-performance liquid chromatographic analysis, plasma 949
Hyperlipidemic agents—itanoxone, physicochemical and analytical characteristics, 1245
Hyperuricemic agents—itanoxone, physicochemical and analytical characteristics, 1245
Hypnotic agents—flunitrazepam, quantitation by radioimmunoassay, human plasma, 230
Hypnotics—temazepam, effect of age and gender on disposition and elimination, 1104
Hypocholesterolemic agents—clofibrate, effect of microcapsule wall thickness on release characteristics, 430
Hypoglycemics—improved absorption through increased hydrophilicity, 67
oral—effect of antacids, dissolution, adsorption, hypoglycemic activity, 621

I

Ibuprofen—analysis, high-pressure liquid chromatography, plasma, 944
—determination in dog serum with automated sample preparation, 1347
—determination of serum binding by ultrafiltration, 146
—high-pressure liquid chromatographic determination in human plasma, 514
Imaging agents, potential—radiolabeled 1,2,3-selenadiazoles, synthesis and biodistribution, 91
Imidazoles, 4-substituted—synthesis and evaluation for inhibition of histidine decarboxylase, 341
Imide analogs—effects on enzymes required for cholesterol and fatty acid synthesis, serum cholesterol and triglyceride levels, mice, 326
Imipramine—microbial metabolism, identification of metabolites, fungi, 151
—simultaneous determination with desipramine and their 2-hydroxy metabolites, ion-pair reversed-phase high-performance liquid chromatography, 257
Immunoglobulins—role in pharmaceutical analysis, fluorescence immunoassays of drug–carrier protein conjugate, 469
Immunology—production of tolerance to urushiol using 3-*N*-pentadecylcatechol, guinea pigs, 785
Impurity, radiochemical—of radiolabeled drugs, effect on determination of plasma protein binding of drugs, 1372
Indapamide—pharmacokinetics in dogs, 1310
—semiautomated assay in biological fluids, 306
Indomethacin—high-pressure liquid chromatographic determination using fluorometric detection, human plasma and urine, 458
Inhalation products—testing procedure for establishing the reproducibility of metered-dose aerosol valves, 1085
Injection solutions—high-performance liquid chromatographic method for simultaneous determination of hydroxyzine hydrochloride and benzyl alcohol, 697
Instantaneous input hypothesis—comparison with conventional extrapolation method, dogs, 1037
4-Iodobiphenyl—metabolism in rats, distribution studies, 546
Iodochlorhydroxyquin—high-performance liquid chromatographic analysis, plasma, 889
***o*-Iodohippuran, radioiodinated**—kit preparation evaluated and compared with commercial products, biodistribution studies in rats and rabbits, 312
Ion-pair extraction—determination of hematoporphyrin using chlorpromazine, 1294
Iopanoic acid—absorption from *in situ* rat small intestine, optimal perfusion rate determined, 239
IR spectroscopy—analysis, anilinomethanesulfonate derivatives, synthesis and structure elucidation, 863
spectroscopy—identification of cyclic sulfonylthiourea derivatives, antidiabetic activity in mice, 952
spectroscopy—observed artifacts due to pellet preparation, 968
Isopilocarpine—analysis in the presence of pilocarpine and pilocarpic acid, ophthalmic solutions, 1046
—high-performance liquid chromatographic analysis in the presence of pilocarpine, ophthalmic solutions, 446
Isosorbide dinitrate—pharmacokinetics, intravenous administration compared in nonhuman primates, 1270
Itanoxone—GLC determination in biological fluids, 860
—physicochemical and analytical characteristics of itanoxone, 1245

J

JOURNALS
Journal of Pharmacy, 234
Medicinal Research Reviews, 582

K

Kaolin—interactions with quinidine, *in vitro*, 999
Kinetics, absorption—blood cyclacillin levels after intravenous, intraportal, and intraduodenal administration, *in situ* rat intestinal loops, 772
—analysis of relationship between partition coefficient and biological response, 57
—dissolution of carboxylic acids, effect of pH under unbuffered conditions, 13
—dissolution of phenylbutazone, 1358
—hydrolysis of *trans*-cinnamic anhydride catalyzed by pyridine, 4-dimethylaminopyridine, and *N*-methylimidazole, 235
—mathematical method for analysis of pharmacological effects on constant-rate intravenous drug infusion, 578
—polystyrene microspheres, distribution and clearance in dogs following intravenous administration, drug delivery system, 660
—of reaction of trinitrobenzene-sulfonate with human serum albumin, 1297
—6-selenoguanosine, oxidative, degradation in aqueous solutions, selenium compounds, 634
—stability of *N*-formimidoylthienamycin in aqueous solution, 272

L

β-Lactam antibiotics—stability of *N*-formimidoylthienamycin in aqueous solution, 272

Levodopa—adsorption and metabolism, intestinal segments, dogs, bioavailability, dosage form design, 1157
—bioavailability, effect of administration route, metabolism, intestinal microorganisms, levodopa decarboxylase, 730
Levothyroxine sodium—high-performance liquid chromatographic analysis in tablet formulations, 131
Lidocaine analogs—synthesis, analysis of vasoactivity, intraperitoneal and intravenous administration, 699
—first-pass clearance in healthy volunteers and epileptic patients compared, 969
—GLC assay in human plasma, 229
hydrochloride—injectable solutions of epinephrine using stability-indicating high-performance liquid chromatography, 1215
Linear system approach—evaluation of pharmacokinetics of cimetidine, 32
Liothyronine sodium—high-performance liquid chromatographic analysis in tablet formulations, 131
Liposomes—simple formulas for calculating number and surface area of liposomes, heterogeneous populations, 173
—synthesized and fractionated using size exclusion chromatography on different gel media, 874
Liquid chromatographic assay—improved results for fluorouracil in presence of ftorafur, 1163
Liquid chromatography—analysis, doxycycline in human urine and feces, 226
Liquid nonelectrolytes—aliphatic and aromatic hydrocarbons, aqueous solubility and partition coefficients obtained experimentally compared with calculated values, 502

M

Macromolecules—effect on aqueous solubility of cholesterol and hormone drugs, 442
Magnesium hydroxide—electrophoretic mobility in aqueous solution, 486
Magnesium salicylate—physicochemical properties, tableted tetrahydrate and anhydrous forms, effect of calcium stearate on dissolution rate, 961
Magnesium stearate—effect on tablet disintegration during mixing, 1328
Magnolia grandiflora L.—antimicrobial activity of phenolic constituents, agar well diffusion assay, 951
Magnolol—phenolic constituent of *Magnolia grandiflora* L, antimicrobial activity, 951
Mass fragmentography—determination of saccharin in human biological fluids, plasma kinetics and urinary excretion, 871
—determination, timolol, plasma and urine, 573
Mass spectrometry—analysis, anilinomethanesulfonate derivatives, synthesis and structure elucidation, 863
—detection of phthalate esters by selected-ion monitoring, 346
Mathematical models—influence of administration route on drug delivery to a target organ, 1344
Mathematics—method for analysis of pharmacological effects on constant-rate intravenous drug infusion, 578
Matrix, microcapsules—formalized gelatin, calcium alginate, and calcium sulfate, influence of matrixes on properties of nylon-encapsulated pharmaceuticals, 372
Medicinals—sodium chloride equivalents, cryoscopic properties, and hemolytic effects determined for 29 drugs, 1161
Melting-point effect–correlation between water solubility and octanol–water partition coefficient, 1176
—correlation between water solubility and octanol–water partition coefficient, response, 1177
Meperidine—metabolism, urinary excretion in mice, rats, guinea pigs, rabbits, cats, and dogs, 867
—and metabolites, TLC identification and GLC determination in biological fluids, rat, dog, and human, 482
Mercaptopurine—irreversible binding to human serum proteins, 1290
Metabolism—absorption and bioavailability of captopril, gavage and dietary administration, mice and rats, 885
—of caffeine, plasma levels of metabolite theobromine following oral administration of caffeine to dogs, 579
—effect of sulfadimethoxine on thiopental metabolism in rats, *in vitro* and *in vivo* studies, 323
—ethinyl estradiol in rats and dogs, first-pass metabolism and possible gut wall metabolism, 403
—4-iodobiphenyl and metabolites, distribution studies in rats, 546
—of meperidine in mice, rats, guinea pigs, rabbits, cats, and dogs, 867
—procainamide and *N*-acetylprocainamide, pharmacokinetics in rats, compared with human data, 299
Metabolites—merperidine, TLC identification and GLC determination in biological fluids of rat, dog, and human, 482
—of meperidine, urinary excretion, mice, rats, guinea pigs, rabbits, cats, and dogs, 867
microbial—imipramine, identification, fungi, 151
microbial—phencyclidine, identification, 155
neutral and acidic—biotransformation of α-pinene, β-pinene, pinane, 3-carene, carane, myrcene, and *p*-cymene in rabbits, 406
urinary—of rutin, GLC–mass spectrometric analysis, humans, 780
Methazolamide—time course and disposition in human plasma and red blood cells, 75
Methenamine—dissolution profile using dissolution simulator, 1017
—evaluation of 10 products, urinary excretion of formaldehyde, 596
Methimazole—potential new prodrugs, evaluation of mesoionic 6-substituted 1-methylimidazo[2,1-*b*][1,3]thiazine-5, 7-diones, 1322
Methotrexate—sustained serum concentrations in patients with GI obstruction, pharmacokinetics, 1194
Methoxsalen—high-performance liquid chromatographic analysis, human plasma, 965
Methscopolamine nitrate—high-pressure liquid chromatographic analysis tablets, 820
Methylation—salicyluric acid in urine, high-pressure liquid chromatography, 1090
***p*-Methylbenzoylformic acid**—model organic compound used for determination of renal accumulation, pharmacokinetics, 295
α-Methylene-γ-butyrolactones—synthesis and evaluation for antibacterial and antineoplastic activity, 84
Methylglyoxal—preparation of microcapsules of methylglyoxal, methylglyoxal bis(guanylhydrazone), or methylglyoxal–ascorbic acid complex, decomposition in aqueous solution, 385
Methylparaben—high-performance liquid chromatography for assaying components of injectable solutions, 1215
Methylphenidate—effects on behavior and neurochemistry, rats, coadministration wtih dextroamphetamine, 816
3 - Methyl - 5 - phenylpyrazolesulfonylurea derivatives—preparation and evaluation for antidiabetic activity, 602
Methylprednisolone—17- and 21-succinates, hydrolysis and acyl migration, initial rate studies, 181
***N*-Methylpromethazine methylsulfate**—hepatic first-pass effect in dogs, plasma concentration–time curves, 947
Methylsulfinylmethyl 2-acetoxybenzoate—kinetics and mechanism of hydrolysis, 750
—percutaneous absorption and metabolism, aspirin prodrugs, 756
Methylxanthines—solubility profiles using extended Hildebrand–Scatchard equation, 1115
Mevalonic acid—analogs synthesized as potential cholesterol biosynthesis inhibitors, 1007
Micellization—cetaben sodium solubilization in surfactant and lipid solutions, 924
Michaelis–Menten equation—computational problems of compartment models, parameter estimation, 733
kinetics—first-pass effect, nonlinear approach, 195
Microbial metabolism—imipramine, identification of metabolites, fungi, 151
Microbial metabolites—phencyclidine, identification of metabolites, 155
Microcapsules, acacia–gelatin—sulfamethoxazole, electrophoretic properties compared, 302
—clofibrate, effect of wall thickness on release characteristics, 430
gelatin–acacia—capsule-size effect on permeability toward sodium chloride, 456
Microencapsulation—sulfamethoxazole, spray drying with cellulose acetate phthalate and colloidal silica, montmorillonite, or talc, polymorphism, 1256
—symposium, chlorothiazide release rates evaluated from plain tablets, compressed tablets of microcapsules, and microcapsules *in vitro* and *in vivo*, 376
—symposium, doxorubicin-bearing magnetic microspheres, *in vivo* fate of localized low dose, 389
—symposium, incorporation of influenza virus antigens into polymer nanoparticles compared with their absorption onto polymer nanoparticles, vaccines with and without adjuvant evaluated for protection against influenza in mice and heat inactivation, 367
—symposium, influence of matrixes on properties of nylon-encapsulated pharmaceuticals, 372
—symposium, magnetic microspheres synthesized with immunological specificity through incorporation of staphylococcal protein A, immunoglobulin G–blood cell binding studies, 387
—symposium, preparation of microcapsules of methylglyoxal and derivatives for gradual release in aqueous solution, 385
—symposium, preparation of microcapsules and microspheres containing fine hydrophilic particles of silica gel beads, modified nylon 12, and phenacetin using water-soluble egg albumin, heat coagulation method, evaluation of factors affecting size, size distribution, and percent of microencapsulated particles, 358
—symposium, preparation of nanograde-sized polyamide microcapsules containing hemolysate, effect of temperature, emulsifier concentration, and applied potential on capsule-size distribution, 354
—symposium, preparation and release characteristics of potassium chloride microcapsules, 391
—symposium, preparation of viable microencapsulated hepatoma cells and pancreatic islets, semipermeable membranes, 351
—symposium, sustained-release delivery system for phenylpropanolamine, coated ion-exchange resin–drug complex, 379
—symposium, various microencapsulation techniques compared, glass and polymeric shells, microencapsulation of fuel pellets, 364
Microparticles—L-asparaginase-containing polyacrylamide microparticles, prolongation of effect by implantation of immobilized enzyme, rats, 684
Microsomal enzyme system—effect of elevated blood glucose levels, rats, 695
Microspheres—albumin, characterization by field-flow fractionation, 1350
magnetic—as drug carriers, doxorubicin, *in vivo*, 389
polystyrene—acute hemodynamic effects and blood pool kinetics following intravenous administration to dogs, drug delivery system to target organs, 660
Mitochondrial function—effects of chronic emetine treatment, 343
Mixing—of multicomponent cohesive powders, evaluation of homogeneity using multivariate statistical analysis, 247
—of multicomponent cohesive powders, evaluation of homogeneity using three mixing indexes based on statistical analysis, 243
Model membrane systems—polyurethane copolymers, permeability and sorption characteristics, 1313
—polyurethane copolymers, synthesis and analysis,

mass transport properties, 571
Model simulations—sustained serum methotrexate concentrations in patients with GI obstruction, pharmacokinetics, 1194
Models, dissolution—for *n*-component, nondisintegrating spheres, 1331
mathematical—compartment models with Michaelis–Menten-type elimination, computational problems, parameter estimation, 733
mathematical—equation for direct calculation of complexation constants using solubility method, 108
mathematical—Langmuir and parabolic models compared for free drug concentration estimation, equilibrium dialysis, 802
mathematical—linear free energy relationship derived for calculation of pKa of polysubstituted purines, 425
mathematical—prediction of dynamic flow rates of powder granulations from static flow measurements, 711
mathematical—relationship between partition coefficient and biological response, kinetic analysis, 57
mathematical—simple formulas for calculating number and surface area of liposomes, 173
pharmacokinetic—convective diffusion model, relationship between intestinal absorption clearance and intestinal perfusion rate, rats, 239
pharmacokinetic—for phenobarbital distribution, metabolism, and elimination, rats, 1233
pharmacokinetic—procainamide and *N*-acetylprocainamide metabolism in rats, compared with human data, 299
pharmacokinetic—two-compartment models, computer simulations of their characteristics and clinical consequences, 141
Molecular connectivity indexes—relationship between molecular volume and electronic composition, mathematical estimation of valence state electronegativity, 583
Molecular structure—quantitative method for ranking solvent polarity, 930
Mucopolysaccharides—inhibition of sulfation by salicylates and thiosulfates, 49
Multicomponent systems—extreme vertexes design in formulation development, butoconazole nitrate solubility 897
Multivitamin–mineral formulations—high-pressure liquid chromatography, folic acid, 1273
Multivitamin preparations—simultaneous high-pressure liquid chromatographic assay of various water-soluble vitamins, 1014
Muscle, skeletal—relaxant properties evaluated in dantrolene-related compounds, mice, 1088
Muscle relaxants—xilobam, analysis, determination of decomposition products, stability assessment, 778
Myocardial imaging—use of radiopharmaceuticals, 1
Myxin—high-performance liquid chromatographic assay in cuprimyxin-containing creams, 1024

N

Nadolol—high-pressure liquid chromatographic analysis, 336
Nafronyl oxalate—high-pressure liquid chromatographic analysis in stability studies, 39
Naphazoline—spectrophotometric assay in dosage forms using complex formation with chloranil, 127
Naphthalene—solubility study, extended Hansen, extended Hildebrand, and UNIFAC approaches compared, 1260
Narcissin—isolation from *Strumpfia maritima* (Rubiaceae), 682
Neomycin—stability in ophthalmic solutions containing edetate disodium, 960
Neostigmine—acetylcholine analog, synthesis and preliminary pharmacology of neostigmine analogs, quantification by GLC using flame-ionization detection, 433
Neuroleptic agents—haloperidol and bromperidol, tissue distribution studied in rats and rhesus monkeys using external scintigraphy and serial sacrifice, 985
Niacinamide—simultaneous high-pressure liquid chromatographic analysis with pyridoxine, riboflavin, and thiamine in multivitamin products, 99
Nialamide—comparison of rotamer populations in solid state and in solution, conformation determined by IR and NMR spectroscopy and X-ray crystallography, 284
Nitrofurantoin—dissolution profile using dissolution simulator, 1017
Nitroglycerin—loss from solution to plastic intravenous containers, a theoretical treatment, 798
—ointments, effect of method of application on pharmacokinetics, humans, 1368
—pharmacokinetics, intravenous infusion in normal subjects, 1054
—stability of ointment at elevated temperatures, 832
NMR spectroscopy—analyses of quinidine and other cinchona alkaloids, impact of stable conformation on protonation site, polar and nonpolar solvents, 679
—analyses, quinidine and oxidation products, conformation and configuration assigned, 675
^{13}C-NMR spectroscopy—determination of resonance multiplicities, brucine, 81
—tropane and *N*-substituted nortropane spirohydantoins, determination of preferred conformation, 87
Noninvasive dissolution measurement—of solid dosage forms using perturbed angular correlation, *in vivo* and *in vitro*, 1325
Norethindrone–mestranol combinations—high-performance liquid chromatography, content uniformity studies, 702
Nylon microcapsules—preparation and properties, various matrixes and drugs, effects of pH, matrix, and encapsulated species on retention of drug during formulation, 372

O

Ointments—high-pressure liquid chromatographic determination of anthralin, 1205
—nitroglycerin, effect of method of application on pharmacokinetics, humans, 1368
Oleic acid—effect of concentration on free and protein bound warfarin concentration, humans, 114
One-phase end-point change system—two phase titration, amine drugs, 1286
Optical characterization—low solubility compound, 5-(tetradecyloxy)-2-furancarboxylic acid, 1152
Optical crystallography—substance identification of diliturate derivatives of amine drugs, 704
Oral bioavailability—parameters of triamterene administered as suspensions in lipid and aqueous vehicles and lactic acid solution, 1131
Oxalate—*in vitro* binding by various anion-exchange resins and aluminum hydroxide, 1065
4(5*H*)-Oxazolones—tetracycline ring A analogs, synthesis, 496
Oxfendazole—high-performance liquid chromatographic analysis of cow milk, 858
Oxidation products–quinidine, conformation and configuration assigned to oxidation products, NMR analysis, 675
Oxime derivatives—synthesis, comparison as potential anticholinergics, 558
Oxymorphone derivatives—binding to disintegrating agents compared, Freundlich adsorption isotherm, 709
Oxytetracycline—fluorometric determination in small blood and tissue samples, 186

P

P-388 lymphocytic leukemic cells—antileukemic activity of helenalin, brusatol, and bruceantin, and their esters, 1147
***Panax trifolia* L.**—two dimensional TLC analysis of ginsenosides from root, 89
Pancreatic islets—viability within microcapsule demonstrated by insulin release pattern and histological staining, 351
Papaver bracteatum—colorimetric determination of thebaine in extract, 102
Paraben preservatives—contamination in theophylline olamine enema solutions, high-performance liquid chromatographic analysis, identification and quantitation, 589
Parabens—calculation of solubility parameters in normal alkanols, 170
Parmentier–Führer equation—energy relations in tablet compression, polymeric materials and granulations, 1005
Particle characterization—by field-flow fractionation, 1350
Partition coefficient—octanol–water, correlation with water solubility, 1176
—octanol–water, correlation with water solubility, response, 1177
—relationship with biological response, kinetic analysis, 57
—relationship between drug transport rate constants and partition coefficients, 1081
Partitioning—octanol–water partition coefficients, experimental values compared with calculated values, aliphatic and aromatic hydrocarbons, liquid nonelectrolytes, 502
Patent blue violet—physicochemical characteristics, 122
Pectin—interactions with quinidine, *in vitro*, 999
Pellets—observed artifacts due to preparation, IR spectrometry, 968
Penicillin G sodium—spectrophotometric assay in dosage forms using complex formation with chloranil, 127
Penicillins—interactions with a nonpolar, macroporous styrenedivinylbenzene copolymer stationary phase, 994
3-*n*-Pentadecylcatechol—poison ivy component, effect of vehicle on GI absorption, rats, 829
—production of tolerance to urushiol, guinea pigs, 785
Perfluorohexyl bromide—tissue and blood plasma levels in dogs after oral and intratracheal administration, 1199
Perfusion rate—optimum, *in situ* intestinal absorption studies, rats, 239
Perhexiline maleate—high-performance liquid chromatographic assay, human plasma, 320
Permeability—*n*-alkanols through hairless mouse skin strata separated by thermal and stripping techniques, 52
—effect of edetate disodium on goldfish membrane, 1128
—effect of hydration on water and alkanol absorption through Swiss mouse skin, comparison with hairless mouse, 1212
—gelatin–acacia microcapsules, evaluated for capsule-size effect, 456
—polyurethane copolymers, model membrane system, synthesis and analysis, 571
—polyurethane copolymers, model membrane systems, permeability and sorption characteristics, 1313
Perturbed angular correlation—noninvasive dissolution measurement *in vivo* and *in vitro*, 1325
Pharmaceutical solids, polymorphic—griseofulvin and its solvates, investigation using laser Raman spectroscopy, physicochemical stability, desolvation, 789
Pharmacokinetic linearity—desipramine hydrochloride, humans, 1079
Pharmacokinetic models—two-compartment models, computer simulations of their characteristics and clinical consequences, 141
Pharmacokinetics—aminoglutethimide, bioavailability, binding to blood constituents, 1040
—analysis, computational problems of compartment models with Michaelis–Menten-type elimination, parameter estimation, 733
—bretylium tosylate, rats, compared with human studies, 667
—captopril in dogs and monkeys, continuous intravenous infusion, 1108
—cimetidine, evaluation by linear system approach, 32
—cyclacillin, intestinal absorption *in situ*, blood levels after intravenous, intraportal, and intraduodenal administration to rats, 772
—determination of renal clearance of procainamide

using arterial and venous plasma, rabbits, 1373
—direct linear plotting method of parameter estimation, 1093
—effect of antacid on theophylline, tablets and timed-release capsules, 599
—effect of human blood preservation on *in vitro* protein binding, 1168
—effect of method of application on nitroglycerin ointments, humans, 1368
—first-pass effect, nonlinear approach to solution of Michaelis–Menten equation, 195
—fluorometholone compared with pilocarpine, mechanistic studies on transcorneal permeation, rabbits, 1026
—general equation for measurement of drug removal by extracorporeal devices, 345
—indapamide, dogs, 1310
—instantaneous input hypothesis, comparison with conventional extrapolation method, dogs, 1037
—intravenous chlorpheniramine maleate in children, 1284
—isosorbide dinitrate, intravenous administration compared in nonhuman primates, 1270
—mathematical method for analysis of pharmacological effects on constant-rate intravenous drug infusion, 578
—method for analysis of percent dissolved–time data, 535
—model for phenobarbital distribution, metabolism, and elimination, rats 1233
—nitroglycerin, intravenous infusion in normal subjects, 1054
—plasma ethmozin levels, high-performance liquid chromatography, humans, 462
—point–area deconvolution algorithm compared with instantaneous midpoint–input deconvolution method, calculation for *in vivo* drug input functions, 831
—prednisolone, protein binding, rabbits, 1201
—procainamide and *N*-acetylprocainamide, rat blood, urine, and feces, compared with human data, 299
—propranolol, conventional and slow-release formulations compared, 1030
—proxyphylline, diuretics, N^9-demethylation, 542
—quinidine formulations, evaluation for variations in bioavailability, humans, 524
—relative bioavailability determined for drugs with changing biological half-lives, alternative method to plasma concentration–time curve method, 109
—renal accumulation of model organic anions, rats, 295
—simplified physiologically based method to estimate steady-state volume of distribution, 967
—single-point maintenance dose prediction, theoretical analysis, 1174
—sulfadimethoxine, protein binding, cattle, 1068
—sulfisoxazole, comparison in humans, dogs, and swine, 981
—sustained serum methotrexate concentrations in patients with GI obstruction, 1194
—theophylline, oral and intravenous administration, concentration-dependent clearance, 452

Phase solubility—interaction of phenolic compounds with esters, 1225

Phenacetin—preparation of microcapsules and microspheres of phenacetin using egg albumin, heat coagulation method, 358

Phencyclidine—analysis of 1-piperidinocyclohexanecarbonitrile and its hydrobromide salt as synthetic contaminants, 106
—identification of pyrolysis product phenylcyclohex-1-ene in smoke, 1002
—microbial metabolism, identification of metabolites, 155

Phenethylamines—structure–activity relationships, compared with other hallucinogens, animal, human, and *in vitro* studies reviewed, literature survey, 839

Pheniramine maleate—high-pressure liquid chromatographic analysis, tablets, 820

Phenobarbital—*N*-hydroxymethyl derivative synthesized, structure confirmed by NMR and elemental analyses, potential prodrug, 855
—physiologically based model for distribution, metabolism, and elimination kinetics in rats, 1233
—quantitation of *p*-hydroxyphenobarbital by GC and GC–mass spectrometry in urine, plasma, and hepatic microsomes, 1218
—simultaneous determination with theophylline and ephedrine hydrochloride by high-pressure liquid chromatography, conventional and sustained-action tablet formulations, 804
—solubility in various binary and ternary solvent systems, 1172

Phenolic compounds—interaction with esters using hexane–ester cosolvent systems, phase solubility and partitioning methods, 1225

Phenols—amino acid esters as prodrugs, synthesis and analysis, 881

Phenylalkyl primary amines—GLC analysis using nitrogen detection, rat serum, brain, and liver, 813

Phenylbutazone—degradation products, TLC, qualitative and quantitative analyses, UV reflectometric measurements on plates, 460
—dissolution kinetics, 1358

Phenylcyclohex-1-ene—pyrolysis product of phencyclidine identified in smoke, 1002

Phenylpropanolamine—high-pressure liquid chromatographic analysis in human plasma, *O*-phthalaldehyde derivatization, 707
hydrochloride—high-pressure liquid chromatographic analysis, tablets, 820
—microencapsulated with ion-exchange resin, new sustained-release delivery system, effect of particle size, coating, and dosage form on bioavailability, 379

Phenytoin—anticonvulsant activity, intraperitoneal dosage, blood and brain concentrations, 618
—teratogenic effects on mice, 631

Photosensitizer—methoxasalen, high-performance liquid chromatographic analysis, human plasma, 965

pH–rate profile—cefadroxil, degradation kinetics and mechanism, intramolecular aminolysis to produce piperazinediones, buffer and temperature effects, 1120

Phthalates—interference with oxprenolol assay using GLC with electron-capture detection, 346

Physicochemistry—aspirin derivatives, property modification strategies based on enzyme specificities, synthesis and pharmaceutical properties, 1299
—effect of adsorbed carbonate on surface charge and physical characteristics of aluminum hydroxide gel, 638
—effect of hydrochlorides on solubility, common ion effect, 594
—modification strategies based on enzyme substrate specificities, carboxypeptidase A hydrolysis of aspirin derivatives, 1307
—modification strategies based on enzyme substrate specificities, α-chymotrypsin hydrolysis of aspirin derivatives, 1304

Pilocarpine—analysis in the presence of isopilocarpine and pilocarpic acid, ophthalmic solutions, 1046
—high-performance liquid chromatographic analysis in the presence of isopilocarpine, ophthalmic solutions, 446
—reversed-phase high-performance liquid chromatographic analysis with isopilocarpine, pilocarpic acid, and isopilocarpic acid in ophthalmic pilocarpine formulations, 96

Piperazine—spectrophotometric assay in dosage forms using complex formation with chloranil, 127

Piperazinediones—cefadroxil degradation kinetics and mechanism, intramolecular aminolysis, 1120

1-Piperidinocyclohexanecarbonitrile—nonaqueous titrimetric analysis as synthetic contaminant of phencyclidine, 106

Pirprofen—effect on protein binding of warfarin and tolbutamide, 1370

pKa_1 values, apparent—benzothiadiazines, semiaqueous potentiometric determination, 317

Plasma clearance—plasma caffeine levels, plasma theophylline levels, 395

Plastic containers—loss of nitroglycerin from intravenous plastic containers, a theoretical treatment, 798

Plasma protein binding—interaction between valproic and salicylic acids, rhesus monkey, 1279
—zomepirac sodium in plasma from humans, rats, mice, and rhesus monkeys, 818

Plasticizers—phthalate, analytical contaminant, 346

Platelets—free fatty acid-induced aggregation, solubilized and nonsolubilized fatty acids, 975

Platinum—determination in serum and ultrafiltrate, flameless atomic absorption spectrophotometry, 500

Point-area deconvolution algorithm—compared with instantaneous midpoint–input deconvolution method, drug absorption, calculation for *in vivo* drug input functions, 831

Poison ivy—3-*n*-pentadecylcatechol component of urushiol, effect of vehicle on GI absorption, rats, 829
—production of tolerance to urushiol using 3-*n*-pentadecylcatechol with autologous blood cells, guinea pigs, 785

Polarimetry—analysis of pilocarpine and isopilocarpine, ophthalmic solutions, 1046

Polarity index—solvents, quantitative method based on molecular structure, 930

Polyacrylamide—microparticles containing L-asparaginase, prolongation of effect by implantation, rats, 684

Polyamines—synthesis of derivatives, cancer chemotherapy, 956

Polyethylene glycol 4000—effect on dicumarol dissolution, stability, and absorption, 1353

Poly(*Nα*,*Nε*-L-lysinediyliterephthaloyl) microcapsules—containing hemolysate, prepared by interfacial polymerization using electrocapillary emulsification, 354

Polymers—poly(methyl methacrylate) and aluminum hydroxide used as adjuvants in influenza vaccine, effect of polymer on protection against influenza in mice and heat inactivation, 367
—shell fabrication, fuel pellets, various microencapsulation techniques compared, 364
—various polymers and waxes investigated for microencapsulation of potassium chloride, 391

Polymorphism—microencapsulation of sulfamethoxazole, spray drying with cellulose acetate phthalate and colloidal silica, montmorillonite, or talc, 1256

Polyols—mechanism of interaction with aluminum hydroxide, 1101

Polysorbate 80—effect on tetracycline absorption across everted rat intestine, 269

Polyvinylpyrrolidone—interaction with 32 pharmaceuticals of diverse chemical structure, sorption and desorption studies, 738

Potassium chloride—preparation and release characteristics of microcapsules, 391

Potentiometric titration—aluminum chlorohydrate, physicochemical properties determined, IR spectroscopy and pH-stat titration, 762
—analysis of 1-piperidinocyclohexanecarbonitrile and its hydrobromide salt as synthetic contaminants of phencyclidine, 106

Potentiometry, semiaqueous—benzothiadiazines, determination of apparent pKa_1 values, 317

Povidone—interaction with aromatic compounds, evaluation of complex formation by factorial analysis, 1252

Powder flow—tensile strength, consolidation ratio relationships, 927

Powders—compression cycles at various maximum pressures for substances expected to undergo plastic deformation, 222
—densification by concavo-convex roller compactor, effects on flowability, 288
granular—relationship between flow rates of granular powders through stationary and moving orifices, 711
—multicomponent mixing of cohesive powders, evaluation of homogeneity using multivariate statistical analysis, 247
—multicomponent mixing of cohesive powders, evaluation of homogeneity using three mixing indexes based on statistical analysis, 243

Prednisolone—dose-dependent protein binding and pharmacokinetics, rabbits, 1201
—modified method for colorimetric determination in dog plasma, 810
—protein binding in blood collection techniques, 1160
Procainamide—and metabolite *N*-acetylprocainamide, pharmacokinetic study in rat urine, blood, and feces, compared with human data, 299
—renal clearance, determination using timed-interval method, rabbits, 1373
Prodrugs—of *p*-acetamidophenol, amino acid esters, 881
aspirin—activated ester-type prodrugs synthesized and evaluated for analgesic activity, *in vitro* and *in vivo* studies, 743
aspirin—methylsulfinylmethyl 2-acetoxybenzoate, kinetics and mechanism of hydrolysis, 750
—of guanazole, synthesis and evaluation as antineoplastic agents, 1281
—of methimazole, evaluation of mesoionic 6-substituted 1-methylimidazo [2,1-*b*] [1,3]thiazine-5,7-diones, 1322
—methylsulfinylmethyl 2-acetoxybenzoate and related aspirin agents, percutaneous absorption and metabolism, 756
potential—*N*-hydroxymethyl derivatives of allopurinol, glutethimide, and phenobarbital synthesized, structures confirmed by NMR and elemental analyses, 855
potential—*N*-hydroxymethyl derivatives of uracil synthesized, structures confirmed by NMR and elemental analyses, 850
Progesterone—nasal absorption compared with that following intravenous and intraduodenal administration, rats, 466
—permeation through hydrogel membranes, 216
Prolonged-release drugs—preparation of spherical matrixes from liquid suspension, sulfamethoxazole and sulfanilamide, 913
Propildazine—degradation in water, ionization constants, pKa determination, identification of degradation products, 334
Propiram—bioavailability in humans, tablet *versus* solution, 521
Propranolol—absorption studied in chronic *in situ* ileal and jejunal loops in dogs, 516
—analysis, high-performance liquid chromatography, human plasma, 688
—high-performance liquid chromatographic assay with 4-hydroxypropranolol, conventional and slow-release formulations compared, 1030
Proquazone—erythrocyte partitioning and equilibrium dialysis methods evaluated for determination of plasma protein binding of drug, 252
Prostaglandins—binding to human serum proteins, equilibrium dialysis of radiolabeled prostaglandins, 945
—transport through silicone rubber, effect of lipophilicity, *in vitro* release profiles, 562
***N*-Protected glycine** activated esters—evaluation for antifertility activity, 60
Protein binding—binding of warfarin to human serum albumin, effect of plasma oleic acid concentration on free and bound warfarin concentration, 114
human plasma—arylmalonylamino 1-oxacephem stereoisomers, effect on renal clearance, 112
—proquazone in human plasma, erythrocyte partitioning and equilibrium dialysis methods evaluated, 252
—prostaglandins E_1 (alprostadil), E_2 (dinoprostone), $F_{1\alpha}$ and $F_{2\alpha}$ (dinoprost) to human serum proteins, equilibrium dialysis of radiolabeled prostaglandins, 945
rat plasma—new antibacterial agent, arylmalonylamino 1-oxacephem stereoisomers, effect on renal clearance, comparison with human data, 113
—sulfadimethoxine, pharmacokinetics, cattle, 1068
Proteins—adsorption onto silicone-coated glass surfaces, 493
Protoporphyrin—determination by ion-pair extraction with chlorpromazine, 1294
Proxyphylline—metabolism after oral administration, N^3-demethylation, 542
Pseudoephedrine hydrochloride—measurement of dissolution using chloride-ion electrode, 1288
***d*-Pseudoephedrine**—radioimmunoassay, bioequivalency studies, immediate- and sustained-release tablets, 624
Psychotherapeutic agents—dihydroergotoxine, *in vitro* dissolution method for sublingual tablets, 796
Psychotropic agents—chlorpromazine, high-performance liquid chromatographic analysis, 1043
Purines—quantitative structure–activity relationships, prediction of pKa for polysubstituted purines from pKa of monosubstituted purines, linear free energy relationship equations, 425
Puromycin—acyclic analogs, synthesis and analysis, evaluation for inhibition of protein synthesis and antiviral and antibacterial activity, 1169
Pyrazolodiazepinones—equilibrium reaction of zolazapam, 691
Pyridoxine—simultaneous high-pressure liquid chromatographic analysis with niacinamide, riboflavin, and thiamine in multivitamin products, 99
Pyrolysis—formation of phenylcyclohex-1-ene from phencyclidine in smoke, 1002

Q

Quinidine—bioavailability and pharmacokinetic variations of various quinidine formulations studied in humans, 524
—impact of stable conformation on protonation site, effect of polar and nonpolar solvents on conformation, NMR analyses, 679
—interactions with kaolin and pectin, *in vitro*, 999
—oxidation products prepared, conformation and configuration assigned, NMR analyses, 675

R

Radioimmunoassay—determination of carteolol in human plasma, 990
—flunisolide, human plasma or serum, 900
—*d*-pseudoephedrine, human plasma, bioequivalency studies, immediate- and sustained-release tablets, 624
—quantitation of flunitrazepam, compared with electron-capture GLC, human plasma, 230
Radiolabeled compounds—[4-^{14}C]theophylline, synthesis, 576
Radionuclide imaging agents, potential—^{141}Ce-labeled polystyrene microspheres, acute hemodynamic effects and blood pool kinetics evaluated in dogs following intravenous administration, 660
myocardial—radioiodinated benzoylcholine analogs synthesized and evaluated for use as myocardial-imaging agents, mice, 439
Radionuclides—radiolabeled bromperidol and haloperidol, tissue distribution studied in rats and rhesus monkeys using external scintigraphy and serial sacrifice, 985
Radiopaque contrast agents—perfluorocarbons, perfluorohexyl bromide, tissue and plasma levels in dogs after oral and intratracheal administration, 1199
Radiopharmaceuticals, iodinated—benzoylcholine analogs, synthesis and evaluation for use as myocardial-imaging agents, mice, 439
—*o*-iodohippuran labeled with iodine 123 and with iodine 131, kit preparation method developed and compared with commercial products, biodistribution studies in rats and rabbits, 312
—^{99m}Tc-labeled iminodiacetic acid derivatives, electrophoretic determination of charge on carrier-free ^{99m}Tc-labeled complexes, synthesis, evaluation of net biliary excretion, 436
—use in myocardial imaging, 1
Receptor binding activity—cyclopropyl analogs of stilbene and stilbenediol, 399
Reinecke salt—determination of dimenhydrinate, spectrophotometry, 690
Release—of microcapsules of methylglyoxal, methoglyoxal bis(guanylhydrazone), or methylglyoxal–ascorbic acid complex, decomposition in aqueous solution, 385
Release rate—effect of ethyl myristate on release of 4-hexylresorcinol from petrolatum, quantitative analysis, 939
—theoretical comparison of drug release into sink and nonsink conditions, 1243
Remineralization—bovine teeth, fluoride delivery devices, effect of film thickness and particle size on remineralization, 907
—of demineralized bovine tooth enamel and hydroxyapatite pellets, 904
—human teeth *in vitro*, fluoride delivery devices, effect of surface treatment on remineralization, 910
Renal accumulation—*p*-methylbenzoylformic acid, pharmacokinetics, rats, 295
Renal clearance—arylmalonylamino 1-oxacephem stereoisomers, effect of plasma protein binding, humans, 112
—determination of procainamide using arterial and venous plasma, rabbits, 1373
—new antibacterial agent, arylmalonylamino 1-oxacephem stereoisomers, effect of plasma protein binding, comparison of rat and human data, 113
Renal dysfunction—evaluation of methods for producing renal dysfunction, 117
Resonance multiplicities—brucine, 81
Retinol, all-*trans*—fluorometric determination in rat serum, 685
Riboflavin—simultaneous high-pressure liquid chromatographic analysis with niacinamide, pyridoxine, and thiamine in multivitamin products, 99
Rutin—GLC–mass spectrometric analysis, urinary metabolites in humans, 780

S

Saccharin—GLC–mass fragmentographic determination in human biological fluids, plasma kinetics and urinary excretion, 871
Salicylamide, aspirin—spectrofluorometry, as major constituent in multicomponent tablets, 641
—sulfoconjugation and glucuronidation, 308
Salicylate—effect on rectal absorption of theophylline, 71
Salicylates—inhibition of mucopolysaccharide sulfation, 49
nonaspirin—simultaneous GLC analysis with aspirin in tablet formulations, 167
Salicylic acid—analysis, spectrofluorometry, impurity in multicomponent analgesic tablets, 641
—interaction studies with zomepirac sodium, effect on plasma protein binding, 818
—kinetics following oral administration of aspirin as tablet and two buffered solutions, 262
—plasma protein binding with valproic acid, rhesus monkey, 1279
—simultaneous high-pressure liquid chromatographic analysis with aspirin in multicomponent tablets, 64
Salicyluric acid—methylation during high-pressure liquid chromatography, 1090
Scar tissue—technique for preparing appendage-free skin on the hairless mouse, 835
Sedatives—simultaneous high-performance liquid chromatographic assay of theophylline, ephedrine hydrochloride, and phenobarbital, 783
1,2,3-Selenadiazoles—synthesis and biodistribution of radiolabeled compounds as potential adrenocorticosteroid imaging agents, 91
6-Selenoguanosine—oxidative degradation in aqueous solutions, kinetics, 634
Semipermeability—membranes of microencapsulated viable hepatoma cells and microencapsulated viable pancreatic islets, 351
Sennosides A and B—high-pressure liquid chromatographic analysis, separation of isomers from crude drug and pharmaceutical preparations, 727
Separation—biological activity in natural products, dry column chromatography, 329
Sepiolite—potential as excipient for drugs subject to oxidative degradation, 189
Serum albumin, human—effect on decomposition rates of arylmonomethyltriazenes, 892
Sheep—topical drug delivery, literature survey, 1181
Silica gel, spherical beads—preparation of microcapsules and microspheres of silica gel beads using egg albumin, heat coagulation method, 358

Silicates—effect of poly-2-vinylpyridine-*N*-oxide on silicate-induced hemolysis, 657
Silicone-coated glass surfaces—adsorption of drugs and proteins, 493
Single-point maintenance dose prediction—pharmacokinetics, theoretical analysis, 1174
Size exclusion chromatography—of liposomes on different gel media, 874
Skeletal muscle relaxant activity—dantrolene sodium-related compounds synthesized and evaluated for activity, mice, 1088
Skin—technique for preparing appendage-free skin on the hairless mouse, examination of scar tissue, 835
Skin cleanser—chlorhexidine gluconate, antimicrobial activity, simulation of contamination, 964
Skin separation techniques—separation of hairless mouse skin strata by thermal and stripping techniques, permeability of *n*-alkanols through separated strata, 52
Smoke—identification of phenylcyclohex-1-ene, a pyrolysis product of phencyclidine, 1002
Sodium chloride equivalents—data for 29 drugs, 1161
Sodium sulfate—absorption after oral administration, single and divided dose, bioavailability, humans, 331
Solids, crystalline—calculation of solubility parameters, 170
Solid-state decomposition—alkoxyfuroic acids with alkyl chain lengths of $n = 8–18$, 1095
Solubility—barbituric acids in aqueous sodium alkyl sulfonate, thermodynamics, 1238
—benzoic acid in simple binary and ternary solvents, monomer and dimer models, 1033
—cholesterol and hormone drugs, effect of macromolecules, 442
—dependence on melting point, crystalline compounds, 971
—direct calculation of complexation constants using new equation, 108
—effect of hydrochlorides, common ion effect, 594
—methylxanthines in mixed solvents, extended Hildebrand–Scatchard equation, 1115
—micellization of cetaben sodium in surfactant and lipid solutions, 924
—of naphthalene in various solvents, extended Hansen, extended Hildebrand, and UNIFAC approaches compared, 1260
parameters—calculation for crystalline solids, 170
—phenobarbital in binary and ternary solvent systems, 1172
—water, correlation with octanol–water partition coefficient, 1176
—water, correlation with octanol–water partition coefficient, response, 1177
Solvent polarity—quantitative method based on molecular structure, 930
Solvent systems—various binary and ternary, phenobarbital solubility, 1172
Sorption—interactions of 32 pharmaceuticals of diverse chemical structure with cross-linked insoluble polyvinylpyrrolidone, 733
Spectrofluorometry—determination of salicylic acid, salicylamide, and acetylsalicylic acid in multicomponent analgesic tablets, 641
Spectrophotometry—determination of dimenhydrinate with reinecke salt, 690
Spectroscopy, IR—aluminum chlorohydrate, structure proposed, 758
IR—analysis, aluminum chlorohydrate, physicochemical properties determined, 762
IR—mechanism of interaction between polyols and aluminum hydroxide gel, 1101
—itanoxone, physicochemical and analytical characteristics, 1245
laser Raman—investigation of griseofulvin and its solvates, physicochemical stability, desolvation, 789
Spermidine—effects of gastric emptying in rats, structure–activity relationships, 347
Spermine—effects on gastric emptying in rats, structure–activity relationships, 347
Spheres—*n*-component, nondisintegrating, general model for dissolution rates, 1331
Spherical agglomeration—preparation of spherical matrixes of prolonged-release drugs from liquid suspension, sulfamethoxazole and sulfanilamide, 913
Sprays—GLC analysis of menthol, phenol, benzocaine, and pyrilamine maleate in aerosol form, 1151
Stability—*N*-formimidoylthienamycin in aqueous solution, reaction kinetics, compared to other β-lactam antibiotics, 272
—neomycin in solutions containing edetate disodium, 960
—nitroglycerin ointment at elevated temperatures, 832
Staphylococcal protein A—incorporation into microsphere matrix, immunological specificity, 387
Stereoisomers, arylmalonylamino 1-oxacephem—new β-lactam antibacterial agent, renal clearance, plasma protein binding, humans, 112, 113
—nicotine, binding affinity and disposition in rats, 1292
Stereotyped behavior—ergolines, synthesis of 6-alkyl derivatives of 6-nor-9,10-dihydrolysergic acid methyl esters and evaluation in rats, 1319
Steroids—analysis in topical pharmaceuticals, high-pressure liquid chromatography, 530
—conjugated estrogens, quantitative determination by capillary GLC, 1072
Stilbene and stilbenediol—cyclopropyl analogs, pharmacological activity in mice and rats, 399
Stimulants—dextroamphetamine and methylphenidate, effects on behavior and neurochemistry, rats, 816
Structure–activity relationships—2-(3-alkylaminoalkylamido)pyrroles synthesized and evaluated for anesthetic activity, antiarrhythmic activity and CNS toxicity in guinea pigs and mice, 537
—2-amino-*N*-substituted succinimide derivatives, synthesis and evaluation for anticonvulsant activity, 192
—carbamazepine, cyheptamide, and phenytoin compared for anticonvulsant activity, 618
—catecholamine analogs synthesized and tested for antitumor activity, mice, 806
—*N*-chloroacetyl derivatives of *para*-substituted phenylalanines tested for growth inhibition in microbial antitumor prescreen, 464
—2,3-dehydrodeoxamuscarone and *cis*- and *trans*-dehydrodeoxamuscarines, molecular requirements of cholinergic receptors, dualism of receptor active sites, 489
—equilibrium reaction of zolazepam, 691
—interaction of biliary contrast agents with native and modified human serum albumin, optical studies of warfarin and diazepam binding sites, 549
—3-methyl-5-phenylpyrazolesulfonylurea derivatives and antidiabetic activity, 602
—mevalonic acid analogs as inhibitors of cholesterol biosynthesis, 1007
—phenethylamines, compared with other hallucinogens, animal, human, and *in vitro* studies reviewed, literature survey, 839
quantitative—monosubstituted and polysubstituted purines, choice of parameters for prediction of pKa, 425
—relationship between drug transport rate constants and partition coefficients, 1081
—the role of R side chain on sulfamate sweeteners, 933
—selected tricyclic oxime *O*-ethers as potential anticholinergics, synthesis, 558
—spermidine and spermine, effects on gastric emptying in rats, 347
—structural functions of six sugars evaluated for sweetness, 277
—substituted aminoanthraquinone derivatives synthesized and evaluated for antiproliferative activity, 1011
—substituted 3,5-diarylpyrazolesulfonylurea derivatives and antidiabetic activity, 606
—synthesis and evaluation of 4-substituted imidazoles for inhibition of histidine decarboxylase, 341
—tripyrrole derivatives of congocidine synthesized and evaluated for antiparasitic activity in mice, *in vivo* and *in vitro* studies, 822
—usefulness of molecular connectivity indexes, mathematical estimation, relationship between molecular volume and electronic composition, 583
Structure stability—mechanism of interaction between polyols and aluminum hydroxide gel, 1101
Strumpfia maritima—biological and phytochemical investigation, isolation of narcissin, 682
1-[(4-Substituted-1,2,3-thiadiazol-5-yl)arylmethyl]-4-methylpiperazines—synthesis, antihistaminic and anticholinergic activity, 510
Succinimides—derivatives, anticonvulsant effects, synthesis and analysis, 963
Sugars—relative sweetness, onset time, and duration of response determined for six sugars, structural functions of the sweet pharmacophore, 277
Sulconazole—reversed-phase high-pressure liquid chromatographic analysis in plasma, 1338
Sulfadimethoxine—effect on elimination and distribution of thiopental in rats, *in vitro* and *in vivo* studies, 323
—protein binding, pharmacokinetics, cattle, 1068
Sulfamates—sweeteners, structure–activity analysis, the role of R side chains, 933
Sulfamethoxazole—drug release behavior, preparation of spherical matrixes from liquid suspension, 913
—microcapsules and coacervates, electrophoretic properties compared, 302
—microencapsulated, polymorphism, spray drying with cellulose acetate phthalate and colloidal silica, montmorillonite, or talc, 1256
Sulfanilamide—drug release behavior, preparation of spherical matrixes from liquid suspension, 913
Sulfate, inorganic—effect on conjugation and glucuronidation of salicylamide, 308
Sulfisoxazole—pharmacokinetics in humans, dogs, and swine, 981
Sunscreens, potential—urocanic acid, synthesis of alkyl esters by Wittig reaction, 98
Suppositories—evaluation of a bead-bed dissolution apparatus, drug release rate, 646
Surfactants—effect on drug release of controlled-release dosage forms, 1248
—effect of polysorbate 80 on tetracycline absorption across everted rat intestine, 269
—micellar solubilization of cetaben sodium, 924
Suspending agents—effect of poly-2-vinylpyridine-*N*-oxide on silicate-induced hemolysis, 657
Sweet pharmacophore—structural function, relative sweetness of six sugars tested, 277
Sweeteners, artificial—saccharin, GLC and mass fragmentographic determination of saccharin in biological fluids, humans, 871
—structure–activity analysis of sulfamates, the role of R side chains, 933
Synthesis and analysis—vasoactive agents, lidocaine analogs, intraperitoneal and intravenous administration, 699
Syringes, disposable—leaching of 2-(2-hydroxyethylmercapto)benzothiazole, isolation, identification, and quantitation, 1139

T

Tablet compression—energy relations, polymeric materials and granulations, 1005
Tablet formulation—analysis of viscoelastic behavior during unloading and postcompression, 476
Tablet manufacture—compression cycles at various maximum pressures for substances expected to undergo plastic deformation, 222
Tableting machine—tablets produced from modified tableting machine with flexible die wall compared with those compressed conventionally, 613
Tablets—acetaminophen, bioavailability, *in vitro* and *in vivo* properties of three commercial tablets compared, 422
—compressed with modified tableting machine compared with those conventionally compressed, 613
—disintegration, effect of magnesium stearate during mixing, 1328
Teeth, bovine—remineralization of demineralized tooth enamel and hydroxyapatite pellets, 904

bovine—remineralization using fluoride delivery devices, effect of film thickness and particle size on remineralization, 907
human—remineralization *in vitro* using fluoride delivery devices, effect of surface treatment on remineralization, 910
Temazepam—effect of age and gender on disposition and elimination, 1104
Tensile strength—powder flow behavior, relationship to consolidation ratio, 927
Tension cell—gel structure measurement of aluminum hydroxycarbonate gel, 936
Teratogenicity—effects of cortisone and phenytoin on mice, 631
Terpenoids—α-pinene, β-pinene, pinane, 3-carene, carane, myrcene, and *p*-cymene, neutral and acidic metabolites, biotransformation in rabbits, 406
Tetracaine—determination by high-performance liquid chromatography, 569
Tetracycline—absorption, effect of polysorbate 80, everted rat intestine, 269
—fluorometric determination in small blood and tissue samples, 186
—synthesis of ring A analogs, 496
5-(Tetradecyloxyl)-2-furancarboxylic acid—optical characterization using a polarizing microscope and spindle stage, 1152
Thebaine—colorimetric determination in *Papaver bracteatum*, 102
Theobromine—caffeine metabolite, plasma levels following oral administration of caffeine to dogs, 579
Theophylline—effect of antacid on bioavailability, tablets and timed-release capsules, 599
magnesium salicylate—synthesis and properties, 204
olamine—contaminants, identification and quantitation, high-performance liquid chromatographic analysis, 589
—pharmacokinetic interaction with caffeine, 395
—pharmacokinetics, oral and intravenous administration, concentration-dependent clearance, 452
radiolabeled—synthesis, 576
—rectal absorption, effect of salicylate, 71
—simultaneous determination with ephedrine hydrochloride and phenobarbital by high-pressure liquid chromatography, conventional and sustained-action tablet formulations, 804
Theoretical release profiles—drug release rates modified by sink and nonsink conditions, 1243
Thermochemistry—monomer and dimer models for solubility of benzoic acid in simple binary and ternary solvents, 1033
Thermodynamics—interfacial transfer kinetics of nonionized barbituric acid derivatives in the two-phase transfer cell, 1265
—solubility of barbituric acids in aqueous sodium alkyl sulfonate, 1238
Thiadiazines—synthesis from 1-phthalazine thiosemicarbazides, evaluation for anticonvulsant activity, 94
Thiamine—simultaneous high-pressure liquid chromatographic analysis with niacinamide, pyridoxine, and riboflavin in multivitamin products, 99
Thiazides—plasma *versus* urine analysis in bioavailability/bioequivalence study, 833
Thiazinamium methylsulfate—hepatic first-pass effect in dogs, plasma concentration–time curves, 947
Thiazines—synthesis from 1-phthalazine thiosemicarbazides, evaluation for anticonvulsant activity, 94
Thiazoles—synthesis from 1-phthalazine thiosemicarbazides, evaluation for anticonvulsant activity, 94
Thiopental—effects of temperature and protein concentration on plasma and tissue binding, interspecies differences, 1049
—elimination and distribution in rats, effect of sulfadimethoxine on thiopental metabolism, *in vitro* and *in vivo* studies, 323
Thiosemicarbazide—synthesis of hexestrol derivatives, evaluation of anticonvulsant and anticancer activities, 1075
Thiosulfates—inhibition of mucopolysaccharide sulfation, 49
Thioureas—synthesis, hexestrol derivatives, evaluation of anticonvulsant and anticancer activities, 1075
Thioxanthene derivatives—chlorprothixene and degradation product, GLC–mass spectrometric analysis, gastric aspirate, 812
Thyroid inhibitors—methimazole evaluation of mesoionic 6-substituted 1-methylimidazo [2,1-*b*] [1,3]thiazine-5,7-diones, 1322
Timolol—extraction, derivatization, mass fragmentographic determination, plasma and urine, 573
TLC—analysis, phenylbutazone and degradation products, 460
—detection and identification of 16α- and 16β-methyl epimers of 9-fluoro-11β-hydroxy-16-methylandrosta-1,4-diene-3,17-dione, impurities in dexamethasone, betamethasone, and related drugs, 415
—identification of meperidine and metabolites in biological fluids of rat, dog, and human, 482
—identification of unchanged progesterone following nasal administration to rats, compared with intravenous and intraduodenal administration, 466
Tolbutamide—improved absorption through increased hydrophilicity, 67
—protein binding in presence of pirprofen, 1370
—simultaneous high-performance liquid chromatographic assay with carboxytolbutamide, human plasma, 1166
Topical drug delivery—to cattle and sheep, literature survey, 1181
Tranquilizers—chlorprothixene, GLC–mass spectrometric analysis, gastric aspirate, degradation product, 812
—clorazepate dipotassium and monopotassium, high-performance liquid chromatographic analysis, solid dosage forms, 793
—temazepam, effect of age and gender on disposition and elimination, 1104
Transfer kinetics—thermodynamics, nonionized barbituric acid derivatives in the two-phase transfer cell, 1265
Triamcinolone acetonide—GLC–mass spectrometric analysis, cell culture media, 917
Triamterene—high-performance liquid chromatographic analysis, plasma, 949
—poor solubility in lipid and aqueous vehicles, 1131
—simultaneous determination by high-performance liquid chromatography with hydrochlorothiazide, capsule formulations, 1083
Tricyclic antidepressants—desipramine hydrochloride, pharmacokinetic linearity, bioavailability, comparison of two tablet dose levels, humans, 1079
Triglyceride levels—effects of imide analogs on enzymes required for cholesterol and fatty acid synthesis, 326
Trinitrobenzenesulfonate—kinetics of reaction with human serum albumin, 1297
Tris(2-butoxyethyl)phosphate—leached substance altering protein binding of selected drugs, 1160
Trisulfapyrimidines—combination drug product, dissolution testing using automated high-pressure liquid chromatography, 764
Tropane and *N*-substituted nortropane spirohydantoins—PMR and ^{13}C-NMR spectra, determination of preferred conformation, 87
Two-phase titration—amine drugs, one-phase endpoint change system, 1286
Two-phase transfer cell—thermodynamic dependence of interfacial transfer kinetics of nonionized barbituric acid derivatives, 1265

U

Ultrafiltration—evaluation for use in clinical serum binding determinations, 146
Uniformity—statistical simulation of the proposed 75/75 requirement, 673
Uracil—*N*-hydroxymethyl derivatives synthesized, structures confirmed by NMR and elemental analyses, potential prodrugs, 850
Uranyl nitrate injection—evaluation for producing renal dysfunction, 117
Urinary tract antibacterials—evaluation of 10 methenamine products, excretion of formaldehyde, 596
Urocanic acid—alkyl esters, synthesis *via* Wittig reaction, 98
Ursodeoxycholic acid—effect on cholesterol gallstone dissolution *in vitro*, compared with chenodeoxycholic acid, 713
Urushiol—poison ivy component of 3-*n*-pentadecylcatechol, effect of vehicle on GI absorption, rats, 829
—production of tolerance using 3-*n*-pentadecylcatechol with autologous blood cells, guinea pigs, 785
USP assay—modification for calcium gluceptate, 968
UV spectrophotometry—analysis of pilocarpine and isopilocarpine, ophthalmic solutions, 1046

V

Vaccine, influenza—virus antigen incorporated into and adsorbed onto polymer nanoparticles, vaccines with and without adjuvant compared for protection in mice and against heat inactivation, 367
Valproic acid—plasma protein binding interaction with salicylic acid, rhesus monkey, 1279
Valve delivery—metered-dose aerosols, testing procedure for establishing reproducibility, 1085
Vasoactive agents—synthesis, analysis, intraperitoneal and intravenous administration, lidocaine analogs, 699
Vasodilators—amiodarone, high-pressure liquid chromatography in biological fluids, 1366
coronary—perhexiline, high-performance liquid chromatographic analysis in human plasma, 320
—isosorbide dinitrate, pharmacokinetics compared in nonhuman primates, 1270
—nafronyl oxalate, high-pressure liquid chromatographic analysis in stability studies, 39
—nitroglycerin ointments, effect of method of application on pharmacokinetics, humans, 1368
—nitroglycerin, pharmacokinetics, intravenous infusion in normal subjects, 1054
—stability of nitroglycerin ointment at elevated temperatures, 832
Vehicle volume—small *versus* large vehicle volumes in oral availability in rats, 1131
Venous pharmacokinetics—instantaneous input hypothesis and conventional extrapolation method compared, dogs, 1037
Verapamil—high-performance liquid chromatography, fluorescence detection, canine plasma, 800
Viloxazine—high-pressure liquid chromatographic analysis, human plasma and urine, 220
Viscoelastic behavior—analysis of tablets during unloading and postcompression, 476
Vitamin A—fluorometric determination in rat serum, 685
Vitamins—niacinamide, pyridoxine, riboflavin, and thiamine, simultaneous high-pressure liquid chromatographic analysis in multivitamin products, 99
water soluble—simultaneous high-pressure liquid chromatographic analyses in multivitamin preparations, 1014
Volume of distribution—estimation, simplified physiologically based method, 967

W

Warfarin—effect of plasma oleic acid concentration on free and protein bound warfarin concentration, protein binding, humans, 114
—interaction studies with zomepirac sodium, effect on plasma protein binding, 818
—protein binding in presence of pirprofen, 1370
Wittig reaction—synthesis of alkyl esters of urocanic acid, 98

X

Xanthan gum—interaction with magnesium carbonate, aluminum hydroxide, zinc oxide, and calcium carbonate, 554
Xanthine derivatives—metabolism of proxyphylline in humans, 542

—theophylline magnesium salicylate, synthesis and properties, 204
Xilobam—analysis, determination of decomposition products, stability assessment, 778
X-ray diffraction—aluminum chlorohydrate, structure proposed, 758

Z

Zero point of charge—magnesium hydroxide, 486
Zolazepam—analysis of equilibrium reaction, 691
Zomepirac sodium—plasma protein binding studies in plasma from humans, rats, mice, and rhesus monkeys, interaction studies with warfarin and salicylic acid, 818